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Abbreviations 
AID   Autoimmune disease 
AMP   antimicrobial peptides 
APC   antigen presenting cell 
BMDC  Bone-marrow derived dendritic cell 
Breg   regulatory B cell 
CD   Cluster of differentiation 
ELISA   Enzyme-linked immunosorbent assay 
GALT   gut-associated lymphoid tissue 
HEK   Human embryonic kidney 
IBD   Inflammatory bowel disease 
IEC   intestinal epithelia cell 
IFNγ   Interferon γ 
IgA   immunoglobulin A 
IL-   Interleukin- 
LPS   Lipopolysaccharide 
LBP   LPS binding protein 
MAMP  Microbe-associated molecular pattern 
MD-2   Myeloid differentiation protein 2 
mLN   mesenteric lymph nodes 
NF-κB   nuclear factor 'kappa-light-chain-enhancer' of activated B-cells 
OMV   Outer membrane vesicle 
PGN   peptidoglycan 
PP   Peyer’s patches 
PSA   Polysaccharide A 
PRR   Pattern recognition receptor 
Rag1-/-  Recombination-activating protein 1-deficient 
Th   T helper 
TLR   Toll-like receptor 
TNF   Tumor necrosis factor 
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Summary 
 
The composition of the intestinal microbiota affects the host organism in manifold 
ways by the digestion of nutrient, colonization resistance against pathogens and 
especially by influencing and priming the immune system. Consequently, a balanced 
microbiota composition, mainly consisting of symbiotic and pathobiotic commensal 
bacteria of the Firmicutes and Bacteroidetes phyla, is beneficial for the host by 
maintaining a healthy and homeostatic immune state. Symbionts generally possess 
important immunomodulatory functions to regulate inflammatory immune processes 
whereas pathobionts cause non-beneficial or detrimental effects on the host under 
certain genetic or environmental pre-conditions by promoting inflammatory immune 
processes. Alteration or dysbiosis of a complex intestinal microbiota has already 
been shown to be associated with the progression of various autoimmune diseases 
such as inflammatory bowel diseases, multiple sclerosis, type-1 diabetes and even 
neurological disorders such as autism. 
In particular, the interaction of microbes with the host immune system and the 
subsequent activation and differentiation of certain immune cells are crucial for the 
development of inflammatory or regulatory processes.  
For this reason, we focused on and investigated the immunogenicity-dependent 
potential of the commensals Bacteroides vulgatus (weak immunogenic) and 
Escherichia coli (strong immunogenic) to modulate and regulate the immune system 
of the host via the direct or indirect interaction with antigen-presenting dendritic cells 
and B cells. We could (1) identify the production of bacterial outer membrane vesicles 
as an important inter-kingdom signaling mechanism exhibiting immunomodulatory 
properties to prime host target cells; (2) demonstrate the activation and differentiation 
of a tolerant dendritic cell phenotype initiated by symbiotic B. vulgatus to maintain 
and restore immune homeostasis; (3) elucidate the induction of regulatory B cells via 
pathobiotic E. coli as an decisive counter-regulation mechanism suppressing pro-
inflammatory processes which are self-triggered and dependent on the bacterial 
immunogenicity.  
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Zusammenfassung  
 
Die Zusammensetzung der intestinalen Mikrobiota beeinflusst den Wirtsorganismus 
auf vielfältige Weise durch die Unterstützung beim Verdau von Nährstoffen, die 
Bildung einer Besiedlungsresistenz gegen Krankheitserreger und insbesondere 
durch die Aktivierung und Modulation des Immunsystems. Deshalb ist eine 
ausgewogene Mikrobiota-Zusammensetzung, die hauptsächlich aus symbiotischen 
und pathobiotischen kommensalen Bakterien der Phyla Firmicutes und Bacteroidetes 
besteht, für den Wirt von Vorteil, da sie einen gesunden und homöostatischen 
Immunzustand aufrechterhält. Symbionten besitzen im Allgemeinen wichtige immun-
modulatorische Funktionen, um entzündliche Immunprozesse zu regulieren, 
wohingegen Pathobionten unter bestimmten genetischen oder umweltbedingten 
Voraussetzungen keine vorteilhaften oder sogar schädliche Wirkungen auf den Wirt 
ausüben, indem sie inflammatorische Prozesse fördern. Es wurde bereits gezeigt, 
dass eine Veränderung oder Dysbiose einer komplexen Darmmikrobiota mit der 
Entstehung und Fortschreiten verschiedener Autoimmunerkrankungen wie chronisch 
entzündlichen Darmerkrankungen, Multipler Sklerose, Typ-1-Diabetes und sogar 
neurologische Störungen assoziiert ist. 
Insbesondere die Interaktion von Mikroben mit dem Wirts-Immunsystem und die 
anschließende Aktivierung und Differenzierung bestimmter Immunzellen sind 
entscheidend für die Entwicklung entzündlicher oder regulatorischer Prozesse. 
Aus diesem Grund konzentrierten und untersuchten wir das immunogenitäts-
abhängige Potenzial der kommensalen Bakterien Bacteroides vulgatus (schwach 
immunogen) und Escherichia coli (stark immunogen), um das Immunsystem des 
Wirts über die direkte oder indirekte Wechselwirkung mit Antigen-präsentierenden 
dendritischen Zellen und B Zellen zu modulieren und zu regulieren. Wir konnten (1) 
die Produktion von bakteriellen Vesikeln der Außenmembran als einen wichtigen 
speziesübergreifenden Signalmechanismus identifizieren, der immunmodulatorische 
Eigenschaften aufweist, um Wirtszielzellen zu primen; (2) die Aktivierung und 
Differenzierung eines toleranten dendritischen Zellphänotyps nachweisen, der durch 
den Symbiont B. vulgatus ausgelöst wird, um die Immunhomöostase 
aufrechtzuerhalten und wiederherzustellen; (3) aufzeigen, dass die Induktion von 
regulatorischen B-Zellen durch den Pathobiont E. coli ein entscheidender 
Gegenregulationsmechanismus zur Unterdrückung von entzündungsfördernden 
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Prozessen darstellt und dass diese Aktivierung von der Immunogenität des 
interagierenden Bakteriums abhängig ist. 
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1. The intestinal microbiota  
During their development, complex eukaryotic organisms are associated with large 
numbers of microbes including bacteria, fungi, viruses, and parasites [1, 2]. 
Colonization with commensal microbes starts in newborns right after birth and 
establishes its highest complexity in adults resulting in the formation of a versatile 
microbial ecosystem – the microbiota [3]. Microbes that live inside and on mammals 
and other complex organisms outnumber the eukaryotic host by an estimated 10-fold 
and thus function as a major selective force shaping eukaryotic evolution. This 
symbiotic relationship leads to the genesis of a metaorganism, sharing a common 
metabolome despite having a separate metagenome, in which both partners benefit 
from each other [4, 5].  
Besides the skin, the respiratory tract and the genitals, the highest numbers and 
variety of commensal bacteria reside in the intestine [6]. The intestinal microbiota 
harbors approximately 1013 microorganisms per gram luminal content predominantly 
occurring in the colon and distal ileum [6]. The mutualistic interaction of the host and 
intestinal microbiota influences and modulates various processes in the host such as 
(I) the extraction and processing of nutrients, (II) the integrity of the intestinal mucosal 
barrier, (III) angiogenesis, (IV) metabolism, (V) the colonization of pathogens, (VI) the 
development of innate and adaptive immune system and even (VII) the activity of the 
enteric nervous system [7-14]. Despite the microbiota has crucial effects, the 
mechanisms by which the gut microbial community influences the biology of the host 
organism remain insufficiently understood.   
    
1.1 Gut microbiota composition 
The composition of the microbiota is subject to a permanent and dynamic 
transformation. Due to many extrinsic and intrinsic properties, the gut microbiota 
composition is highly variable among distinct individuals [15]. Various environmental 
factors, diet, the presence of toxins and medication such as antibiotic treatments, 
influence the assembly of the microbiota. In addition, inherent properties of the host 
such as age, genetic background and psychology individually affect the constitution 
of the intestinal microbiota [16, 17].  
The intestinal microbiota of a healthy adult is mainly composed of seven major 
bacterial phyla: Gram-positive Firmicutes and Actinobacteria as well as Gram 
Introduction 
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negative Bacteroidetes, Proteobacteria, Fusobacteria, and Verrucomicrobia [18]. 
Among these, Firmicutes and Bacteroidetes bacteria represent 90% of all bacterial 
strains in intestinal microbiota [3, 15]. In detail, almost about 2000 different bacterial 
species that encode more than 5 million genes (microbiome) were identified, with 
numbers continuously increasing [19].  
Despite of a permanent dynamic change of this tremendous microbial society, there 
is a constant balanced state in healthy organisms with the aim of maintaining host-
microbiota homeostasis. However in a predisposed host influenced by intrinsic or 
extrinsic factors, a certain microbiota composition can be potentially harmful for the 
organism. This condition is termed as “dysbiosis” or “dysbacteriosis” and may 
predispose the host to a wide range of chronic diseases and infections [20].  
 
1.2 Commensals: symbionts and pathobionts 
The bacterial composition of the intestinal microbiota of a healthy host is diverse and 
consists of a heterogeneous pool of microorganisms. Thereby, microbiota members 
can not only be classified according to their phylogenetic origin but also divided into 
different functional groups, dependent on their effect on the host immune system [1]. 
In general, the gut microbiota is composed of commensals which are nonpathogenic 
or even beneficial for the host [2]. Furthermore, commensals can be subgrouped into 
probiotic, autobiotic/symbiotic and pathobiotic bacteria. Probiotics are usually 
obtained from diet and food supplements and defined by the Food and Drug 
Administration (FDA) and WHO as “live microorganisms which when administered in 
adequate amounts confer a health benefit to the host” [21]. Probiotic strains such as 
Lactobacillus casei and Bifidobacterium bifidum are especially prescribed to patients 
with an altered or disturbed microbiota after gastroenteritis or treatments with 
antibiotics [2, 21]. Symbionts are part of the basic microbiota and are permanently 
associated with the host organism. Symbiotic bacteria such as Faecalibacterium 
prausnitzii, Bacteroides fragilis and Bacteroides vulgatus possess important 
immunomodulatory functions to regulate inflammatory immune processes and to 
maintain host immune homeostasis [2, 22-24]. Pathobionts are defined as resident 
bacteria of the microbiota which can cause non-beneficial or detrimental effects on 
the host under certain genetic or environmental pre-conditions when the composition 
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of the microbiota or the host’s immunity is disturbed [2, 25]. This subgroup includes 
Escherichia coli, Helicobacter hepaticus and Clostridium difficile [1, 26].  
These different properties of symbiotic and pathobiotic bacteria, modulating and 
triggering inflammatory immune reactions in the host, have been demonstrated in 
various studies of our working group focusing on the induction of chronic and acute 
colitis in mice [24, 27-29].  
 
2. Microbiota-dependent autoimmune diseases 
Autoimmune diseases (AIDs) arise from a malfunctioning immune system or an 
abnormal immune response to self-tissue causing inflammation and destruction of 
tissues and/or organs [30]. The pathogenesis is not understood completely, but it is 
proposed that AID is a multifactorial disease in which environmental factors (life-
style, diet, drugs, infections) and certain genetic backgrounds contribute to the 
pathology [31, 32]. Based on their immunogenicity, intestinal symbionts and 
pathobionts have the ability to influence different physiological aspects of the host 
such as the immune system or metabolism and consequently might be a major 
player in autoimmunity and thus contributing to the pathogenesis of several diseases, 
including AIDs [13]. Thereby, the development of pathogenesis can result from an 
inappropriate and overshooting immune response directed against normally harmless 
commensal microbes or an ineffective clearance of immune-stimulatory 
microorganisms by an adequate proinflammatory immune response leading to a 
continuous activation of the immune system [13, 33].  
The manifestation of inflammatory bowel disease (IBD), which is characterized by 
chronic relapsing intestinal inflammation located either transmural in the whole 
gastrointestinal (GI) tract (Crohn’s Disease, (CD)) or only in the mucosa of the colon 
(Ulcerative Colitis, (UC)), is associated with changes in the microbiota composition in 
which a decrease in general complexity but also an increase in certain bacterial 
species is observable [34-36]. A shifted microbiota composition in the colon of IBD 
patients was demonstrated in various studies, for example, the proportion of 
Bacteroides species is markedly decreased in UC patients [32, 37-42]. However, no 
single bacterial strain or combinations of strains have been shown to directly cause 
or prevent IBD in humans.  
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In addition, there are correlative evidences that host gut microbiota can directly 
initiate autoimmunity and influence autoimmune disease that target tissues other 
than the intestine, such as Type 1 diabetes, multiple sclerosis, arthritis and psoriasis 
[43-46]. For instance, mice treated with antibiotics or reared in germ-free conditions 
show attenuated progression of experimental autoimmune encephalitis (EAE) a 
mouse model for multiple sclerosis [47-49]. Moreover, according to latest reports, the 
cause for neurodevelopmental disorders including schizophrenia and autism are 
connected to inflammatory processes suggesting that these diseases could also be 
associated to changes and dysbiosis in the intestinal microbiota [50-54]. These 
findings highlight the crucial influence of a disturbed or altered host microbiota 
composition on the progression of autoimmune disease located in intra- and extra-
intestinal tissue.   
 
3. Microbiota-host interactions 
The gastrointestinal tract is the main site of interaction between microorganisms and 
antigens with the host immune system. To control this intense cross-talk caused by a 
microbial load of >1012 bacteria/cm3 intestinal content, the immune system 
continuously monitors the resident microbiota and evolved certain antimicrobial 
mechanisms to prevent overgrowth of the colonizing microbes which could result in 
serious health consequences including inflammation and sepsis. Simultaneously, the 
Immune system has the challenge of remaining tolerant to food antigens and the 
commensal microbiota. The first strategy of the host to maintain immune 
homeostasis is the minimization of direct contact between intestinal bacteria and the 
epithelial cell surface (stratification), an area of approximate 200 m2 in humans. 
Stratification of microbes by the host is achieved via a microbial and chemical barrier, 
mainly composed of a ~150 µm thick viscous mucus layer [55]. This bisected mucus 
layer is assembled by intestinal goblets cells secreting mucin glycoproteins. The 
inner mucus layer additionally contains secretory immunoglobulin A (sIgA) produced 
by laminal propria plasma cells and antimicrobial peptides (AMPs) secreted by 
Paneth cells preventing microbial translocation across the epithelial barrier [56, 57]. 
The second line of defense consists of a single cell layer (10 µm) of intestinal 
epithelia cells (IECs), including distinct subpopulations connected with tight junctions 
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and associated with cytoplasmic actin and myosin network regulating intestinal 
permeability, which form a continuous physical barrier [58]. The third line of defense 
is composed of a multitude of different lamina propria immune cells forming a more 
specialized immunological barrier directed against penetrant bacteria to confine their 
exposure to the systemic immune system (compartmentalization) [59-62].  
A crucial step for the interplay between microbes and the host immune system and 
activation of the immunological barrier at intestinal epithelial interface is the adequate 
recognition of microbes and microbial compounds by immune cells. Thereby, the 
mucosal immune system can implement a preliminary discrimination between 
commensal bacteria, which provide basal signals to maintain a tolerant immune 
state, or pathogenic bacteria, which provoke maturation of the immune system and 
activation of specialized immune responses [63-65]. Intestinal epithelial, innate and 
adaptive immune cells are able to detect and recognize conserved bacterial 
molecular structures named microbe-associated molecular patterns (MAMPs) via the 
expression of pattern recognition receptors (PRRs) resulting in initiation of 
downstream signaling pathways [66]. Known signaling receptor families are RIG-like 
receptors (RLRs), C-type lectin receptors (CLRs), NOD-like receptors (NLRs) and 
Toll-like receptors (TLRs). RLRs initiate antiviral responses after recognition of viral 
RNAs [67]. CLRs are a large family of PRRs divided into 17 groups which bind 
carbohydrate ligands to induce immunity to fungi, bacteria, viruses, helminths and 
protozoa [68-70]. NLRs are cytoplasmic receptors whose activation caused by 
intracellular pathogenic microbes elicit the expression of cytokines, chemokines and 
defensins [71]. Nucleotide-binding oligomerization domain-containing protein 1 
(NOD1) and NOD2 are specialized NLRs that participate in detecting invading 
pathogenic microbes which multiply intracellularly [72]. The best-characterized PRRs 
in the intestinal mucosa are the type I transmembrane proteins of the TLR family. 
TLRs are composed of an extracellular domain made of Leucine-rich repeats (LRR) 
that recognizes specific MAMPs, a single transmembrane domain (TMD) and an 
intracellular Toll-interleukin 1 receptor (TIR) domain which is responsible for 
downstream signal transduction [73]. Ten human and twelve murine TLRs have been 
characterized, TLR1 to TLR10 in humans, and TLR1 to TLR9, TLR11, TLR12 and 
TLR13 in mice [74]. Nearly all TLRs are present in the human colon and are 
expressed on the cell surface or in internal cell compartments of IECs, macrophages, 
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dendritic cells or B cells [24, 75-78]. The signal transduction after interaction of TLRs 
with the respective MAMPs is mediated via interaction with one of the four identified 
accessory molecules MyD88, MyD88-adaptor-like (Mal/TIRAP), TIR domain-
containing adaptor-inducing interferon-β (TRIF) and TRIF-related adaptor molecule 
(TRAM) and triggers the activation of transcription factors such as nuclear factor 
'kappa-light-chain-enhancer' of activated B-cells (NF-κB), interferon regulatory factor 
(IRF) and activator protein 1 (AP-1) [79-82]. The activation of the transcription factors 
results in the synthesis of certain inflammatory cytokines and type I and type III 
interferons (INFs) dependent on the recognized antigen [83-87].  
The most intensively researched MAMPs that trigger the intestinal immunity of the 
host include lipoproteins/lipopeptides (Lpp), muramic acid which is part of the 
peptidoglycan (PGN) layer of bacterial cell wall, flagellin, unmethylated bacterial DNA 
CpG motifs and lipopolysaccharides (LPS) (Table 1, Figure 1). Extracellular binding 
of Lpps or PGN components leads to a heterodimerization of TLR2 with TLR1 or 
TLR6 respectively whereas the recognition of bacterial flagellin promotes the 
formation of TLR5-homodimers on the cell surface [88, 89]. The presence of CpG 
DNA in endosomes boost the activation of TLR9 [90]. The MAMP with a decisive 
immune response stimulatory property for the host immune system (immunogenicity) 
is LPS which is anchored in the bacterial outer membrane to protect the cell from 
surrounding and potentially harmful environment influences [91, 92] (Figure 1). In 
general, LPS consists of a lipid A part which is considered to mediate the 
immunogenicity of LPS and a core oligosaccharide (OS) (“rough” LPS). LPS which 
contains an additional O-antigen built from repeating units of usually not more than 
five different sugar moieties adjacent to the core OS are named “smooth” [93, 94]. 
The recognition of this general conserved structure by the MD-2/TLR4 receptor 
complex with the help of LPS binding protein (LBP) and soluble or membrane bound 
CD14 results in a conformational change of the MD-2/TLR4 heterodimer to initiate a 
(MD-2/TLR4)2 heterotetramerization [76, 95-100].  
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Table 1. Toll-like receptors with corresponding antigens 
 
Toll-like Receptors (TLRs) 
TLRs agonists/ligands source literature 
TLR1/TLR2 Triacyl lipopeptides Bacteria [101, 102] 
TLR2 
Lipoproteins multiple Pathogens [103] 
Peptidoglycan (PGN) Bacteria [104] 
Porins Bacteria [105] 
Zymosan Fungi [106] 
N-Glycan Fungi [107] 
GPI-mucin Protozoa [108] 
Envelope glycoproteins Viruses [109] 
TLR2/TLR6 
Diacyl lipopeptides Bacteria [110] 
Lipoteichoic acid (LTA) Bacteria [111] 
TLR3 
Double-stranded RNA Viruses [112, 113] 
Poly (I:C) 
Synthetic analog of double- 
stranded RNA 
[114] 
TLR4 
Lipopolysaccharide (LPS) Bacteria [91, 115] 
Glycoinositol-phospholipids Protozoa [116] 
Envelope glycoproteins Viruses [117] 
Host-derived HMGB1 and HSPs Endogenous [118, 119] 
TLR5 Flagellin Bacteria [29] 
TLR7 Single-stranded RNA Viruses [120-122] 
TLR8 Single-stranded RNA Viruses [121, 123] 
TLR9 
Unmethylated CpG DNA 
Bacteria 
[124] Protozoa 
Viruses 
Mitochondrial DNA Endogenous [125, 126] 
TLR10 unknown unknown - 
TLR11 
unknown uropathogenic Bacteria [127] 
Profilin Parasites [128] 
TLR12 unknown unknown - 
TLR13 unknown unknown - 
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3.1 Outer membrane vesicles 
For the inter-kingdom cross-talk between microbe and host and the interaction with 
the immune system, involvement of a whole and viable bacteria cell is not 
fundamental, since, as described previously, specific bacterial structures (PGN, LPS, 
Flagellin, DNA, LPS) are sufficient to promote the activation of an immune response. 
With the release and secretion of MAMPs which are small enough to transfer through 
the mucus and IEC layer, bacteria are able to manipulate and modulate the immune 
system of the host without a direct physical interaction with the target cells [129] 
[130]. Moreover, microbes not only locally influence the immune status at the sites of 
colonization, they can also affect peripheral immune cell populations and contribute 
to disease pathology at distal sites [86, 131].  
In this context, the biogenesis and release of outer membrane vesicles (OMVs) by 
Gram-negative bacteria represent a secretion pathway combining the long-distance 
traveling ability of small soluble bacterial products with mimicking the characteristics 
of the whole bacterial cell [24, 132, 133]. Usually, these spherical structures, ~20-250 
nm in diameter, are composed of the outer membrane (OM) of the bacterial cell 
surrounding a periplasmic space. Consequently by the assembly, OMVs contain a 
multitude of cellular structures and components which differ from vesicle to vesicle 
depending on the parental cell. The protein profile of OMVs is comprised of OM 
structure proteins, porins, ion channels, transporter molecules as well as periplasmic 
and cytosolic enzymes and proteins [134, 135]. In particular incorporated enzymes 
such as proteases, peptidase, nucleases and β- lactamases and also toxins and 
other virulence factors have a decisive influence on the interaction with the host. In 
addition to proteins, OMVs deliver phospholipids as important agonist for PRRs of 
host target cells [136, 137]. Interestingly, the phospholipid composition of the OM of a 
viable bacterial cell differs in comparison to the composition of the OM of secreted 
vesicles. In Pseudomonas aeruginosa, the OM consists predominantly of 
phosphatidylethanolamine whereas P. aeruginosa OMVs include a phospholipid 
bilayer with higher proportion of phosphatidylglycerol [135]. As important MAMP, LPS 
are also present as component of OMVs [137]. Furthermore, RNA and DNA are 
transported via OMVs in the form of circular plasmids, linearized plasmids and 
chromosomal fragments after active transfer across the periplasm during the 
biogenesis or after the uptake of extravesicular DNA fragments [138, 139].  
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In the first step of the OMV biogenesis, the OM is detached from the peptidoglycan 
due to faster growth of the OM membrane compared to the inner membrane (IM) 
[140, 141]. Additionally, the accumulation of periplasmic materials such as misfolded 
proteins and PGN fragments between the OM and the peptidoglycan leads to an 
increased turgor resulting in the bulging of the OM [142]. Degradation of covalent and 
non-covalent protein interaction of the OM and the PGN layer leads to an 
enlargement of the vesicle volume and ultimately to the formation of bottleneck 
shape constriction ending in the blebbing of the OMV in the extracellular milieu 
(Figure 1).  
 
Figure 1. Biogenesis of bacterial outer membrane vesicles (OMVs). Due to a faster growth of the 
outer membrane (OM) in contrast to the peptidoglycan (PGN) layer and the inner membrane (IM) a 
bulge is formed. Concurrently, an increased turgor develops cause of the accumulation of periplasmic 
material such as misfolded proteins. The lateral transfer of proteins and the degradation of covalent 
and non-covalent protein interaction of the OM and the PGN layer lead to an enlargement of the 
vesicle volume and ultimately to the formation of bottleneck shape constriction ending in the blebbing 
of the OMV in the extracellular milieu. 
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The release of OMVs seems to be a strict regulated and conserved process and is 
subject to targeted functions [143] (Figure 2). Under alternating physical and 
chemical environmental conditions, the amount of produced and secreted OMVs by 
the bacteria cell also changes. During nutrition shortage, on the one hand OMVs are 
able to deliver in their lumen transported enzymes which degrade complex 
biomolecules in the extracellular surrounding to make them accessible for the uptake 
by viable bacteria and on the other hand, OMVs can collect and accumulate limited 
metal ions for the association with parental cells [143]. As stress response 
mechanisms during temperature or pH changes, the bacterial cell discharges 
misfolded or overexpressing proteins via OMVs [144]. Furthermore, OMVs act as 
decoys for antibacterial substances or bacteriophages and can consequently reduce 
the concentration of these substances in the surrounding milieu (“passive immunity”) 
[145, 146]. Inactivation of antibiotics by OMV-localized proteases, peptidases and 
other enzymes has also been demonstrated [147]. The far-reaching influences on 
other organisms have OMVs as transport vehicles of different components. OMVs 
carry quorum sensing molecules for the long distance inter- and intraspecies 
communication. Containing small DNA fragments, OMVs are involved in the 
horizontal gene transfer between species [148]. Microorganisms competing for the 
same niche secret antimicrobial substances with bacteriolytic activities via OMVs to 
target specific killing of non-self-bacteria [149-151]. In addition to autolysins, 
virulence factors, cytotoxins and endotoxins are transported by OMVs which results 
in an immune-activating interaction with eukaryotic cells and thus leading to an 
modulation of the host immune system [152]. OMV production may also contribute to 
biofilm formation [144, 153-156]. 
 
The vesicle secretion is regarded as a separate secretion system with advantage for 
the bacterial cell over other systems: (1) bacterial lipids, membrane proteins and 
other hydrophobic molecules can be released from the parental cell; (2) via OMV 
secreted material is protected from active enzymes and components of the 
extracellular space; (3) OMVs enable the transport of luminal and membrane-
embedded accumulated material in high concentrations; (4) MAMPs in the vesicle 
lumen and anchored in the OM of the vesicles are able to interact with the target cell 
and are accessible for the host immune system.   
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Therefore, the release of OMVs equipped with DNA fragments, autolysins, 
cytotoxins, virulence factors and a variety of other biomolecules constitutes a critical 
mechanism for intra- and inter-kingdom communication [24, 143, 157, 158]. 
    
 
Figure 2. Potential functions of outer membrane vesicles (OMVs). OMVs deriving from different 
bacteria fulfill a cornucopia of specialised functions in inter- and intraspecies communication. The 
cargo of OMVs includes quorum sensing proteins, toxins, enzymes for the digestions of nutrients, 
misfolded proteins, DNA/RNA to initiate horizontal gene transfer and other immune-modulatory 
structures such as microbe-associated molecular patterns (MAMPs) which interacting with the host 
immune system. In addition, secreted OMVs are involved in the formation of biofilms and serve as a 
passive immune system for the bacteria by representing a decoy for antibacterial substances, 
bacteriophages and antibiotics. 
 
4. The mucosal immune system 
The mucosal immune system is comprised of a highly specialized and complex 
interplay between innate and adaptive immune mechanisms, which are activated and 
modulated by the interaction of colonizing bacteria with the gut-associated lymphoid 
tissues (GALT) consisting of the Peyer’s patches (PP), mesenteric lymph nodes 
(mLN) isolated lymphoid follicles and cells residing in the lamina propria [159, 160].  
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As soon as commensal microbes surmount the microbial and chemical barrier 
(mucus layer, AMPs, sIgA) and translocate through the physical barrier (epithelial cell 
layer), they are either rapidly engulfed and neutralized by tissue-resident 
macrophages or recognized and captured by PRRs on dendritic cells (DCs) [57, 59]. 
In the latter, these antigen-loaded DCs implement a maturation and licensing and 
traffic from peripheral lymphatic tissue to the mLN to present processed commensal 
antigens via a peptide:MHC complex to naïve T cells and B cells which results in the 
differentiation of commensal-specific T helper (Th) cells and IgA-producing B cells. 
The strength of lymphocyte activation by DCs is dependent on the maturation state of 
the antigen-presenting cell (APC) [28, 91, 161]. The maturation in turn depends on 
the immunogenicity of the recognized microbial antigen and is characterized by a 
high and long-lasting expression of MHC class I or II and co-stimulatory proteins 
such as clusters of differentiation (CD) 40, CD80 and CD86 on the cell surface [24, 
162, 163].  
The re-trafficking of activated commensal-specific lymphocytes to the lamina propria 
and PPs and the prevailing microenvironmental cytokine milieu created by 
intraepithelial lymphocytes (IEL), mast cells (MCs) and macrophages, determine the 
outcome of the immune response. In this context, APC-activated CD4+ T helper cells 
direct the type of immune response against commensals and pathogens: Th1 cells 
(key cytokine: IFNγ, transcription factor: T-bet) are developed due to the response to 
intracellular viral and bacterial pathogens; Th2 cells (key cytokine: IL-4, transcription 
factor: GATA-3) are required for the host defense against extracellular pathogens 
and induction of humoral immunity; Th17 cells (key cytokine: IL-17, transcription 
factor: RORγt) are involved in mucosal immunity and autoimmune disorders; 
regulatory T (Treg) cells (key cytokine: IL-10, transcription factor: FoxP3) are 
responsible for the maintenance of immune homeostasis through suppression of 
differentiation and activity of pro-inflammatory T helper cells [164, 165]. 
 
At steady state, evoked by constitutive sensing of commensal microbes, most IL-17 
and IL-22-producing Th17 and IFNγ-producing Th1 cells are found in the GI tract 
fulfilling important homeostatic roles by inter alia influencing epithelial cell function 
[1]. IL-10-secreting Tregs can also accumulate in the intestine and complement 
immune homeostasis by exhibiting immunosuppressive functions [166]. Especially 
the differentiation of Tregs is initiated by certain commensal microbiota members and 
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their structural cell components as it was demonstrated for the polysaccharide A 
(PSA) of Bacteroides fragilis delivered by outer membrane vesicles [1, 86]. The 
provocation of the mucosal immune system caused by increased numbers of 
commensal and immunogenic bacteria translocating through a leaky epithelium 
resulting in a disturbed Th1/Th2/Th17/Treg balance are believed to be associated 
with pathogenesis of several local and systemic (autoimmune) diseases [164, 167-
169].  
Such a constellation is prevalent in IBD patients, where the epithelial barrier is leaky 
and innate immune responses are altered. In addition, the expressions of PRRs such 
as TLR4 are strongly upregulated leading to a disturbed antigen recognition and thus 
to the induction of Th1 and Th17 cell-driven pro-inflammatory responses [170, 171]. 
Further, IECs, which normally participate in balancing T cell responses, activate 
further effector T cells instead of inducing T cell anergy. The imbalance of activated 
effector and regulatory T cells results in the production and release of inflammatory 
cytokines such as IL-12, IL-18, TNF-like 1A and IFNγ which consequently stimulate 
the secretion of IL-1, TNFα and IL-6 from macrophages [171]. The changed cytokine 
profile in the lamina propria leads to the inhibition of anti-inflammatory cytokine 
secretion such as IL-10 by Tregs and to a mal-functioning counter-regulation of pro-
inflammatory immune processes [1].  
 
As described above, the activation and regulation of the host immune system 
requires the cooperative activities of various cell types that possess specialized 
functions during the response against microbes to either initiate a proper clearance of 
penetrating bacteria or to exhibit immune tolerance for the maintenance of immune 
homeostasis. Especially APCs are an important cell type connecting the innate and 
adaptive immune response by the recognition, transport and presentation of antigens 
to other immune cells and secretion of a certain set of soluble proteins.   
 
4.1 Tolerant dendritic cells (DCs) 
With the production of prominent TLRs, DCs are among the first PRR-expressing 
cells encountering components of the intestinal microbiota [172]. Originated in the 
bone marrow, DCs comprise a heterogeneous leukocyte population patrolling 
lymphoid and non-lymphoid organs [161, 172]. Activated DCs orchestrate the 
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induction of an adaptive immune response against pathogens while simultaneously 
maintaining tolerance to self-antigens and the commensal microbiota [161, 173]. In 
the process, the functionality of DCs is dependent on their maturation state. The 
maturation program in DCs is initiated by antigen sampling such as the binding of 
agonistic LPS to the MD-2/TLR4 complex and determines the efficiency of antigen 
processing and the subsequent antigen presentation [24, 161]. The mature 
phenotype in DCs is characterised by upregulated expression of MHC-II and co-
stimulatory molecules CD40, CD80 and CD86 which are essential for a proper T cell 
activation and accompanied by the secretion of pro-inflammatory cytokines such as 
TNFα, IL-1β, IL-6 and IL-12 [162, 163, 174-176]. Depending on the origin of the 
recognized antigen, DCs can develop different maturation phenotypes which are 
strongly distinct from a classical mature state. It has been demonstrated that semi-
mature or tolerant DCs play an crucial role for the prevention of intestinal 
inflammatory processes by maintaining intestinal immune homeostasis [24, 27, 28, 
91, 177, 178]. This phenotype is hyporesponsive towards subsequent stimuli and 
possess tolerogenic properties by the mediation of unresponsiveness of T cells, the 
induction of Tregs, inhibition of pro-inflammatory Th1 and Th17 cell responses and 
the promotion of T cell apoptosis or anergy [161, 179].    
 
4.2 Regulatory B cells (Bregs) 
Besides DCs, B cells are involved in the establishment of a proper immune response. 
Thereby, B cells, as part of the humoral immune system, are commonly known as 
producers of antibodies augmenting immune responses and hence also contribute to 
the pathogenesis of autoimmune diseases [180]. In addition to the production of 
antibodies, B cells express PRRs such as TLRs and consequently serve as 
professional APCs after encountering MAMPs. They are capable of presenting 
antigens 103-fold to 104-fold more efficiently than non-professional APCs because of 
high expression levels of MHC-II and co-stimulatory proteins such as CD80 and 
CD86, which can induce optimal T cell activation [181, 182]. Additionally, B cells 
provide co-stimulatory signals and produce a multitude of cytokines to promote naïve 
CD4+ T cell differentiation into Th1 or Th2 subsets either by direct interaction (surface 
molecules) or via soluble proteins (cytokine secretion) [183, 184]. A specific B cell 
phenotype with crucial effects on the proliferation and polarization of T helper cells 
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are regulatory B cells (Bregs) [185]. Certain Breg phenotypes are characterized and 
described, but they differ in their expression of surface proteins. However, these 
phenotypes possess similar functionalities including the potent suppression of Th1 
cell differentiation, the inhibition of autoimmune pathogenesis and the maintenance 
of immune homoeostasis [186-193]. A common and most important feature of Bregs 
to perform these regulatory functions is the production and secretion of the anti-
inflammatory cytokine IL-10. IL-10 fulfils regulatory functions by effectively 
suppressing cell-mediated inflammatory responses, thus restoring Th1/Th2 balance 
[194-197]. In addition to the production of IL-10, Bregs express and secrete 
suppressive molecules such as CD73, programmed death ligand 1 (PD-L1), Fas 
ligand (FasL), glucocorticoid-induced tumour necrosis factor receptor-related protein 
ligand (GITRL) and Epstein-Barr virus induced gene 3 (EBI3) and thus possess 
further mechanisms to regulate immune responses in an IL-10 independent manner 
[198-210]. The combination of these molecules perfect regulatory B cells to a strong 
immune-suppressive cell subset maintaining immune homeostasis and even 
attenuating inflammatory processes in autoimmune disease. 
  
 Aim of this work  
 
In previous studies our group could demonstrate that the composition of the intestinal 
microbiota has decisive influences on the induction or prevention of inflammatory 
immune responses affecting the development and progression of colitis. In detail, we 
uncovered the immune regulatory features of an intestinal commensal of the 
Bacteroides genus. The symbiont Bacteroides vulgatus mpk is competent to alleviate 
disease pathologies by inhibition of inflammatory immune processes and restoration 
of immune homeostasis in different mouse models of experimental colitis [27, 176, 
177]. The maintenance of immune tolerance by B. vulgatus is mediated via the 
induction of a semi-mature phenotype in DCs [24, 28]. In contrast, pathobiotic E. coli 
mpk causes pro-inflammatory host responses and exhibits strong colitogenic 
potential in genetically predisposed host (deficient for Rag1 or IL-2) [178].  
Here, we were interested to further decipher the interaction mechanisms of B. 
vulgatus and E. coli with the host and the resulting modulation of the immune system.  
We want to show that the secretion of outer membrane vesicles is a potent inter-
kingdom communication mechanism to prime the host immune system by induction 
of semi-mature DCs. Further, we want to clarify which PRRs are involved in the 
recognition of B. vulgatus or E. coli-derived MAMPs and thus are crucial for the 
differentiation of DCs. To verify these immune-modulatory properties, we investigate 
the immunogenicity-dependent potential of symbiotic B. vulgatus (weak 
immunogenic) and pathobiotic E. coli (strong immunogenic) to regulate the immune 
system of the host via B cells with the main focus on the immune counter-regulative 
properties of regulatory B cells (Bregs). 
Overall, we want show how different commensal members of the microbiota, 
represented by B. vulgatus and E. coli, immunogenicity-dependently activate, 
modulate and regulate the host immune system to maintain immune tolerance and 
even suppress intestinal inflammatory processes in vitro by interplay between DCs, B 
cells and T cells and in vivo in immune predisposed and immune competent host.
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Results of the following submitted or accepted publications and manuscripts 
are summarized and discussed in the individual “Results and discussion” 
sections: 
a Maerz J.K., Steimle A., Lange A., Bender A., Fehrenbacher B., Frick J.S.: 
Outer membrane vesicles blebbing contributes to B. vulgatus mpk-mediated immune 
response silencing. Gut Microbes 9 (1): 1-12 (2018) 
 
b Steimle A., Michaelis L., Di Lorenzo F., Kliem T., Münzner T., Maerz J.K., 
Schäfer A., Lange A., Parusel R., Gronbach K., Fuchs K., Silipo A., Öz H.H., Pichler 
B.J., Autenrieth I.B., Molinaro A. and Frick J.S.: Weak Agonistic LPS Restores 
Intestinal Immune Homeostasis. Molecular Therapy pii: S1525-0016(19)30319-3. 
(2019) 
 
c Maerz J.K., Trostel C., Lange A., Parusel R., Michaelis L., Schäfer A., Yao H., 
Löw H. and Frick J.S.: Bacterial immunogenicity is critical for the induction of 
regulatory B cells in suppressing inflammatory immune responses. Front. Immunol. 
10:3093.doi: 10.3389/fimmu.2019.03093 (2020)  
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1. Outer membrane vesicle secretion contributes to B. vulgatus –
mediated immune response silencing 
 
Bacteroides vulgatus belongs to one of the two predominant phyla of the intestinal 
microbiota: the Bacteroidetes. Bacteroidetes are contribute to host nutrient 
metabolism, maintenance of structural integrity of the gut mucosal barrier, protection 
against pathogens and immunomodulation of the immune response to mediate a 
healthy host-microorganism balance and prevent disease development [18, 211-
213]. 
The immunomodulatory properties of some Bacteroides species have already been 
demonstrated [2, 27, 214]. Especially our group could show that B. vulgatus mpk 
exhibit inflammation-silencing effects leading to the prevention of intestinal 
inflammation in experimental mouse models for colitis [27, 176-178, 215, 216]. The 
anti-inflammatory capabilities of symbiotic B. vulgatus are mediated by the interaction 
with DCs and the resulting differentiation of a semi-mature phenotype maintaining 
immune tolerance [28, 162, 177, 178]. However, direct physical interaction between 
intestinal commensals and DCs in the colonic lamina propria (cLP) is limited due to 
the presence of a thick and almost sterile mucus layer covering the intestinal 
epithelium [24]. Therefore we were interested to identify and investigate the 
responsible interaction mechanisms between B. vulgatus mpk and host immune cells 
for the initiation of maturation programs in DCs [24]. In this context, the biogenesis 
and release of bacterial outer membrane vesicles (OMVs) by Gram-negative bacteria 
represent a possible communication mechanism with host target cells [24]. This 
secretion pathway combines the long-distance traveling ability of small soluble 
bacterial compounds which facilitated the transport of insoluble molecules by 
mimicking the characteristics of the whole bacterial cell and translocation not only 
through the mucus layer but also the intestinal epithelial cell barrier and entering the 
systemic circulation and affecting the permeability of the blood-brain barrier [24, 132, 
133, 157, 158, 217-220]. Derived from the bacterial outer membrane, OMVs 
transport certain MAMPs which modulate the innate and adaptive immune responses 
by either directly or indirectly interacting with PRRs of host target cells and 
consequently regulate the course of inflammation in various disease models in mice 
[10, 217, 221-223].  
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These findings reveal B. vulgatus-derived OMVs as interesting immunomodulatory 
bacterial components that can function as potential inducers of tolerant, semi-mature 
DCs.  
 
B. vulgatus produce OMVs which are internalized by CD11c+ cells 
Secretion of OMVs by B. vulgatus (OMVBV), the direct interaction with immature 
BMDCs and the capability to induce semi-mature DCs have to be assessed. Bacteria 
were incubated under different culture conditions and for different time periods to 
demonstrate the ubiquitous bulging of the outer membrane and the release of OMVs, 
which could be verified by transmission electron microscopy (TEM) (publication a, 
figure 1A). In addition, an internalisation timeline assay using CD11c+ DCs in 
combination with different concentrations of fluorescein isothiocyanate (FITC)-labeled 
vesicles was established and performed (publication a, figure 1G). After an 
incubation time of 30 min with 5 µg µL-1 OMVs, the population of CD11c+OMVBV
+ 
cells increased with reaching a maximum of 86.3% after 180 min. Our results are in 
accordance with other studies demonstrating that OMVs derived from B. fragilis, B. 
thetaiotaomicron or E. coli Nissle 1917 promote their immunomodulatory properties 
via the uptake and entrance of epithelial cells and macrophages [217, 221, 224]. 
 
B. vulgatus OMVs induce tolerant CD11c+ cells 
To verify that the interaction of B. vulgatus-derived OMVs modulates the immune 
response in vivo and in vitro in an inflammation-silencing manner, the activation and 
maturation of CD11c+ dendritic cells after 24 h stimulation with different vesicle 
concentrations compared to the challenge with viable, weak immunogenic B. 
vulgatus and strong immunogenic E. coli was determined (publication a, figure 1B)  
[24, 27, 225]. The stimulation of BMDCs with isolated OMVBV leads to the 
comparable maturation state and semi-mature DCs phenotype like the stimulation 
with viable B. vulgatus since the analysis of MHC-II and T cell co-stimulatory proteins 
CD40, CD80 and CD86 was represented by a similar intermediate surface 
expression (publication a, figure 1D). These results are in line with the characteristics 
of a semi-mature or tolerant phenotype of CD11c+ cells: the inability to promote a 
pro-inflammatory immune response by the induction and activation of Th1 or Th17 
cells [161]. In addition to the lower expression of MHC-II, CD40, CD80 and CD86 in 
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tolerant CD11c+ BMDC in comparison to the fully maturated cell phenotype (e.g. 
provoked by viable E. coli), the hyporesponsiveness towards subsequent maturation 
stimuli is part of the definition of semi-mature DCs [28, 176, 226]. Therefore further 
re-stimulation experiments were performed and could demonstrate that a first 
immune priming of CD11c+ DCs with OMVBV or the viable bacteria result in the 
preservation of the maturation state despite of a second immune challenge with 
strong immunogenic E. coli. Both MHC-II expression and secretion of the pro-
inflammatory cytokine by BMDCs is lower and unaltered compared to PBS-primed 
and E. coli-challenged cells (publication a, figure 1F).  
Thereby it was demonstrated that B. vulgatus secreted OMVs mimic the 
characteristics of the whole bacterial cell and were sufficient to induce tolerance in 
CD11c+ cells by the prevention of further maturation processes and pro-inflammatory 
responses. 
 
OMV-mediated immunomodulatory properties signal via host TLR2 and TLR4 
The interaction of B. vulgatus-derived OMVs with CD11c+ DCs and the resulting 
promotion of semi-mature DCs with tolerant immunomodulatory properties were 
proven. However for further experiments and possible therapeutical application, the 
exact mechanisms of bacteria-host recognition and the involved PPRs and MAMPs 
for signal transduction have to be identified. TLR4- as well as TLR2-agonists are 
prominent MAMPs exhibiting strong immunogenic properties and can be integrated 
into OMVs [76, 93, 227-229]. The stimulation of human embryonic kidney (HEK) cells 
overexpressing murine TLR2 and CD14/TLR4/MD-2 receptor complex with OMVBV 
resulted in a concentration-dependent activation of the NF-κB signaling pathway and 
consequently to the secretion of IL-8. This confirmed the presence and transport of 
both TLR2- and TLR4- antigens by B. vulgatus-derived OMVs (publication a, figure 
2A). For validation, BMDCs isolated from Tlr2-/-, Tlr4-/- and Tlr2-/-xTlr4-/- mice were 
stimulated with OMVBV, viable B. vulgatus or E. coli (publication a, figure 2B). The 
deficiency of both TLRs on the cell surface leads to a complete impairment of antigen 
recognition independent of the used stimulus as implied by the low expression of 
MHC-II and CD40 and a marginal secretion of TNFα and IL-6 of Tlr2-/-xTlr4-/- CD11c+ 
BMDCs (publication a, figure 2C) [24].  
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The still increased expression of MHC-II and CD40 as well as the secretion of TNFα 
and IL-6 in Tlr2-/- BMDCs underline the importance of a TLR4 agonist for the 
maturation of DCs since maturation signals are markedly diminished in Tlr4-/- CD11c+ 
BMDCs. However, to confirm that TLR4 ligands obtained by OMVBV or viable B. 
vulgatus are solely sufficient to induce hyporesponsiveness and tolerant DCs and to 
investigate the involvement of TLR2 agonist, Tlr2-/- BMDCs were primed with OMVBV, 
viable B. vulgatus or E. coli for 24 h and challenged for additional 16 h with E. coli 
(publication a, figure 2D). The deficiency of TLR2 on BMDCs leads to susceptibility to 
further stimuli characterized by a changed and increased expression of MHC-II and 
enhanced production of the cytokines TNFα and IL-6 in OMVBV and viable B. 
vulgatus-primed and E. coli-challenged BMDCs compared to mock control 
(publication a, figure 2E). Consequently, an additional TLR2-dependent signaling is 
accessory required for adequate activation and differentiation of semi-mature BMDCs 
and suggests that both TLR4 and TLR2 ligands are requisite for the induction of 
tolerant BMDC to prevent pro-inflammatory responses. 
These findings are in line with previously published results demonstrating the anti-
inflammatory activity of OMV-transported Polysaccharide A (PSA) sensed via host 
TLR2 and TLR4 receptors [221, 230]. The binding of PSA to TLR2 leads to the 
induction of FoxP3+ regulatory T cells which regulates the activation of host immune 
system and maintenance of immune homeostasis [22, 24, 231]. In addition, the 
simultaneous interaction of different MAMPs with different host receptors might result 
in complementary, synergistic or antagonistic effects that modulate innate and 
adaptive immunity [24, 232-235].  
In conclusion, OMVs derived from symbiotic intestinal commensal B. vulgatus exhibit 
host immune system modulatory and regulatory properties by mimicking the parental 
bacterial cell. Furthermore, with their combined qualities of crossing physical barriers 
and the mediation of endotoxin tolerance and even cross-tolerance in DCs via the 
delivery of different MAMPs to target immune cells, the production of OMV 
represents an important key feature of this symbiotic strain to prevent from intestinal 
inflammation in the host [24].  
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B. vulgatus -mediated induction of tolerant DC phenotype and the resulting 
restoration of intestinal immune homoeostasis is dependent on the weak agonist LPS 
As demonstrated above, the involvement of host TLR4 is mainly responsible for the 
activation and differentiation of host immune cells after antigen recognition. 
Lipopolysaccharides (LPSs), generated by Gram-negative bacteria, are one of the 
most abundant TLR4 agonists promoting potent immunomodulatory effects [91]. 
These effects ranging from strong immunogenic activation of the host immune 
system (agonistic) to a complete block of immune responses (antagonists), are 
dependent on the chemical structure and composition of lipid A which determine the 
biological activity of LPS [91, 93, 228, 236]. To avoid overstimulation of intestinal 
immune cells by the large load of strong agonistic LPS present in the GI content 
resulting in an overshoot of the immune response, the host developed and initiated 
endotoxin tolerance mechanisms [91]. The induction of endotoxin tolerance has been 
detected in vitro and in vivo both in animal models and humans but the underlying 
molecular mechanisms still remain incompletely understood [91, 237]. One 
mechanism is established by the semi-maturation of DCs characterized by 
hyporesponsiveness toward a second LPS (endotoxin) encounter through receptor 
desensitization as a result of a first LPS stimulus [24, 91, 161, 238].  
As already demonstrated in previous experiments, OMVBV and viable B. vulgatus 
induce tolerant CD11c+ cells exhibiting immunomodulatory properties and 
consequently contributing to the prevention of inflammation processes in several 
mouse models for experimental colitis (publication a, figure 1F) [24, 27, 28, 216]. It is 
conceivable that this effect is mainly mediated by the interaction of LPS derived from 
OMVBV and viable B. vulgatus (LPSBV) with the respective PRR. To verify the 
hypothesis that LPSBV is crucial for the induction of hyporesponsive CD11c
+ cells, 
LPS of B. vulgatus or E. coli (LPSEC) were isolated and purified by the removing cell, 
growth medium and capsular contaminations and the enzymatic treatment to exclude 
proteins and nucleic acids [91]. Stimulation of CD11c+ BMDCs with LPSBV or LPSEC 
resulted in the same BMDC phenotype as stimulation with the respective bacteria 
from which the LPS was isolated (publication b, figure 3A) [91]. To confirm the 
hyporesponsiveness of LPSBV-primed BMDCs towards a secondary stimulus, cells 
were subsequently challenged with either E. coli or PBS as a negative control 
(publication b, figure 3B). The results demonstrate that isolated LPS of B. vulgatus 
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induces hyporesponsive semi-mature CD11c+ cells (publication b, figure 3C). To 
confirm that isolated LPSBV provides the same semi-maturation-inducing capacities 
and mediates prevention of intestinal inflammation in mice with established colitis 
comparable to viable B. vulgatus, T cell-transplanted Rag1-/- mice were administered 
with LPSBV (publication b, figure 4A) [24, 28, 91, 178]. The treatment after 4 weeks of 
T cell transfer and colitis induction with LPSBV and B. vulgatus led to a significantly 
lower intestinal inflammation compared to non-treated mice elucidated by H&E-
stained colonic sections and histological colitis score (publication b, figure 4B+C). 
This result infers that administration of purified LPSBV reduces established intestinal 
inflammation in a mouse model of experimental colitis [91].  
Detailed studies on the breakdown of the exact structure of B. vulgatus-derived LPS 
and the binding to host PRR are ongoing; however, it is suggested that the weak 
agonistic activity of LPSBV for the interaction with the MD-2/TLR4 receptor complex 
ameliorate inflammation processes through the induction of semi-mature CD11c+ 
cells and consequently through the mediation of endotoxin tolerance toward strong 
immunogenic endotoxins [24, 91].   
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2. Bacterial immunogenicity is critical for the induction of tolerant and 
regulatory immune cell phenotypes resulting in the suppression of 
inflammatory immune responses 
 
In preceding experiments, the immune regulatory features of the intestinal 
commensal Bacteroides vulgatus mpk were investigated. By the induction of a 
tolerant semi-mature phenotype in dendritic cells, B. vulgatus is competent to inhibit 
inflammation development and maintain immune homeostasis in immune 
compromised host [24, 27, 28, 176, 177]. In contrast, the stimulation with pathobiotic 
E. coli induces fully mature DCs characterized by a high expression of T cell 
activation markers and strong production of pro-inflammatory proteins, concluding 
that a potent TLR activation provided by strong immunogenic bacteria leads to 
enhanced immune responses, aggravating the course of disease [24, 27, 28, 161, 
176-178]. Thus, the different immunogenic properties of commensal bacteria affect 
the differentiation and maturation of certain immune cells. The immunogenicity of 
bacteria is pivotal for the strength of provoking an immune response. As 
demonstrated in recently published studies, the immunogenicity is dependent on the 
structure of different MAMPs (e.g. LPS) and consequently to the binding affinity to 
PRRs (publication a, publication b) [24, 91].   
To investigate the immunogenicity-dependent potential of weak immunogenic B. 
vulgatus and strong immunogenic E. coli on the activation and differentiation of other 
immune cells (in addition to DCs) and consequently the modulation and regulation of 
host immune system, the direct interaction of bacteria with naïve B cells was 
analysed.  
The fact that B cells play a critical role during the onset and course of inflammatory 
processes is indisputable and has been demonstrated in many studies in both mouse 
and humans e.g. multiple sclerosis (MS) [239-241]. However, B cells are not only the 
producer of antibodies but also fulfill multifaceted functions within the immune 
system. B cells are capable of efficiently present recognized antigens by the high 
expression of MHC-II and, in combination with costimulatory proteins such as CD80 
and CD86 and the secretion of soluble proteins, induce optimal T cell activation [242, 
243]. 
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Therefore, it is important to discriminate between the versatile functions of B cells. 
More and more studies have revealed that the depletion of B cells leads to an 
aggravation of disease in many autoimmune disorders such as inflammatory bowel 
disease (IBD) and rheumatoid arthritis (RA) [244]. B cells were shown to mediate an 
anti-inflammatory effect in mice that spontaneously develop chronic colitis, exhibiting 
more severe disease in the absence of B cells [245-249]. Even in experimental 
autoimmune encephalomyelitis (EAE), an animal model for MS, CD20 antibody-
mediated B-cell depletion substantially exacerbated the disease when the treatment 
was initiated before EAE induction [250-252]. This may link the activation of 
functional B cells with a suppressive effect in inflammation by promoting immune 
tolerance. The beneficial influence of B cells during inflammatory processes is 
primarily attributable to a specific B cell population – regulatory B cells (Bregs) [185, 
186]. The main features of Bregs include the potent suppression of Th1 cell 
differentiation, the inhibition of autoimmune pathogenesis and the maintenance of 
immune homoeostasis [187]. Only few studies have been published that investigate 
the direct interaction of B cells with viable bacteria in vitro and in vivo. It has thus far 
been shown that several bacterial and viral pathogens, as well as parasites, 
manipulate B cell function directly to modulate host immune responses as part of an 
immune evasion strategy facilitating their survival and prolonging infection 
(publication c) [210, 253-256]. 
Therefore, the focus is on the different activation and induction of Bregs by 
commensal bacteria with low immunogenicity (B. vulgatus) and strong 
immunogenicity (E. coli) in vitro, the cellular interplay between B cells, DCs and T 
cells to mimic in vivo like condition and the emerging potential to maintain immune 
tolerance and even suppress intestinal inflammation processes in vivo. 
 
B cell activation and maturation via strong immunogenic E. coli are TLR-dependent 
To show the direct interaction of B cells with B. vulgatus and E. coli and the 
recognition of MAMPs via B cell-expressed PRRs, viability and proliferation of wild 
type (WT) and Tlr2-/-xTlr4-/- isolated naïve B cells after stimulation for several time 
periods were analyzed. The longevity and proliferation of naïve B cells is strongly 
dependent on a potent stimulus provided by strong immunogenic E. coli since 
survival of B cells decreased significantly 24 h after stimulation with PBS (mock) or B. 
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vulgatus (publication c, figure 1A+B). In addition, TLR2xTLR4-deficiency on naïve B 
cells caused a hyporesponsiveness of B cells toward E. coli and B. vulgatus resulting 
in an increased mortality and lack of proliferation, indicating that the activation of 
naïve B cells depends on a robust bacterial interaction with TLR2 or TLR4 on the 
surface of B cells. Interestingly, maturation and differentiation of naïve WT B cells, 
characterized by the increased production and expression of MHC-II, CD80, CD86 
and IgM, were significantly upregulated in response to strong immunogenic E. coli 
(publication c, figure 1C). In addition, the maturation of B cells was TLR2/4 
dependent since Tlr2-/-xTlr4-/- splenic B cells did not express high levels of activation 
markers, regardless of the used bacterial stimulus. 
  
Strong immunogenic E. coli induces differentiation of regulatory B cell phenotypes 
Similar to the differentiation and maturation of CD11c+ DCs, the strong immunogenic 
properties of E. coli led to a profound proliferation, activation and maturation of naïve 
B cells whereas the stimulation with B. vulgatus resulted in semi-mature cell 
phenotypes. However, no definitive tolerant phenotype exhibiting immune regulatory 
capabilities has been identified and characterized for B cells. Though, by the 
expression of suppressive molecules and the secretion of anti-inflammatory cytokine 
(e.g. IL-10), a subset of activated B cells named regulatory B cells possess 
regulatory properties to modulate immune responses. Therefore, the percentage of 
the best characterized Breg subsets: B10 cells, T2-MZP cells and Tim-1+ B cells, at 
several time points after stimulation with strong immunogenic E. coli or low 
immunogenic B. vulgatus in comparison to unstimulated B cells was determined 
[257]. The induction of all three analyzed Breg phenotypes and the secretion of the 
anti-inflammatory cytokine IL-10 were significantly enhanced after stimulation with E. 
coli in comparison to B. vulgatus or PBS, whereas only low levels of pro-inflammatory 
TNFα were detectable (publication c, figure 2B+C). Furthermore, Bregs mediate their 
immune regulatory properties through the expression of membrane-bound and 
secretion of soluble suppressive molecules CD73, PD-L1, FasL, GITRL and EBI3. E. 
coli, but not B. vulgatus stimulation of naïve splenic WT B cells resulted in a 
significantly elevated productions of these immune suppressive proteins (publication 
c, figure 2D).  
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As interim conclusion, it has been demonstrated that, in contrast to the induction of 
tolerant DCs, the activation and differentiation of immune regulatory B cells requires 
a potent immunogenic stimulus provided by E. coli.   
 
E. coli-stimulated B cells inhibit DC activation and maturation 
To investigate the influences of immunomodulatory features exhibited by E.coli-
induced Bregs on other immune cells and the host immune system, the maturation of 
immature CD11c+ BMDCs in co-culture with isolated B cells in direct contact or 
separated via Transwell membranes after stimulation with B. vulgatus or E. coli was 
determined (publication c, figure 3A). The presence of naïve B cells during the 
stimulation of DCs with E. coli led to an inhibition of DC maturation indicated by a 
significantly reduced expression of MHC-II, CD40, CD80 and CD86 and significantly 
diminished secretion of pro-inflammatory TNFα in comparison to the maturation level 
of E. coli activated DCs in single cell culture (publication c, figure 3B+C). This effect 
was observed in both direct and indirect DC-B cell co-cultures stimulated with E. coli. 
However, the maturation of DCs was slightly more suppressed in direct interaction 
with B cells stimulated with E. coli. Fittingly, the concentration of IL-10 in co-culture 
supernatant was highest in E. coli-stimulated samples (publication c, figure 3C). 
The interaction of DCs with E. coli-stimulated B cells significantly inhibited antigen-
presentation function and consequently T cell activation ability of CD11c+ DCs, 
marked by a reduced expression of DC activation and maturation markers and an 
alleviated secretion of pro-inflammatory cytokines. This suppression of DC 
maturation was mediated by distinct regulatory properties of E. coli-induced Bregs. 
Furthermore, maturation of DCs was even more reduced in co-culture stimulation 
where DCs and E. coli-stimulated B cells had direct cell-cell contact. This is in line 
with previous findings that the stimulation of B cells with E. coli led to an increased 
upregulation of suppressive molecules like PD-L1, FasL and GITRL on the B cell 
surface and that these proteins, in combination with secreted cytokines, characterize 
the strong anti-inflammatory feature of Bregs [206, 210, 258]. 
 
E. coli-primed B cells inhibit T cell activation and induce Treg differentiation 
It has been demonstrated in previous experiments, that E. coli- induced Bregs have 
crucial influences on the antigen-presentation activities of other APCs. For this 
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reason, it is important to elucidate the impact of B cell-driven regulatory mechanisms 
on the subsequent processes of the adaptive immune response: the activation, 
proliferation and polarization of T helper cells. Schmidt et al. revealed that Ag-pulsed 
splenic B cells possess a stronger T cell stimulatory capacity than CD11c+ DCs and 
that activated CD4+ T cells favor Th2 polarization in vitro [259]. Therefore, a 
proliferation and polarization assay with PBS, B. vulgatus or E. coli -primed WT B 
cells pulsed with Ova-peptide and subsequently co-cultured with naïve CFSE-
labelled CD4+CD44- T cells isolated from OT-II mice, which express an Ova peptide-
specific TCR were implemented (publication c, figure 4A). The proliferation of naïve 
CD4+ T cells was significantly lower in co-cultures with E. coli-primed B cells 
(publication c, figure 4B). The cultivation of T cells with naïve unstimulated B cells led 
to an intense T cell proliferation and a polarization towards Th1 and TH17 cells. In 
contrast, T cells incubated with E. coli-primed B cells favored a polarization shifted 
towards Th2 cells and Tregs (publication c, figure 4B+C). B. vulgatus-primed B cells 
also polarized T cells in a Th2 and Treg direction but simultaneously induced Th1 
and Th17 cells leading to a more pro-inflammatory Th1/Th2/Th17/Treg balance [167-
169]. 
 
Strong immunogenic E. coli counter-regulates inflammation via activated B cells 
during DSS-induced inflammation 
In the in vitro experiments, B cells, especially regulatory B cells, play a crucial role 
during the initiation of immune responses and that B cells can directly or indirectly 
affect the function of other immune cells by their regulatory properties. This led to the 
hypothesis that in a host having a functional B cell immunity, E. coli with its 
immunogenic potential counter-regulates inflammatory processes via the strong 
induction of regulatory cell populations and can consequently help to maintain 
immune homeostasis. 
To verify this hypothesis, germfree WT mice were colonized with B. vulgatus or E. 
coli for 4 weeks via drinking water and administered 2% DSS for 7 days in order to 
correlate the bacteria-dependent induction of regulatory B cells in spleen and 
mesenteric lymph nodes (mLN) with the disease pathology (publication c, figure 5A). 
Colonization of germfree mice with E. coli, but not with B. vulgatus, resulted in 
significantly reduced weight loss and a lower disease activity index in comparison to 
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germfree mice in response to DSS-administration (publication c, figure 5B+C). 
Additionally, the histological score of tissue damage in the colon was significantly 
attenuated in E. coli-colonized mice but not in B. vulgatus-associated mice as 
compared to germfree animals (publication c, figure 5D). Further, the increased 
absolute numbers of CD11b+Gr1+ neutrophils in the spleen and the infiltration of 
these neutrophils in the colonic tissue implied a severe inflammatory state in 
germfree mice after DSS treatment in comparison to E. coli-colonized mice. 
Interestingly, the influx of neutrophils was also reduced in B. vulgatus-colonized mice 
as compared to germfree mice (publication c, figure 5E). The percentage of CD4-
CD19+IL10+ regulatory B cells in the spleen and mLN was significantly increased in 
E. coli-colonized mice in comparison to B. vulgatus-colonized and germfree animals 
(publication c, figure 6A). This enhanced Breg induction correlated with a lower 
histological score, whereas highly inflamed mice showed a minimal activation of 
regulatory B cells in the spleen and mLN (publication c, figure 6B). In addition, we 
analyzed the polarization of CD4+ T cells in all three DSS-administered groups. No 
significant differences were observed in the Th2 cell differentiation between the 
groups. However, E. coli-colonized mice showed a significant increase of regulatory 
T cells (CD19-CD4+CD25+FoxP3+) in the spleen and mLN, whereas the proportion of 
Th1 (CD19-CD3+CD4+IFNγ+) and Th17 (CD19-CD3+CD4+IL-17+) cells was 
significantly reduced in the mLN in comparison to germfree or B. vulgatus-colonized 
DSS-treated mice (publication c, figure 6C).  
Here it was demonstrated: (I) B cells can be activated directly by commensal 
members of the host microbiota and, depending on the immunogenic potential of the 
encountered bacterial species, activated B cells can mint strong regulatory cell 
phenotypes to promote immune tolerance; (II) the intensified induction of Bregs by E. 
coli can counter-regulate pro-inflammatory immune responses in a healthy host 
inherently caused by the same bacteria; (III) this regulation mechanism may serve as 
a feedback loop to maintain immune homeostasis and even attenuate inflammatory 
processes in autoimmune disease. 
 
 CONCLUSION  
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In this work, two regulation-mechanisms of the host immune system to prevent 
inflammatory responses and maintain immune homeostasis in healthy and immune 
compromised host have been elucidated. The induction of these mechanisms is 
dependent on the immunogenicity of commensal bacteria and the resulting strength 
of cell activation after the interaction between MAMPs delivered via OMVs or viable 
bacteria with TLRs of target immune cells.  
On the one hand, weak immunogenic signal provided by B. vulgatus is beneficial in 
genetically predisposed host (deficient for Rag1 or IL-2) in the course of inflammation 
whereas in these genetic backgrounds the administration of strong immunogenic E. 
coli aggravates the disease progression due to the lack of a functional B cell 
immunity which can restore immune tolerance in a healthy host by counter-regulating 
the induced pro-inflammatory immune response [27, 91, 178]. These findings may be 
attributed to the induction of tolerant DCs by weak immunogenic B. vulgatus 
preventing pro-inflammatory immune responses by the mediation of endotoxin 
tolerance and to the induction of fully maturated DCs by strong immunogenic E. coli 
triggering an excessive immune response, aggravating the course of disease in 
immune compromised host (Figure 3) (publication c).  
Thus, B cell immunity is inoperative, either due to the lack of mature B cells (Rag1-/-), 
the disturbed proliferation and induction of Bregs (IL-2-/-) or the dysfunction of Bregs 
(IL-10-/-) in all three colitis mouse models. Hence in these colitis models, a potent 
immune-stimulatory signal mediated by strong immunogenic E. coli exacerbated 
inflammation, since important counter-regulation mechanisms (such as the induction 
of Bregs) for the compensation of overshooting immune responses malfunctioning. 
Similar observation could be made with the bacterium Helicobacter hepaticus. H. 
hepaticus is a member of the mouse microbiota colonizing the lower intestine and 
activating innate immunity via Toll-like receptors without inducing immune pathology 
in a healthy host [260]. H. hepaticus thus induces an anti-inflammatory immune 
response through the activation of regulatory macrophages to maintain immune 
homeostasis [261]. However, in immune-deficient IL-10-/- or Rag2-/- mice, H. 
hepaticus triggered exacerbated intestinal inflammation as a result of aberrant 
regulatory T cell function [262-264]. In conclusion, strong immunogenic bacteria, 
which are benignant commensals in a healthy host, provoke an uncontrolled 
activation of the immune system in hosts with a dysfunctional immune response, 
leading to inflammatory processes and the exacerbation of disease severity.  
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On the other hand and in contrast, in this comparative study including B. vulgatus 
(low immunogenic) and E. coli (strong immunogenic), it was demonstrated that the 
potent stimulation of naïve B cells with E. coli resulted in a strong activation and 
differentiation of Breg phenotypes in vitro and in vivo leading to an anti-inflammatory 
balance of Th1/Th2/Th17/Treg cells, marked by a pronounced differentiation of 
Tregs, which is important for the maintenance of immune homeostasis in a healthy 
host and decisive for the prevention of inflammation development and consequently 
the possible reason for the extenuated inflammation in E. coli-colonized and DSS 
treated mice [167-169]. It has already been published in mouse models for T1D that 
strong immunogenic bacteria have inflammation-suppressive properties and can 
even prevent the onset of disease, on the condition that the host provides a 
functional immune system [265]. 
 
In summary, the presented results directly link different characteristics of commensal 
bacteria with the immune response of the host and thus provide new insights in the 
inter-kingdom communication between commensals and their hosts. These findings 
may contribute in developing therapeutical approaches for treating inflammatory 
bowel disease and other microbiota-dependent autoimmune diseases. 
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Figure 3. Immune modulation mechanisms via activation of regulatory cell phenotypes induced by 
immunogenic bacteria. Depending on the immunogenicity of a bacterial antigen, APCs (immature 
DCs and naïve B cells) are activated differently through the recognition of MAMPs (e.g. LPS or PGN) 
through Toll-like receptors. Interaction of weak agonistic viable B. vulgatus, OMVBV or LPSBV leads to 
semi-maturation of CD11c
+
 DCs exhibiting tolerant properties. Binding of strong agonistic E. coli 
results in the fully maturation of DCs expressing high amount of MHC-II and T cell co-stimulatory 
proteins and secreting increased levels of immune-modulatory cytokines. In contrast, potent 
stimulation of B cells (e.g. by strong immunogenic E. coli) induces the differentiation and 
proliferation of regulatory B cell phenotypes such as B10 cells (CD19
+
CD5
+
CD1d
+
IL10
+
), T2-MZP cells 
(CD19
+
CD21
hi
CD23
hi
CD24
hi
) and Tim-1
+
 B cells (CD19
+ 
Tim-1
+
) characterized by an upregulated 
expression and strong secretion of suppressive mediators. Primarily through secreted IL-10, Bregs 
can inhibit DC and macrophage maturation and function and consequently dampen their antigen 
presentation capacity to activate and polarize T cells. Moreover, Bregs can regulate T-cell responses 
by suppressing the proliferation and polarization of effector T cells (in particular TH1 and TH17 cells). 
These effects are mediated by secreted factors (IL-10, TGFß, and Ebi3/IL-35) and membrane-bound 
molecules including MHC-II, CD73, PD-L1, FasL and GitrL at the interface between B cells and T cells 
[266]. Regulatory B cells also crosstalk with Treg cells to promote their expansion and support their 
function. (+): induction/activation, (-): inhibition. semi-mature DCs (intermediate expression of DC 
maturation markers); LPS (lipopolysaccharide); PGN (peptidoglycan); OMV (outer membrane vesicle); 
TLR (toll-like receptor); iDC (immature dendritic cell); CD (cluster of differentiation); PD-L1 
(programmed death ligand 1); FasL (Fas ligand); GitrL (glucocorticoid-induced tumour necrosis factor 
receptor-related protein ligand); IL- (interleukin-); TCR (T cell receptor); TGFß (transforming growth 
factor ß); Th (T helper cells); Tim-1 (T cell Ig and mucin 1); IFNγ (interferon γ); TNFα (tumour-necrosis 
factor α); T-bet (T-box transcription factor); RORγt (RAR-related orphan receptor gamma); GATA-3 
(Trans-acting T-cell-specific transcription factor GATA-3); FoxP3 (Forkhead box protein P3) (Adapted 
from publication c). 
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ABSTRACT
The Gram negative intestinal symbiont Bacteroides vulgatus mpk is able to prevent from induction of
colonic inflammation in Rag1¡/¡ mice and promotes immune balance in Il2¡/¡ mice. These
inflammation-silencing effects are associated with B. vulgatus mpk-mediated induction of semi-
mature dendritic cells, especially in the colonic lamina propria (cLP). However the beneficial
interaction of bacteria with host immune cells is limited due to the existence of a large mucus layer
covering the intestinal epithelium. How can intestinal bacteria overcome this physical barrier and
contact the host immune system?
One mechanism is the production of outer membrane vesicles (OMVs) via ubiquitous blebbing of
the outer membrane. These proteoliposomes have the ability to traverse the mucus layer. Hence,
OMVs play an important role in immunomodulation and the maintenance of a balanced gut
microbiota. Here we demonstrate that the stimulation of bone marrow derived dendritic cells
(BMDCs) with isolated OMVs originated from B. vulgatus mpk leads to the induction of a tolerant
semi-mature phenotype. Thereby, microbe- associated molecular patterns (MAMPs) delivered by
OMVs are crucial for the interaction and the resulting maturation of immune cells. Additional to the
binding to host TLR4, a yet unknown ligand to TLR2 is indispensable for the conversion of immature
BMDCs into a semi-mature state. Thus, crossing the epithelial mucus layer and directly contact host
cells, OMV mediate cross-tolerance via the transport of various Toll-like receptor antigens. These
features make OMVs to a key attribute of B. vulgatus mpk for a vigorous acellular prevention and
treatment of systemic diseases.
KEYWORDS
Bacteroides vulgatus;
dendritic cells; immune
response; outer membrane
vesicles
Introduction
The intestinal microbiota provides important features
which are considered to be beneficial for the host
organism, such as (1) the maintenance of the struc-
tural integrity of the intestinal mucosal barrier, (2) the
development of epithelial cell function, (3) host nutri-
ent metabolism, (4) modulation of the immune system
and (5) prevention of bacterial overgrowth.1,2 Hereby,
a certain microbial diversity is considered to be
required for the maintenance of the immune homeo-
stasis and crucial for the optimal functionality and
interaction with the host. Concerning the interplay
between microbiota and the host immune system, a
disturbed or altered composition of the gut micro-
biota, called “dysbiosis,” is associated with the patho-
genesis of both intestinal and systemic immunological
disorders.3 Such a dysbiosis of the intestinal
microbiota, can also influence the disease onset and
progress in a variety of mouse models for autoimmune
diseases (AID) such as rheumatoid arthritis (RA), type
1 diabetes (T1D) and inflammatory bowel disease
(IBD).4-6 This highlights the importance of a deeper
knowledge of the interaction between the host
immune system and the intestinal microbes. Based on
this cross talk, specific modulation of the intestinal
microbiota composition is considered to be used as
therapy for the treatment of microbiota-associated
AID.7,8 Hereby, intestinal commensals are decisive for
the induction (pathobionts) or prevention (symbionts)
of a pathological immune response in a certain pre-
disposed host.9 In this context, members of the genus
Bacteroides were already demonstrated to exhibit sym-
biotic properties concerning the modulation of the
intestinal immune system.10
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Accordingly, Bacteroides vulgatus mpk was already
depicted to mediate inflammation-silencing effects
finally preventing from colitis induction in various
moue models for IBD.1-13 These immune regulatory
properties of B. vulgatus mpk are traced back to the
induction of a tolerant dendritic cell (DC) phenotype
in the colonic lamina propria (cLP) termed semi-
mature.12-14 However, direct physical interaction
between intestinal commensals and cLP DCs is limited
due to the presence of a thick and almost sterile mucus
layer covering the intestinal epithelium. Therefore, we
were interested in how this symbiotic commensal
manages to enhance the communication with host
cells to modulate the immune system.
Instead of direct physically interacting with tar-
get cells, bacteria can communicate with more dis-
tant host environments via secretion of signaling
molecules, such as toxins, quorum sensing mole-
cules and DNA.15 These mechanisms involving
non-viable bacteria provide distinct advantages for
bacteria, since secreted soluble material is smaller
and non-viable.16,17 Therefore, this material can
gain access to environments usually being inacces-
sible for living bacteria. In this context, the biogen-
esis and release of bacterial outer membrane
vesicles (OMVs) by Gram-negative bacteria repre-
sent a secretion pathway combining the long-dis-
tance traveling ability of small soluble bacterial
products with mimicking the characteristics of the
whole bacterial cell by facilitating the transport of
insoluble molecules.18,19 OMV release therefore
constitutes a critical mechanism for intra- and
inter-kingdom communication.20,21 Derived from
the outer membrane of bacteria, OMVs harbour a
broad variety of microbe-associated molecular pat-
terns (MAMPs) which interact with pattern recog-
nition receptors (PRRs) of host target cells, leading
to innate and adaptive immune responses.22,23 It
was shown that the application of OMVs critically
modulates the course of disease in animal models
of intestinal inflammation by either a direct or an
indirect interaction with the intestinal immune sys-
tem.24,25 Hickey et al. even showed that OMVs of
B. thetaiotaomicron can be found in macrophages
of the intestinal mucosa. This implicates a passag-
ing through not only the mucus layer but also
through the intestinal epithelial cell layer.
In this study, we provide evidence that the symbi-
otic commensal B. vulgatus mpk produces OMVs.
This generation of OMVs contribute to the mediation
of the immune-system silencing properties provoked
by this strain via the induction of DC semi-matura-
tion. Thereby, both TLR2- and MD-2/TLR4-mediated
signaling is crucial for this OMV-induced generation
of semi-mature DCs, indicating that TLR2 and TLR4
ligands carried by OMVs are indispensable for the
manifestation of this tolerant DC phenotype. There-
fore, B. vulgatus mpk-caused OMV blebbing seems to
contribute to host-microbe communication at intesti-
nal sites which are hardly accessible for the living
bacterium.
Results
Bacteroides vulgatus mpk outer membrane vesicles
induce tolerance in CD11cC cells
It is well known that components of the intestinal
microbiota have widespread effects on the mucosal
immune system in the intestine.14,26 Hereby, commen-
sal bacteria exhibit important functions for the prim-
ing of immune cells underlying the mucosal epithelial
barrier. However, physical contact between bacteria
and such immune cells is restricted due to the pres-
ence of a large mucus layer covering the intestinal epi-
thelium. Almost all bacteria produce outer membrane
vesicles (OMVs) through bulging of the outer bacterial
membrane.27 These vesicles are able to cross the
mucin layer, finally increasing the probability of inter-
action of mucosal immune cells with bacterial surface
structures such as MAMPs.28 The mechanism of
OMV production is a key characteristic of Gram nega-
tive bacteria and commensal-derived OMVs seem to
be important for the modulation of the host immune
system.29
In previous work, we could demonstrate that B. vul-
gatus mpk modulate the immune response in vivo and
in vitro in an inflammation-silencing manner. This is
mainly mediated by the induction of tolerant CD11cC
cells in the colonic lamina propria, which seem to be
responsible for the maintenance of homeostatic condi-
tions in the intestine.12,13 Several molecular mecha-
nisms for tolerance induction have already been
identified in CD11cC bone marrow derived dendritic
cells (BMDCs).30 Until now, not all immune system-
modulating surface structures of B. vulgatus mpk were
already identified. Therefore, we were interested if this
symbiotic commensal produces OMVs and if this ves-
icle production contributes to the observed immuno-
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modulatory properties of this commensal strain. The
secretion of OMVs can be a response due to environ-
mental stress of the prokaryotic cell.28,31 Therefore, we
incubated the bacteria under different culture condi-
tions and for different periods of time, to elucidate, if
this strain produces OMVs and if this is dependent on
the culturing conditions. We could demonstrate that
B. vulgatus produces vesicles ubiquitarily under non-
detrimental conditions through bulging of the outer
membrane as demonstrated in TEM pictures (Fig. 1a).
To gain information on the immune system modulat-
ing features of OMVs, CD11cC BMDCs were gener-
ated as described and stimulated with B. vulgatus
mpk-derived OMVs (OMVBV) for 24 h (Fig. 1b). After
end of incubation time, BMDCs were checked for sur-
face expression of MHC-II, CD40, CD80 and CD86
by flow cytometry (Fig. 1c, gating strategy) since these
surface markers indicate the maturation status of
CD11cC BMDCs.11,12,14,32 PBS-stimulated BMDCs
were used as a negative control (mock), representing
completely immature CD11cC cells. BMDCs stimu-
lated with pathobiotic E. coli mpk were used as posi-
tive controls, representing mature CD11cC cells, since
CD11cC BMDC stimulation with this strain was dem-
onstrated to induce complete maturation.11 B. vulga-
tus mpk was already demonstrated to induce CD11cC
cell semi-maturation as indicated by intermediate
expression of MHC-II, CD40, CD80 and CD86 which
was significantly lower compared with the expression
of these respective surface proteins of mature CD11cC
BMDCs.11 We could demonstrate that OMVBV pro-
vide the same properties like live B. vulgatus mpk
when used at a concentration of 50 ng mL¡1, since we
could not detect any difference in the expression of
MHC-II, CD40, CD80 and CD86 between CD11cC
cells stimulated with either OMVBV or live B. vulgatus
mpk, respectively (Fig. 1d). Additionally and as con-
firmed for live B. vulgatus mpk, CD11cC cells stimu-
lated with OMVBV provided significantly lower
surface expression of these proteins compared with E.
coli mpk stimulated CD11cC BMDCs. However, the
surface expression of MHC-II and T cell co-stimula-
tory surface proteins of CD11cC BMDCs represents
only a first hint on the maturation of these cells. A key
feature of semi-mature CD11cC cells is tolerance
toward a secondary bacterial stimulus after priming
with B. vulgatus mpk.11 Therefore, we primed
CD11cC BMDCs with either OMVBV, live B. vulgatus
mpk, E. coli mpk or PBS (mock), incubated these cells
for 24 h, changed cell culture medium and challenged
them with either PBS or E. coli mpk (Fig. 1e). We ana-
lyzed the surface expression of MHC-II and the secre-
tion of the pro-inflammatory cytokines TNF and IL-6.
Immature PBS-stimulated CD11cC cells showed a sig-
nificantly increased surface expression of MHC-II as
well as secretion of TNF and IL-6 after challenge with
E. coli mpk. Already mature E. coli mpk primed
CD11cC cells maintained their high expression level
of MHC-II and IL-6 after challenge with E. coli mpk.
Due to the high secretion of TNF during the first 24 h,
indicating a maturation of the BMDCs, secreted TNF
was not detectable in the supernatant of mature
CD11cC cells upon a second challenge with E.coli
mpk after exchange of media.33,34 This is in line with
the literature reporting on a non-responsiveness of
mature BMDCs to additional stimuli.11,32,35 Semi-
mature CD11cC cells stimulated with either live B. vul-
gatus mpk or OMVBV were non-responsive toward
subsequent challenge with E. coli mpk concerning the
surface expression of MHC-II and the secretion of
TNF in the supernatant (Fig. 1f). Furthermore, to pro-
vide evidence for a direct interaction of B. vulgatus-
derived OMVs with antigen-presenting cells, we per-
formed an internalisation timeline assay using
CD11cC BMDCs in combination with different con-
centration of FITC-labeled vesicles. OMVBV were
taken up by cultured BMDCs, leading to an extensive
increase of CD11cCOMVBV
C cell population after 30
minutes as shown in Figure 1g. As shown by Shen
et al., the rapid internalization of vesicles can be
achieved in an actin-dependent manner directing the
expression of surface markers and inflammatory cyto-
kine secretion in BMDCs.24
OMVBV-mediated immunomodulatory properties are
sensed via host TLR2 and TLR4 receptor complexes
We demonstrated that B. vulgatus mpk and its outer
membrane vesicles interact with innate immune cells
and modulate the host immune system in an anti-
inflammatory sense. Though, the exact mechanisms
and involved pattern recognition receptors for signal
transduction were not yet accurately identified. There-
fore, we wanted to describe the responsible receptor
on host target cells for the interaction with microbial
ligands on bacterial cell surface and outer membrane
vesicles, respectively. In this context, Toll-like recep-
tors (TLRs) are the most pivotal pattern-recognition
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Figure 1. Induction of dendritic cell semi-maturation via B. vulgatus OMVs (OMVBV). (a) Evidence for vesicle production derived from the
outer membrane of cultivated Bacteroides vulgatus cell. Black arrows indicate single secreted vesicles of fixed bacterial cells after tolui-
dine blue staining captured with Transmission Electron Microscope (upper picture). Native OMVBV after isolation and purification stained
negative with uranyl acetate (lower picture). (b) Experimental setting for the analysis of surface maturation marker expression on den-
dritic cells after stimulation with OMVs. BMDCs are primed for 24 h with either PBS (mock), B. vulgatus or E. coli as control and addition-
ally with 50 ng mL¡1 OMVBV. (c) Gating strategy for the determination of MHC class II high positive (MHC-II
hiC), CD40, CD80 or CD86
BMDCs. CD11c-negative cells were excluded and the proportion of MHC-II hiC (dot plot), CD40, CD80 or CD86 (histogram) DCs within
the population of CD11cC cells was determined as shown. Dashed line shows negative control. (d) MHC class II hiC, CD40, CD80 or CD86
population CD11cC BMDCs that were primed with PBS (mock), B. vulgatus mpk, 50 ng mL¡1 OMVBV or E. coli mpk for 24 h (n D 4). (e)
Experimental setting for investigation of dendritic cell tolerance after induction of semi-maturation. BMDCs are primed for 24 h with
either PBS (mock) to preserve an immature phenotype, B. vulgatus mpk or 50 ng mL¡1 OMVBV to induce semi-maturation or E. coli to
induce BMDC maturation. After medium change, these cells were secondarily challenged for 16 h with either PBS (mock) as controls or
E. coli to proof non-responsiveness of tolerant cells. (f) Expression of analyzed maturation markers MHC class II, TNF and IL-6 of CD11cC
BMDCs after priming with PBS (mock), B. vulgatus mpk, 50 ng mL¡1 OMVBV or E. coli mpk for 16 h and subsequently challenge with
either PBS (mock) or E. coli mpk for 16 h (n D 4). (g) Flow cytometry analysis of OMVBV internalization by BMDCs. Different concentra-
tions of vesicles were labeled with fluorescein isothiocyanate (FITC) and incubated with cultured DCs for various times. Percentages
show CD11cCOMVBV
C cell populations. Unlabeled OMVs served as negative control (black population in dot plot graph). All statistical
analyses were performed using student’s t test. Error bars represent SD.
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receptors (PRRs) for the detection of MAMPs.36-39
The most abundant MAMPs exhibiting strong immu-
nogenic properties are lipopolysaccharides (LPS),
which are recognized by CD14 and the TLR4/MD-2
receptor complex.14,40-42 Besides TLR4 agonists, TLR2
ligands like bacterial lipopeptides, play a prominent
role regarding target activation of antigen presenting
cells.43-45 In general, TLR4- as well as TLR2- agonists
can be integrated into OMVs and therefore be trans-
ported by these vesicles.46 To characterize the B. vul-
gatus mpk- and OMVBV- associated ligands which
might be relevant for the induction of semi-mature
BMDCs, we used Human Embryonic Kidney cells
(HEK) overexpressing mouse TLR2 or the mouse
CD14/TLR4/MD-2 receptor complex. The resulting
IL-8 secretion into cell supernatant was detected to
determine receptor activation. PBS treated cells served
as negative control, whereas Pam3CSK4 was used as
TLR2 ligand. As demonstrated in Fig. 2a, OMVBV
induced both activation of the TLR2 receptor as well
as CD14/TLR4/MD-2 receptor complex. To validate
these results, we used CD11cC BMDCs derived from
mice deficient for Toll-like receptor 2 (Tlr2¡/¡), TLR4
(Tlr4¡/¡) and for both receptors (Tlr2¡/¡xTlr4¡/¡).
CD11cC BMDCs of wt and Tlr2¡/¡, Tlr4¡/¡ and
Tlr2¡/¡xTlr4¡/¡ mice were generated as described
and primed with OMVBV for 24 h (Fig. 2b). CD11c
C
cells were harvested and analyzed for surface expres-
sion of MHC-II and CD40 (Fig. 1c, gating strategy).
Additionally, the amount of secreted pro-inflamma-
tory TNF and IL-6 was detected. The deficiency of
both TLRs on the cell surface leads to a complete loss
of antigen recognition independent of the used stimu-
lus as indicated by the low expression of MHC-II and
an abolished secretion of TNF of Tlr2¡/¡xTLR4¡/¡
CD11cC BMDCs. In accordance with the findings
generated with HEK cells (Fig. 2a), the activation of
the TLR4/MD-2 receptor complex via B. vulgatus
mpk- secreted OMVs is decisive for the main outcom-
ing signal. In addition, the expression of MHC-II, the
costimulatory proteins and the secretion of the inflam-
matory cytokines in Tlr2¡/¡ stimulated BMDCs is
nearly as strong as in the wt cells after challenging
with E.coli mpk, B. vulgatus mpk or high concentra-
tion of OMVBV. Nevertheless, we also observed a
dose-dependent increase of all analyzed proteins upon
stimulation of Tlr4¡/¡ CD11cC BMDCs with purified
OMVBV, pointing out that the TLR2 receptor is com-
petent to recognize agonistic structures present in
OMVBV. Furthermore, TLR2-dependent signaling is
also involved in vesicle- induced BMDC activation
and maturation (Fig. 2c). This observation prompted
us to elucidate whether the contact of host immune
cells with a bacterial TLR4 agonist such as LPS alone
is sufficient for the activation and differentiation of
tolerant BMDCs or whether an additional TLR2 acti-
vation is accessory required for adequate induction of
BMDC semi-maturation. Therefore, BMDCs were
generated from Tlr2¡/¡ mice, primed with OMVBV
for 24 h and challenged with E. colimpk for additional
16 h (Fig. 2d). As mentioned before, this experimental
setting is required to check for tolerance in semi-
mature BMDCs. We could verify that a TLR2-depen-
dent signaling is necessary for tolerance induction in
BMDCs, since Tlr2¡/¡ failed to become tolerant upon
priming with B. vulgatus mpk or OMVBV as demon-
strated by the high expression of MHC class II and the
enhanced secretion of TNFa upon E. coli mpk chal-
lenge (Fig. 2e).
Discussion
In this study, we demonstrated that the Gram negative
symbiotic commensal B. vulgatus mpk produces outer
membrane vesicles (OMV). This OMV blebbing
mechanism seems to contribute to the immune
response modulating properties of this strain which
was demonstrated in several previous studies.
B. vulgatus mpk-derived OMVs (OMVBV) induced
tolerance in CD11cC BMDCs in a TLR4 and TLR2
dependent manner. However, the defined vesicle-asso-
ciated receptor ligands were not identified. Neverthe-
less, simultaneous activation of both receptors was
required to induce effective DC tolerance. In line with
Shen et al. and Hickey et al.24,25,27 this feature indi-
cates an additional mechanism how B. vulgatus mpk
as a symbiotic commensal, modulates the immune
system at mucosal interfaces. As Bacteria are separated
from the host intestinal mucosa by a thick mucus layer
that is thought to impede a direct contact between
luminal bacteria and the intestinal mucosa,47 the shed-
ding of OMVs by B. vulgatus is of special importance
since OMVs can diffuse through the mucin layer.25,48
This underlines the role of OMVs for the modulation
of intestinal immune cells. These characteristics make
OMVBV to an important attribute of B. vulgatus mpk
for an effective passive protection and treatment of
systemic diseases.
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Figure 2. Induction of dendritic cell tolerance via OMVBV is TLR2 and TLR4 dependent. (a) Stimulation of Human embryonic kidney (HEK)
cells overexpressing murine TLR 2 or 4. HEK cells are primed with PBS (mock), B. vulgatus mpk, various concentrations of OMVBV or E. coli
mpk for 24 h. Pam3CSK4 served as TLR2 specific control. (b) Experimental setting for the analysis of surface maturation marker expres-
sion on dendritic cells after stimulation with OMVs. wt, Tlr2¡/¡, Tlr4¡/¡ and Tlr2¡/¡xTlr4¡/¡ BMDCs are primed for 24 h with either PBS
(mock), B. vulgatus or E. coli as control and additionally with increasing concentrations of OMVBV. (c) MHC class II
hiC or CD40 population
(CD11cC) (normalized to mock) and secreted concentration of TNF or IL-6 of wt and TLR-deficient BMDCs that were primed with PBS
(mock), B. vulgatus mpk, different concentrations of OMVBV or E. coli mpk for 24 h (n D 4). (d) Experimental setting for investigation of
dendritic cell tolerance after induction of semi-maturation in Tlr2¡/¡ DCs.BMDCs are primed for 24 h with either PBS (mock) to preserve
an immature phenotype, B. vulgatus or OMVBV to induce semi-maturation or E. coli to induce BMDC maturation. After medium change,
these cells were secondarily challenged for 16 h with either PBS (mock) as controls or E. coli to proof non-responsiveness of tolerant
cells. (e) Expression of analyzed maturation markers MHC class II, TNF and IL-6 of CD11cC BMDCs of TLR2¡/¡ mice after priming with
PBS (mock), B. vulgatus mpk, OMVBV or E. coli mpk for 16 h and subsequently challenge with either PBS (mock) or E. coli mpk for 16 h (n
D 4). All statistical analyses were performed using student’s t test. Error bars represent SD.
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Gram negative bacteria are able to deliver a chemi-
cally diverse spectrum of cargo protected from the
external environment over long distances by the help
of outer membrane vesicles.49 Though, OMVs can
cross physical barriers which are impermeable for the
whole bacterium such as the intestinal mucus layer,
gain access to the intestinal epithelium and therefore
to the underlying immune cells present in the intesti-
nal lamina propria.24,25,28,48 This makes OMV bleb-
bing to an important immune modulating
mechanism. Considering pathogens, vesicles of Salmo-
nella enterica or Helicobacter pylori harbour virulence
factors to enhance bacterial survival and the ability to
colonize host mucosal tissues.50,51 This leads to a strin-
gent immune reaction and local inflammation.52
However, OMVs derived from commensal symbiotic
bacteria were demonstrated to be involved in main-
taining or restoring immune homeostasis in the
intestine.53,54 For example, Bacteroides fragilis, repre-
senting an intestinal commensal, produces OMVs and
interacts with the host immune system by delivering a
capsular polysaccharide (PSA) to dendritic cells.21,55
The release of PSA in OMVs induces immune-modu-
latory effects, activates regulatory T cells and prevents
from experimental colitis.24 However, a general role
for OMVs in mediating immune responses, account-
ing for all OMV-producing commensal, was not yet
demonstrated.31,56
Findings using live B. vulgatus mpk cells indicate
that this symbiotic bacterium prevents from disease
induction in different mouse models for experimental
colitis.12,13 In this context, B. vulgatus mpk promotes
the maintenance of the immune equilibrium via
induction of tolerant semi-mature dendritic cells in
the intestine and the resulting regulation of host
Cathepsin S activity and secretion in these antigen-
presenting cells.32 In this study, we demonstrated that
OMVs derived from B. vulgatus mpk contribute to
these observed effects since they interact with bone
marrow derived dendritic cells, leading to a semi-
mature phenotype characterized by a low expression
of T cell activation and maturation markers as well as
pro-inflammatory cytokines.
Innate immune cells recognize conserved microbial
ligands through pattern recognition receptors (PRRs)
leading to immunologic responses. For example, Poly-
saccharide A (PSA) from Bacteroides fragilis is recog-
nized by TLR2. In consequence, the binding of PSA to
TLR2 leads to the induction of FoxP3C regulatory T
cells which affect both the development and homeo-
stasis of the host immune system.57,58 Our study now
reveals that OMVBV also contain TLR2 activating
ligands which are, in consequence, necessary for the
induction of tolerant BMDCs. Since these tolerance-
inducing effects are abolished in TLR2- deficient
BMDCs, a TLR2-dependent intracellular signaling is
indispensable for OMVBV-mediated induction of tol-
erance in BMDCs. These observations indicate that
both receptors, MD-2/TLR4 and TLR2, are required
for the induction of DC tolerance. In addition to the
LPS in the outer membrane, OMVs of B. vulgatus
mpk contain and a yet unidentified TLR2 agonist, as it
is e.g. the case for PSA in vesicles secreted by B. fragi-
lis. Interestingly, the genome of B. vulgatus mpk con-
tains 9 different loci coding for capsular
polysaccharides (e.g., glycosyltransferases and polysac-
charide export outer membrane proteins), indicating
the presence of a TLR2-interacting polysaccharide on
the outer membrane of the bacterium cell and on
vesicles derived from B. vulgatus mpk.46 But the com-
parison of the various loci in B. fragilis and B. vulgatus
revealed different arrangements of the genes necessary
for the biosynthesis of capsular polysaccharides (data
not shown). This implicates, that polysaccharides
present in B. vulgatus mpk has a different structure as
compared with the capsular polysaccharide produce
by B. fragilis.
The presence of a TLR4- and TLR2- ligand on the
outer membrane indicates that the mechanism by
which OMVBV induce tolerance in DCs is not origi-
nated in classical endotoxin tolerance. Usually, low
doses of one TLR agonist desensitize the host to subse-
quent stimulation with a related agonist or endo-
toxin.59-61 However, the addition of a Toll-like
receptor (TLR) ligand can also induces tolerance to
subsequent challenges with other stimuli that signal
through one or more different TLRs (cross-tolerance).
Since outer membrane vesicles harbor various differ-
ent TLR ligands, OMVBV might even mediate TLR-
cross-tolerance. The simultaneous interaction of dif-
ferent MAMPs with different receptors might there-
fore result in complementary, synergistic or
antagonistic effects that modulate innate and adaptive
immunity.62-64
In summary, outer membrane vesicles derived from
the symbiotic intestinal commensal of B. vulgatusmpk
play a pivotal role in modulating and regulating
immune responses of the host. With their combined
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qualities of crossing physically barriers and the media-
tion of endotoxin tolerance and even cross-tolerance
in dendritic cells via the delivery of different microbial
ligands to immune cells, the production of OMV rep-
resents an important key feature of this symbiotic
strain, to prevent from intestinal inflammation in the
host. Due to these properties, OMVBV might even rep-
resent a potential therapeutical tool to hamper or
recover from inflammatory bowel diseases (IBD) and
other systemic inflammatory disorders.
Materials and methods
Cultivation of bone marrow derived dendritic
cells (BMDCs)
Bone marrow cells were isolated and cultivated for
differentiation as described previously.65 At day 7 after
isolation, resulting CD11c positive, bone marrow
derived dendritic cells (BMDCs) were harvested and
used for stimulation.
Cultivation of human embryonic kidney
cells (HEK cells)
Before stimulation, cryoconserved cell stocks were
thawed and cultured in DMEM media supplemented
with 10% FCS, 1% Penicillin/Streptomycin up to
passage 7.
Stimulation of bone marrow derived dendritic cells
Two £ 106 BMDCs were stimulated with either
PBS or B. vulgatus mpk or E. coli mpk at a MOI of
1 or various concentrations of B. vulgatus-derived
OMVs (5, 50, 500, 5000 ng mL¡1). Cells were stim-
ulated for a maximum of 24 hours. If a second
challenge was used, media were changed and cells
were restimulated with either PBS or E. coli mpk
MOI 1 for a maximum of 16 hours. Additionally,
exogenous TGF (Sigma-Aldrich) 20 ng mL¡1 and
prostaglandin E (Sigma-Aldrich) 1 mM were used
as positive and Toll-like receptor- independent
control.
Stimulation of human embryonic kidney cells
Two £ 104 HEK cells were stimulated with either PBS
or B. vulgatusmpk or E. colimpk at a MOI of 1 or var-
ious concentrations of B. vulgatus-derived OMVs (5,
50, 500 ng mL¡1). Cells were stimulated for a
maximum of 24 hours. FSL-1 (10, 100 ng mL¡1) and
Pam3CSK4 (30, 300 ng mL¡1) (both InvivoGen) were
used as positive and TLR2-specific agonist.
Flow cytometrical analysis
Multi-color FCM analyses were performed on a FACS
LSRII (BD Biosciences). All fluorochrome-coupled
antibodies were purchased from BD Biosciences. Data
were analyzed using the FlowJo software (Tree Star
Inc., USA).
Cytokine analysis by ELISA
For analysis of IL6, TNF and IL1ß concentrations in
cell culture supernatants, ELISA Kits purchased from
BD Bioscience were used according to the manufac-
turer’s instructions.
Bacteria cultivation
The bacteria used for stimulation of the murine den-
dritic cells were Escherichia coli mpk and Bacteroides
vulgatus mpk. The E. coli mpk strain was grown in
Luria-Bertani (LB) medium under aerobic conditions
at 37C. Bacteroides vulgatus was grown in Brain-
Heart-Infusion (BHI) medium and anaerobic condi-
tions at 37C.
Detection of secreted OMVs
Part of the cultured bacteria suspension was sedi-
mented for 2 h and fixed with Paraformaldehyde-
Glutaraldehyde Solution (Karnovsky’s Fixative) in a
rate of 7:2 (A:B) for 1 h at room temperature after
removal of excess fluids. Following, for the stabili-
zation of proteins and lipids samples were post-
fixed in osmium tetroxide. Fixed cells are then
embedded in agar and washed in 0.1 M cacodylate
buffer. Addition of uranyl acetate for 1 h enhanced
membrane stabilization and improved overall con-
trast. Dehydration was performed with an ETOH
dilution row, followed by transfer in epoxide solu-
tion. The polymerization of the agarose pad was
achieved via incubation for 20 h at 45C and plus
48 h at 60C. For visualization, the semi-thin sec-
tions were treated with toluidine blue staining.
Images were recorded with Zeiss Libra 120 Trans-
mission Electron Microscope.
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Isolation protocol and microscopy of purified OMVs
Cultured B. vulgatus mpk suspension was slightly vor-
texed and centrifuged for 10 min at 10,000 x g.
Supernatant was vacuum sterile filtrated and vesicles
were pelletized for 2 h at 38,000 x g. Pellets were resus-
pended in sterile PBS and mixed with Iodixanol
(OptiPrep) density gradient solution to prepare a 40%
working solution. Subsequently, a dilutions serial with
decreasing densities of 40%, 35%, 30%, 25%, 20% and
5% OptiPrep was assembled and stacked up in an
appropriate ultracentrifugation tube. The samples
were fractionated for 3 h at 280,000 x g and the devel-
oped, vesicle containing layers were collected. The iso-
lated vesicles were natively held via the grid-on-drop
technic and stained for negative imaging via TEM
with uranyl acetate.
FITC-labeling of isolated vesicles
Isolated and purified OMVs were incubated in the
dark for 1 h with 1 mg mL¡1 Fluorescein isothiocya-
nate (FITC) at room temperature. Suspension was
washed twice with HEPES buffer and centrifuged for
30 min at 52,000 x g. The pellet containing fluores-
cence-labeled OMVs was resuspended in sterile PBS.
Determination of OMVs concentration
for stimulation experiments
To ensure a standardized application of vesicles and
invariant stimulation of BMDCs and HEK cells, the
exact concentration of every OMV batch was calcu-
lated and defined by the PierceTM BCA Protein Assay
Kit using the manufacturer’s instructions.
Mice
C57BL/6J mice were purchased from Charles River
Laboratories. Toll-like receptor 2 and 4 deficient
(Tlr2¡/¡, Tlr4¡/¡) mice were provided by Jackson
Laboratory. All animals were kept and bred under SPF
conditions. For isolation of bone marrow, only female
mice aged 6–12 weeks were used. Animal experiments
were reviewed and approved by the responsible insti-
tutional review committee and the local authorities.
Statistics
Statistical analyses were performed using the unpaired
student’s t test. For comparing in vitro results, samples
were considered to be biologically independent if
the samples were generated from BMDCs from differ-
ent mice. Differences were considered to be statisti-
cally significant if p < 0.05. Error bars, if shown,
represent § standard deviation (SD).
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Generated by gram-negative bacteria, lipopolysaccharides
(LPSs) are one of the most abundant and potent immunomod-
ulatory substances present in the intestinal lumen. Interaction
of agonistic LPS with the host myeloid-differentiation-2/Toll-
like receptor 4 (MD-2/TLR4) receptor complex results in
nuclear factor kB (NF-kB) activation, followed by the robust
induction of pro-inflammatory immune responses. Here we
have isolated LPS from a common gut commensal, Bacteroides
vulgatus mpk (BVMPK), which provides only weak agonistic
activity. This weak agonistic activity leads to the amelioration
of inflammatory immune responses in a mouse model for
experimental colitis, and it was in sharp contrast to strong ag-
onists and antagonists. In this context, the administration of
BVMPK LPS into mice with severe intestinal inflammation
re-established intestinal immune homeostasis within only
2 weeks, resulting in the clearance of all symptoms of inflam-
mation. These inflammation-reducing properties of weak
agonistic LPS are grounded in the induction of a special type
of endotoxin tolerance via the MD-2/TLR4 receptor complex
axis in intestinal lamina propria CD11c+ cells. Thus, weak
agonistic LPS represents a promising agent to treat diseases
involving pathological overactivation of the intestinal immune
system, e.g., in inflammatory bowel diseases.
INTRODUCTION
Inflammatory bowel diseases (IBDs) are characterized by chronic re-
lapsing intestinal inflammation, with Crohn’s disease (CD) and ulcer-
ative colitis (UC) being the most frequent and clinically relevant
forms of this disease complex.1 The etiology of IBD is considered to
be multifactorial, with genetics,2 environmental factors,3 and intesti-
nal microbiota composition4 contributing to the pathology. Therapy
of IBD in humans is currently focused on symptomatic treatment,
often by means of immunosuppression.5 Furthermore, IBD patients
require intensive medical intervention, rendering IBD not only a
major health care but also a growing economic challenge.6 This un-
derlies the need for novel, low-priced, and innovative therapeutic
approaches.
It is widely accepted that the composition of the intestinal microbiota
contributes to the progression and outcome of IBD. However, not
only the presence, abundance, or proportion of certain live microbial
species account for such microbiota-mediated effects. Indeed, the
structure, and consequently the endotoxicity, of lipopolysaccharides
(LPSs) from gram-negative bacteria determines the outcome of
inflammation in a mouse model for experimental colitis.7 Further-
more, the composition and variety of the intestinal LPSome strongly
impact its inflammation-promoting or homeostasis-preserving prop-
erties.8 This makes LPS an interesting potential drug to target dysre-
gulated intestinal immune responses.
LPS, in its smooth form, consists of three distinct domains: (1) an
O-specific polysaccharide (O-chain); (2) a core oligosaccharide
(core OS); and (3) the lipid A, which anchors LPS to the outer
leaflet of the bacterial cell wall.9 With its highly conserved overall
structure and composition, LPS represents an important microbe-
associated molecular pattern (MAMP), playing an essential role
for the recognition of bacterial invasion by the host innate immune
system10,11 through recognition by the host myeloid-differentiation-
2/Toll-like receptor 4 (MD-2/TLR4) receptor complex. Importantly,
the chemical structure of LPS, primarily the detailed composition of
lipid A, drastically influences its biological activity, ranging from
strong activation of the innate immune system in the case of
agonistic LPS to a complete block of immune responses in the
case of antagonists.10,12 This different behavior is reflected in diverse
binding modes of such lipid A structures to the MD-2/TLR4 recep-
tor complex.13
Given the high amount of endogenous LPS in the gastrointestinal
lumen, it is important for the mammalian host to avoid overstimula-
tion of immune cells. Two crucial mechanisms contribute to
achieving this aim: (1) a tight intestinal epithelial barrier protecting
underlying immune cells in the lamina propria (LP) from luminal
LPS, and (2) the induction of endotoxin tolerance.
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Endotoxin tolerance denotes a phenotype of antigen-presenting cells
that are hyporesponsive toward a second LPS (endotoxin) stimulus
through receptor desensitization as the result of a first LPS stim-
ulus.14,15 Although being a well-documented phenomenon, the mo-
lecular mechanisms underlying endotoxin tolerance still remain
incompletely understood. Endotoxin tolerance has been observed
both in vitro and in vivo in animal models as well as in humans.16
The hyporesponsiveness of endotoxin-tolerant cells is reflected in
their inability to express and secrete pro-inflammatory cytokines,
such as interleukin (IL)-12, IL-6, and IL-1b, in response to a second
LPS stimulus.14 However, the detailed pattern of tolerant genes is cell
type dependent.16 Noteworthy, not only cytokine expression is dras-
tically reduced during endotoxin tolerance but also surface expression
of T cell-activating molecules, such as major histocompatibility com-
plex (MHC) class II and CD40.17,18
Endotoxin tolerance is established while LPS-stimulated antigen-pre-
senting cells undergomaturation characterized by increased expression
of pro-inflammatory cytokines and MHC class II surface expression.
So-called semi-mature cells, however, exhibit tolerance toward a sec-
ondary LPS stimulus, but they fail to express pro-inflammatory cyto-
kines in response to the first, semi-maturation-inducing stimulus.19
For example, the well-documented mouse gut commensal Bacteroides
vulgatusmpk (BVMPK) induces semi-matureCD11c+ cells in the intes-
tinal LP, which is thought to contribute to immunomodulating proper-
ties of this bacterial strain, resulting in the prevention of colitis induction
in several mouse models for experimental colitis.20–22 BVMPK belongs
to the bacterial phylum Bacteroidetes, which represents the most abun-
dant gram-negative phylum in themammalian gut.23Notably, not only
BVMPK but also other Bacteroides species, such as Bacteroides fragilis
(BF), provide beneficial and host immune system-modulating
properties.24 In this context, BF is of particular interest since its advan-
tageous properties were demonstrated to be rooted in a structural
component: the zwitterionic polysaccharide A (PSA).
Here we demonstrate that BVMPK drastically reduced already estab-
lished intestinal inflammation in mice, thus leading to a complete heal-
ing of damaged intestinal tissue. Intriguingly, this effectwasmirroredby
using a structural component other than PSA: LPS. BVMPK LPS was
found to exhibit weak agonistic activity for interaction with the host
MD-2/TLR4 receptor complex, and the administration of purified
BVMPK LPS re-established intestinal immune homeostasis in a mouse
model for experimental colitis. Theweak agonistic properties of this LPS
are thought to be responsible for its active amelioration of inflammation
through the induction of semi-mature LP CD11c+ cells. Hence, weak
agonistic LPS might be a novel and effective therapeutic agent for the
treatment of intestinal inflammatory disorders such as IBD.
RESULTS
BVMPK Actively Ameliorates Established Inflammatory
Reactions in a Mouse Model for Experimental Colitis, as
Confirmed by Non-invasive In Vivo PET Imaging
We have already demonstrated that mouse gut-associated commensal
BVMPK exhibits anti-inflammatory properties in various different
mouse models for experimental colitis.20–22 These anti-inflammatory
properties appeared when BVMPKwas administered before the onset
of disease, resulting in the prevention of microbiota-mediated intes-
tinal inflammation. This prompted us to verify whether this
commensal was also capable of reducing inflammatory reactions in
an already inflamed environment. Since we aimed to induce long-
term chronic inflammatory conditions, we chose a T cell transplanta-
tion model25 using Rag1-deficient mice, which fail to express func-
tional T and B cells.26 Upon transplantation of naive CD4+ T cells,
these Rag1/ mice develop a chronic form of intestinal inflamma-
tion, which is highly dependent on the microbiota composition.27
Therefore, we transplanted Rag1/ mice harboring a highly
dysbiotic microbiota (DYSM)7 with 5  105 naive wild-type (WT)
CD4+CD62L+CD45Rbhi T cells. The composition of the microbiota
is described in the Materials and Methods. At 4 weeks after T cell
transplantation, mice were administered 5  108 viable BVMPK/mL
drinking water until the end of the experiment. BVMPK-containing
drinking water was renewed every 2 days, and anaerobic BVMPK re-
mained viable under these conditions due to its aerotolerant proper-
ties (data not shown). Untreated Rag1/mice were used as negative
controls, and T cell-transplanted mice that were not administered
BVMPK were used as positive controls (Figure 1A).
Since we aimed to real-time monitor the progression of intestinal
inflammation in each individual, we injected all mice with [18F]-fluo-
rodeoxyglucose ([18F]FDG), and we performed non-invasive in vivo
positron emission tomography (PET). [18F]FDG is suitable for the
detection of ongoing inflammatory processes in living animals, since
sites of inflammation are depicted as regions with higher [18F]FDG
uptake in PET scans compared to non-inflamed surrounding
environments.28 However, some organs such as heart and bladder
generally provide a basic tracer uptake signal independent of their in-
flammatory status. We monitored the colonic [18F]FDG uptake over
time from all mice used for this experiment. Therefore, each mouse
was injected with [18F]FDG, and PET imaging was performed at
the day of T cell transplantation (week 0) as well as 4, 6, and 8 weeks
after T cell transplantation (Figure 1B). The obtained data were cor-
rected for decay, due to the half-life time of [18F], and normalized to
the injected activity per animal.
As demonstrated in the upper panel of Figure 1B, non-transplanted
Rag1/mice provided low [18F]FDG uptake during the whole obser-
vation period, indicating no ongoing inflammatory processes in the
colon. In line with previous publications,7,22 Rag1/mice harboring
a DYSM and transplanted with naive T cells exhibited severe colonic
inflammation, as illustrated by a high colonic [18F]FDG uptake at
weeks 4 and 6 (Figure 1B, middle panel). Since the inflammation in
these animals exceeded an ethically justifiable level, these animals
had to be sacrificed at week 6. As a third group, T cell-transplanted
Rag1/ mice, displaying severe signs of intestinal inflammation at
week 4 (Figure 1B, lower panel), were administered viable BVMPK
via drinking water from week 4 to week 8 after T cell transplantation.
In these mice, we observed a considerable reduction in colonic [18F]
www.moleculartherapy.org
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FDG uptake already after 2 weeks. Another PET scan at week 8
revealed comparably low [18F]FDG uptake, indicating that the in-
flammatory processes, visible at week 4, were cleared by BVMPK
administration. The PET results were confirmed by a reduced histo-
logical score and a reduced IL-17 expression in BVMPK-fed T cell-
transplaned Rag1/ mice, as compared to only T cell-transplaned
Rag1/ mice (Figures 4B–4D).
This clearly demonstrated that the anti-inflammatory properties of
the commensal BVMPK did not only prevent the induction of inflam-
mation in T cell-transplanted Rag1/ mice, as published previ-
ously,22 but also actively ameliorated already established colonic
inflammation, alleviating symptoms of colitis in this mouse model.
Induction of Hyporesponsive CD11c+Cells Is a CommonFeature
of Various Bacteroides Species
We have already demonstrated that BVMPK-mediated suppression
of intestinal inflammation strongly correlates with the induction of
a hyporesponsive or so-called semi-mature phenotype of LP
CD11c+ cells.7,22 We assumed that such hyporesponsive LP CD11c+
cells were responsible for the observed inflammation-preventing
and -reducing effects in in vivomodels for experimental colitis. Since
Bacteroidetes represents the major gram-negative phylum in the
human intestine,29,30 we aimed to examine the semi-maturation-
inducing properties of Bacteroides species other than BVMPK,
namely, B. dorei (BD), B. vulgatus ATCC8482 (BV8482), BF, and
B. thetaiotaomicron (BTIO).
It was already demonstrated that BVMPK induced semi-maturation
in vitro in bone marrow-derived dendritic cells (BMDCs). This
phenotype is characterized by low but measurable secretion of IL-6
with the simultaneous absence of secretion of other pro-inflammatory
cytokines, such as tumor necrosis factor (TNF), IL-12, and IL-1b, as
well as the absence of anti-inflammatory IL-10.22,31 Furthermore,
semi-mature BMDCs (smBMDCs) only provide slightly increased
surface expression of MHC class II, CD40, CD80, and CD86.22,31 In
general, LP CD11c+ cells strongly resemble BMDCs, as shown by
comparable expressions of CD45, CD11b, and CD103 while being
CD3neg, Ly6Gneg, Ly6Gneg, CD45Rneg, and CD64neg (Figure S1).
Therefore, we used BMDCs to assess whether Bacteroides strains
Figure 1. Administration of Live B. vulgatusmpk Reduces Intestinal Inflammation in Rag1–/–Mice with Established Colonic Inflammation, as Confirmed by
Non-invasive In Vivo PET Imaging
(A) Experimental setup: Rag1/ mice harboring a highly dysbiotic microbiota were transplanted with CD4+ T cells to induce intestinal inflammation as described. 4 weeks
after T cell transplantation, mice started receiving liveB. vulgatusmpk (BVMPK) in the drinking water at a concentration of 5 108mL1. BVMPK treatment was continued for
4 more weeks. 8 weeks after T cell transplantation, mice were sacrificed and analyzed. As controls, one group was transplanted without the following BVMPK administration
and one group was not T cell transplanted. (B) High-resolution non-invasive small animal in vivo PET imaging. 8.3 ± 1.3 MBq [18F]FDG was injected into the tail vein of each
mouse. Static PET scans were performed at the day of T cell transplantation and repeated 4, 6, and 8 weeks after T cell transplantation. Data were corrected for decay and
normalized to the injected activity. PET images of one representative individual per group are depicted (n = 8–10 mice per group). Organs providing high-intensity signals
(heart, bladder, and inflamed colon) are labeled in the upper left panel.
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other than BVMPK induce the effects of hyporesponsiveness in
CD11c+ cells.
BMDCs were generated from the bone marrow of WT C57BL/6N
mice, and they were stimulated for 16 h with PBS (mock) as a negative
control as well as with BVMPK, BD, BF, BV8482, and BTIO. E. coli
mpk (EC) was used as a positive control to induce fully mature
BMDCs.22 All bacteria were added to BMDCs at an MOI of 1. As
demonstrated by the low secretion of IL-6, the absence of IL-10 and
TNF, as well as by only slightly increasedMHC class II and CD40 sur-
face expressions, all tested Bacteroides strains induced comparable ef-
fects in BMDCs, which were comparable to BVMPK-induced effects,
therefore suggesting the induction of semi-maturation by all tested
Bacteroides strains (Figures 2A and S2). As expected, EC stimulation
led to the strong secretions of IL-6, IL-10, and TNF as well as
increased MHC class II and CD40 surface levels.
A characteristic feature of BVMPK-induced semi-mature (sm)
CD11c+ cells is hyporesponsiveness toward further bacterial stimuli
in terms of surface expressions of MHC class II, CD40, CD80, and
CD86 as well as secretions of cytokines, such as TNF, but not IL-6.
Therefore, we primed BMDCs with BVMPK, BD, BV8482, BF,
BTIO, or EC for 24 h and challenged them with EC. Importantly, me-
diumwas changed between prime and challenge to determine whether
primed cells were still capable of secreting pro-inflammatory cyto-
kines in response to EC challenge. As seen in Figure 2B, IL-6 secretion
was not reduced in Bacteroides-primed and EC-challenged BMDCs
compared to unprimed EC-challenged BMDCs. IL-10 secretion was
generally low among all different stimulus combinations. However,
priming of BMDCs with all tested Bacteroides strains resulted in the
tolerance of TNF expression after EC challenge in contrast to un-
primed BMDCs. In line with this, priming of BMDCs with all tested
Bacteroides strains resulted in (significantly) lower MHC class II and
CD40 surface expressions after EC challenge compared to EC-primed
BMDCs. However, these results point at the induction of semi-matu-
ration and, therefore, tolerance toward TNF and surface T cell-acti-
vating surface molecule expression by all tested Bacteroides species.
Thus, the induction of smBMDCs is not a unique property of BVMPK.
Figure 2. Induction of Hyporesponsive CD11c+ Cells Is a Common Feature of Various Bacteroides Species
(A) Stimulation of CD11c+ bone marrow-derived dendritic cells (BMDCs) generated from WT C57BL/6 mice (n = 3 mice) with PBS (mock), E. colimpk (EC), B. vulgatus mpk
(BVMPK), B. dorei (BD), B. vulgatus ATCC8482 (BV8482), B. fragilis (BF), and B. thetaiotaomicron (BTIO) for 16 h at an MOI of 1. Cytokine secretion was detected by ELISA.
Surface expressions of MHC class II and CD40 were detected by flow cytometry, and the population of MHC class II hi+ cells and CD40MFI, respectively, were normalized to
the mock control of BMDCs generated from the same individual. (B) WT BMDCs (n = 3mice) were stimulated with PBS (mock), EC, BVMPK, BD, BV8482, BF, and BTIO at an
MOI of 1 for 24 h (prime). Cell culture medium was removed and exchanged for fresh medium before stimulation (challenge) with EC for an additional 16 h. Cytokine secretion
was detected by ELISA. Surface expressions of MHC class II and CD40 were detected by flow cytometry. Statistical analysis was performed using one-way ANOVA.
p values <0.05 were considered to be statistically significant and are indicated with an asterisk (*). Columns and error bars represent mean ± SD.
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Bacteroides Species Share a Conserved Lipid A Synthesis Core
Since stimulation with heat-killed BVMPK, BD, BF, BV8482, and
BTIO also resulted in BMDC semi-maturation as induced by viable
bacteria (see also Figure S3), we supposed the crucial semi-matura-
tion-inducing bacterial factor to be a structural component that is
shared by all these strains. Bacteroides belong to gram-negative bac-
teria and harbor LPS in the outer membrane of the bacterial cell
wall. LPS is known to be one of the most potent surface molecules
and dendritic cell (DC) maturation-inducing components of gram-
negative bacteria. It consists of lipid A, a core oligosaccharide, and
an O-antigen composed of polysaccharides of various lengths. Jacob-
son et al.32 have recently reported on the differences in the poly- and
oligosaccharide portions among BF, BV8482, BD, and BTIO. Since all
these strains induced semi-maturation in our experiments (Figure 2),
we hypothesized that the induction of semi-maturation occurs inde-
pendently of LPS carbohydrate moieties. Therefore, we focused on the
lipid A part. Lipid A of BD and BF was reported to be similar in struc-
ture and composition, being mono-phosphorylated and harboring
only 5 acyl chains.33,34
To identify candidate genes for Bacteroides lipid A biosynthesis, we
performed BLASTP searches against genomes of BV8482, BD, and
BTIOusingBVMPKgenes as reference.We found lipidAbiosynthesis
genes of all investigated Bacteroides spp. to be homologous, since, with
some exceptions for BTIO, the similarities among the sequences ex-
ceeded 90% (Table 1). In the next step, we compared the biosynthesis
genes for BVMPK lipid A with the Raetz pathway of EC (Table 2). We
could clearly show that Bacteroides lipid A synthesis genes differ
significantly from the EC lipid A synthesis genes. The similarities be-
tween the genes were only between 25% and 42%, and the EC genome
was found to lack the BVMPK_0774 and BVMPK_3353 (Table 2).
These differences probably result in different lipid A compositions.
The observed gene homology among the lipid A cores of BVMPK,
BD, BTIO, and BV8482 is in line with our hypothesis that immuno-
genic effects on dendritic cells by all tested Bacteroides spp. are
mediated by their typical LPS. Correspondingly, EC, which produces
a different type of LPS, induced clearly different effects. Overall, this
suggests that the structure of Bacteroides spp. LPS is a crucial determi-
nant for the induction of semi-maturation in CD11c+ cells. Work is
ongoing to establish the chemical structure of LPS from BVMPK
(LPSBV) and its structure-activity relationship.
Isolated LPS of BVMPK Induces Hyporesponsive Semi-mature
CD11c+ Cells
To verify the hypothesis that Bacteroides spp. LPS is crucial for the in-
duction of hyporesponsive CD11c+ cells, we isolated LPSBV as well as
from EC (LPSEC), which contains a strongly agonistic bis-phosphor-
ylated and hexaacylated lipid A. We generated BMDCs from WT
C57BL/6 mice, and we stimulated these cells with either viable
BVMPK or EC at anMOI of 1. Additionally, BMDCs were stimulated
with purified LPSBV or LPSEC, both at concentrations of 50 ng1/106
BMDCs for a total of 16 h. As shown in Figure 3A, stimulation of
BMDCs with LPS resulted in the same BMDC phenotype as stimula-
tion with the respective bacteria from which the LPS was isolated.
Both, BVMPK and LPSBV stimulation led to low expressions of
MHC class II, CD40, CD80, and CD86 (Figure 3A) as well as to a
low secretion of IL-6 and an absence of TNF (Figure 3A). On the con-
trary, stimulation of BMDCs with either EC or LPSEC led to signifi-
cant increases in the surface expressions of MHC class II and T cell
co-stimulatory molecules CD40, CD80, and CD86 as well as to
increased secretions of IL-6 and TNF (Figure 3A).
To assess hyporesponsiveness toward a secondary stimulus, we stim-
ulated BMDCs for 24 h with PBS (mock), BVMPK, LPSBV, EC, and
LPSEC followed by a challenge with either EC or PBS as a negative
control. Importantly, medium was changed between prime and chal-
lenge to determine whether primed cells were still capable of secreting
pro-inflammatory cytokines in response to EC challenge. To deter-
mine the change in the surface expressions of T cell co-stimulatory
molecules in response to EC challenge, we determined the proportion
Table 1. Comparison of the Lipid A Core Synthesis Genes between BVMPK and BV8482, BD, and BTIO
BVMPK BV8482 BD BTIO
ID ID SIM (%) ID SIM (%) ID SIM (%)
BvMPK_3283 BVU_0099 100 HMPREF1064_02220 99 BT4205 82
BvMPK_3832 BVU_0098 99 HMPREF1064_02221 99 BT4206 86
BvMPK_3821 BVU_0097 99 HMPREF1064_02222 99 BT4207 69
BvMPK_4264 BVU_0525 100 HMPREF1064_04085 99 BT3697 84
BvMPK_1137 BVU_1917 99 HMPREF1064_04942 97 BT4004 74
BvMPK_0444 BVU_1603 99 HMPREF1064_03036 96 BT1880 100
BvMPK_1465 BVU_1476 99 HMPREF1064_03097 98 BT2747 66
BvMPK_0774 BVU_1062 98 HMPREF1064_01726 97 BT2152 34
BvMPK_3353 BVU_3834 99 HMPREF1064_04014 96 not identified
BvMPK_0983 BVU_1238 99 HMPREF1064_01498 93 not identified
BvMPK_2934 BVU_3293 99 HMPREF1064_03350 98 BT1854 48
Genetic similarities (SIMs) were calculated by alignment of the genes from BV8482, BD, and BTIO compared to BVMPK. IDs refer to the respective gene identifiers.
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of MHC class IIhi+, CD40+, CD80+, and CD86+ cells in primed and
EC-challenged BMDCs, and we compared them with PBS-challenged
controls that were primed with the same stimulus. Thus, high bars
indicate high responsiveness and low bars indicate tolerance (Fig-
ure 3B). As demonstrated in Figure 3B, both, BVMPK- and
LPSBV-primed EC-challenged BMDCs provided significantly lower
secretion of TNF. Furthermore, increases in CD80 and CD86 surface
expressions in LPSBV-primed and EC-challenged BMDCs were
significantly lower compared to PBS-primed and EC-challenged
BMDCs, indicating the induction of hyporesponsiveness of LPSBV-
primed cells concerning the surface expressions of T cell-activating
molecules. As expected, priming with EC and LPSEC leads to full
DC maturation.
To verify that LPSBV- and BVMPK-induced semi-maturating effects
on BMDCs are rooted in LPS-dependent TLR4 signaling, we pre-
incubated BMDCs for 1 h with the competitive TLR4 antagonist
TAK242 (Figure S4) before stimulation with LPSBV, BVMPK, and
EC for 16 h (Figure 3C). TAK242 pre-incubation abolished cytokine
secretion and modulation of MHC class II and CD40 surface expres-
sions for all the used stimuli. Therefore, we concluded that (1)
BVMPK induces BMDC semi-maturation mainly via its LPS, and
(2) purified LPSBV is sufficient to induce hyporesponsive semi-
mature BMDCs.
TAK242 is described to be a selective TLR4 antagonist,35,36 and our
control experiments confirmed that TAK242 led to an inhibition of
TLR4, but not TLR2, signaling. However, we cannot exclude that
TAK242 may also influence other signaling pathways.
LPS-mediated induction of TLR4 signaling results in the activation of
nuclear factor kB (NF-kB) and, therefore, in the expression of pro-
and anti-inflammatory cytokines. Since BVMPK and EC as well as
LPSBV induce a different cytokine secretion pattern via TLR4
signaling, we compared the NF-kB-activating potential of BVMPK
and EC, as well as of LPSBV and LPSEC. For this purpose, we used
HEK cells expressing the mouse MD-2/TLR4 receptor complex
(mTLR4-HEK) (Figure 3D), and we stimulated them for 16 h. The re-
sulting IL-8 secretion was detected as an indirect measure of MD-2/
TLR4-mediated NF-kB activation, since IL-8 secretion is a direct
consequence of TLR4-mediated NF-kB activation.37 Stimulation of
mTLR4-HEK cells with either viable BVMPK or EC at an MOI of 1
resulted in significantly higher IL-8 secretion from EC-stimulated
cells compared to BVMPK-stimulated cells (Figure 3D, upper panel).
Stimulation of mTLR4-HEK cells with isolated LPSBV or LPSEC re-
sulted in a concentration-dependent increase in IL-8 secretion when
LPSBV was used. LPSEC stimulation resulted in saturated IL-8 secre-
tion, even at concentrations as low as 1 ng mL1 (Figure 3D, lower
panel). The increased IL-8 secretion as a result of NF-kB activation37
indicated significantly stronger activation of LPSEC compared to
LPSBV in mTLR4-HEK cells. Additionally, we measured the phos-
phorylation of S534 of the NF-kB subunit p65 (p-p65) via flow cy-
tometry as a measure of NF-kB transactivation activity38,39 in mouse
BMDCs, in response to either LPSBV or viable BVMPK and EC,
respectively. Stimulation with BVMPK and LPSBV of BMDCs for
30 min resulted in a significantly lower p-p65 induction compared
to EC stimulation (Figure 3E).
Furthermore, we determined intracellular aldehyde dehydrogenase
(ALDH) activity in mouse BMDCs stimulated with viable BVMPK
or EC for 16 h (Figures 3F and S5). ALDH triggers the induction of
inflammation-ameliorating Foxp3+ regulatory T cells (Tregs) by
metabolizing vitamin A-derived retinol into retinoic acid (RA).40
RA has been shown to be a crucial mediator for the induction of
Tregs, and ALDH+ intestinal dendritic cells are considered to be
important mediators for immune homeostasis.19,41,42 BVMPK-stim-
ulated BMDCs showed a significantly higher ALDH activity
compared to EC-stimulated BMDCs, indicating a stronger Treg in-
duction potential.
LPS is known to be a strong agonist for the MD-2/TLR4 receptor
complex. However, it was reported that certain LPS structures also
induce TLR2-mediated signaling, i.e.,Helicobacter pylori LPS,43 while
the TLR2-activating capacity of Porphyromonas gingivalis LPS re-
mains controversial and is probably an experimental artifact due to
a lipoprotein contamination.44 Therefore, these reports raise the
question for a contribution of TLR2 signaling to the LPSBV-mediated
immunogenic effects on CD11c+ cells as well as for a potential
contamination of the used LPSBV preparations, which might, in
consequence, induce TLR2 receptor activation. Concerning potential
and yet unrecognized contaminations, not only lipoproteins but also
the presence of capsular polysaccharides has to be considered. During
the purification process, an additional ultracentrifugation step was
performed to eliminate the presence of capsular polysaccharides
from the LPSBV preparations. Nevertheless, we checked whether sol-
ubilized LPSBV preparations induce TLR2 signaling, since both
Table 2. Comparison of the Lipid A Core Synthesis Genes between BVMPK
and EC MG1655
BVMPK EC MG1655
ID ID SIM
BvMPK_3283 944849 42
BvMPK_3832 944816 36
BvMPK_3821 944882 33
BvMPK_4264 949053 27
BvMPK_1137 944838 31
BvMPK_0444 945526 25
BvMPK_1465 949048 26
BvMPK_0774 not identified
BvMPK_3353 not identified
BvMPK_0983 945863 35
BvMPK_2934 945450 27
Genetic similarities (SIMs) were calculated by alignment of the genes from Escherchia
coli K12 MG1655 (EC MG1655) compared to BVMPK. IDs refer to the respective
gene identifiers.
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Figure 3. Isolated LPS of BVMPK Induces Hyporesponsive Semi-mature CD11c+ Cells
(A) Stimulation of CD11c+ bone marrow-derived dendritic cells (BMDCs) generated from WT C57BL/6 mice (n = 4 mice) with PBS (mock), E. colimpk (EC), B. vulgatus mpk
(BVMPK), E. colimpk LPS (LPSEC), and B. vulgatusmpk LPS (LPSBV). Cytokine secretion was detected by ELISA. Surface expressions of CD40, CD80, CD86, and MHC
class II were detected by flow cytometry. (B) WT BMDCs (n = 4mice) were stimulated with PBS (mock), EC, LPSEC, BVMPK, and LPSBV for 24 h (prime). Cell culture medium
was removed and exchanged for fresh medium before stimulation (challenge) with EC for an additional 16 h. Cytokine secretion was detected by ELISA. Surface expressions
of MHC class II, CD40, CD80, and CD86 were detected by flow cytometry, and the population of MHC class II hi+ cells and CD40 MFI, CD80 MFI, and CD86 MFI were
normalized to the PBS-challenged control of BMDCs generated from the same individual with the same priming stimulus. (C) Stimulation of CD11c+ bone marrow-derived
(legend continued on next page)
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potential contaminants, capsular polysaccharides45–48 and lipopro-
teins49–51 from gram-negative bacteria, would result in TLR2 receptor
activation (Figure S6). We detected minor differences in IL-6 secre-
tion of LPSBV-stimulated WT BMDCs compared to TLR2-deficient
BMDCs, indicating a slight activation of TLR2 by LPSBV (Fig-
ure S6A). However, using TLR2/ BMDCs, we could exclude the
contribution of TLR2-mediated signaling to the induction of hypores-
ponsive semi-mature BMDCs (Figure S6B). Therefore, we conclude
that LPSBV-induced MD-2/TLR4 receptor signaling, but not TLR2
signaling, is crucial for the induction of BMDC semi-maturation.
Taken together, these results indicate a significantly weaker MD-2/
TLR4 receptor activation of LPSBV compared to LPSEC, resulting
in reduced NF-kB transactivation capacity. However, and in contrast
to being a MD-2/TLR4 antagonist, LPSBV actively induced hypores-
ponsive semi-maturation in BMDCs without inducing the expression
of pro-inflammatory cytokines. Thus, we suppose LPSBV to be rather
weak agonistic than antagonistic.
Administration of Purified LPSBV Reduces Established
Intestinal Inflammation in aMouseModel of Experimental Colitis
Since (1) weak agonistic LPSBV provided the same semi-maturation-
inducing capacities as viable BVMPK in BMDCs and (2) BVMPK-
mediated prevention of intestinal inflammation in Rag1/ mice
correlated with the induction of semi-mature LP CD11c+ cells, we
were interested to know if the administration of LPSBV resulted in
the same inflammation-reducing effects in T cell-transplanted
Rag1/ mice. Therefore, we used Rag1/ mice harboring a highly
DYSM, and we induced colonic inflammation through the transplan-
tation of 5  105 naive WT CD4+CD62L+CD45RBhi T cells. At week
4, transplanted mice showed clear signs of colonic inflammation, such
as bloody feces and diarrhea, which is in line with the PET imaging
that was performed to monitor intestinal inflammation (Figure 1B).
At this point, we started to administer viable BVMPK (5  108
bacteria/mL drinking water) as well as LPSBV at a concentration of
160 mgmL1 in the drinking water for 4 additional weeks (Figure 4A).
Mice with a C57BL/6 genetic background, such as Rag1/, were re-
ported to consume around 6 mL drinking water each day,52 suggest-
ing the daily uptake of LPSBV to be around 1 mg/mouse.
Figure 4B illustrates representative H&E-stained colonic sections
from each group taken at the end of the experiment. As expected,
non-treated T cell-transplanted animals showed severe signs of
colonic inflammation (Figure 4B, left panel). However, the LPSBV-
and BVMPK-treated animals exhibited significantly lower intestinal
inflammation (Figure 4B, middle and right panels) compared to
non-treated mice (Figure 4C). CD3+CD4+ T cells isolated from the
colonic LP (cLP) of live BVMPK-treated Rag1/ mice expressed
significantly lower amounts of IL-17 (Figure 4D), thus providing a
clearly reduced Th17 response,53 which crucially contributes to the
induction of colitis in this mouse model.
Furthermore, qRT-PCRs from colonic scrapings revealed that live
BVMPK-treated animals expressed significantly higher amounts of
ALDH mRNA (Figure 4E), which supports our in vitro findings of
a higher Treg-inducing potential of antigen-presenting cells that
encountered BVMPK (Figure 3F).
LPSBV-treated T cell-transplanted Rag1/ mice also provided
significantly lower proportions of IL-17-expressing CD3+CD4+ cLP
T cells as well as higher Aldh mRNA expression in colonic scrapings.
These data indicated that both live BVMPK and isolated LPSBV are
equally able to ameliorate established inflammatory processes in the
large intestine, by downregulating the Th17 immune response pro-
moting cytokines and by favoring Treg-inducing environmental
conditions.
Weak Agonistic LPSBV Is Not a Competitive Inhibitor of Strong
Agonistic LPS
The results obtained from in vivo experiments using Rag1/ mice
raised the question of whether LPSBV acts as a competitive inhibitor
at the MD-2/TLR4 receptor complex-binding site, therefore prevent-
ing agonistic LPS from binding and thus inducing complete CD11c+
cell maturation characterized by pro-inflammatory immune re-
sponses. First, we aimed to determine and compare binding constants
of LPSBV and the prototype agonistic LPSEC to the mouse MD-2/
TLR4 receptor complex. Therefore, we established an optical titration
setting to trigger quasi dissociation constants (KD) of both LPSBV
and LPSEC, using biotinylated LPSBV (bioLPSBV). Prior to that, bio-
LPSBVwas confirmed to provide the identical activation of the mouse
MD-2/TLR4 receptor complex (Figure S7), therefore suggesting that
biotinylation did not affect LPSBV-binding behavior.
We are aware of the fact that we could not determine real KD values,
since we did not know the exact molarity of the used LPS solutions.
The assembly of amphiphilic LPS monomers into micelles, vesicles,
dendritic cells (BMDCs) generated from WT C57BL/6 mice (n = 5 mice) with PBS (mock), BVMPK, EC, and LPSBV either with or without pre-incubation with TLR4 receptor
antagonist TAK242 at 1 h prior to bacterial stimulation. Cytokine secretion was detected by ELISA. Surface expressions of MHC class II and CD40 were detected by flow
cytometry, and the population of MHC class II hi+ cells and CD40 MFI, respectively, were normalized to the untreated mock control of BMDCs generated from the same
individual. (D) Stimulation of mouse MD-2/TLR4 receptor complex expressing HEK cells (mTLR4-HEK) with PBS (mock), EC, and BVMPK at an MOI of 1 (n = 2 experimental
replications with 3 technical replicates, upper panel) or LPSEC and LPSBV at various concentrations (n = 3 technical replicates, lower panel). The resulting IL-8 secretion as a
measure of NF-kB activation was detected by ELISA, and it is indicated by a blue line for mock samples in the lower panel. (E) Stimulation of BMDCs (n = 4 mice) with PBS
(mock), EC, BVMPK, and LPSBV for 30 min. The resulting phosphorylation of intracellular p65, phosphorylated at S534 (p-p65), was detected by flow cytometry. The
resulting MFI was normalized to the mock control of BMDCs generated from the same individual. (F) Stimulation of WT BMDCs (n = 5 mice) with PBS (mock), BVMPK, and
EC at an MOI of 1 for 16 h. ALDH levels in BMDCs were then detected using an Aldefluor ALDH activity assay. Statistical analysis was performed using one-way ANOVA
(A, B, and E) or Student’s t test (C and F). p values <0.05 were considered to be statistically significant and are indicated with an asterisk (*). Columns and error bars represent
mean ± SD.
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or even more complicated structures is highly dependent on the
buffer and ionic strength, and it is, therefore, hardly predictable.
This exacerbated the determination of themolarity of LPSmonomers,
which effectively have access to the receptor, rendering them active
ligands thus contributing to KD values. However, assuming that (1)
bioLPSBV and LPSEC provide a comparable monomeric molecular
weight, (2) bioLPSBV and LPSEC behave in a similar chemical
manner under the experimental conditions, and (3) all experiments
were carried out incubating both LPSs at the same time, we can spec-
ulate that a qualitative comparison using KD values in the unit g L
1
Figure 4. Isolated B. vulgatus mpk LPS Provides the Same Capability to Reduce Intestinal Inflammation in Rag1–/– Mice with Established Colonic
Inflammation as Live B. vulgatus mpk
(A) Experimental setup: Rag1/ mice harboring a highly dysbiotic microbiota were transplanted with naive CD4+ T cells to induce intestinal inflammation as described.
4 weeks after T cell transplantation, mice were not treated (TC only, n = 5), treated with liveB. vulgatusmpk (TC +BVMPK, n = 8) by administration of 5 108 bacteria mL1 in
the drinking water, or treated with isolated B. vulgatus mpk LPS (TC + LPSBV, n = 8) in the drinking water at a concentration of 160 mg mL1. Mice were sacrificed and
analyzed 8weeks after T cell transplantation. (B) Representative H&E-stained colonic sections at week 8. (C) Histological colitis score at week 8, ranging from 0 to amaximum
of 3. (D) Left panel: gating strategy to determine the CD3+CD4+ T cell population in the colonic lamina propria (cLP) at week 8. Right panel: proportion of IL-17+ cells among
the population of cLP CD3+CD4+ T cells, determined by flow cytometry. (E) Relative Aldh2mRNA expression in colonic scrapings at week 8, determined by qRT-PCR. Data
were normalized to Aldh2 mRNA expression in colonic scrapings of non-inflamed non-T cell-transplanted Rag1/ mice. Statistical analysis was performed using Kruskal-
Wallis test (C) or one-way ANOVA (D and E). p values <0.05 were considered to be statistically significant and are indicated with an asterisk (*). Columns and error bars
represent mean ± SD (C and E). Boxplots depict the mean as well as the 25th and 75th percentiles, and whiskers depict the highest and lowest values (D).
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instead of mol L1 is qualifiable for a comparison of their binding af-
finity. We finally determined quasi KD to be 0.412 g L
1 for LPSBV
and 0.304 g L1 for LPSEC (Figure 5A, see also Figure S8 for more
details on optical titration). These data allowed us to conclude that
LPSBV and LPSEC provide similar binding affinity to the mouse
MD-2/TLR4 receptor complex.
Next, we tested the capability of each of these two distinct LPSs to
remove already bound LPS from the receptor complex. Thus, we
incubated mTLR4-HEK cells with different concentrations of either
bioLPSBV or LPSEC for 1 h, and, subsequently, we added the oppo-
site LPS for 1 h and in several concentrations. Subsequent additional
incubation with phycoerythrin (PE)-coupled streptavidin (Strep-PE)
allowed for flow cytometry-based visualization of mTLR4-HEK cell-
bound bioLPSBV (Figure 5B). Pre-incubation with LPSEC followed
by subsequent incubation with bioLPSBV resulted in a low detected
PE fluorescence, fairly independent of the employed LPSEC and bio-
LPSBV concentrations (Figure 5C). This indicated that, once the mu-
rine MD-2/TLR4 receptor complex was bound by LPSEC, bioLPSBV
was not able to remove LPSEC from the receptor-binding site. Pre-in-
cubation with LPSEC, even at low concentrations of 1.25 mg L1,
resulted in a decrease of the PE signal to about 20% of the PE signal
that arose when cells were not pre-incubated with LPSEC (Figure 5C).
Contrariwise, pre-incubation of mTLR4-HEK cells with bioLPSBV
followed by subsequent incubation with LPSEC resulted in a strong
reduction of the PE signal, which is exclusively derived from bound
bioLPSBV, of about 50%, even when low concentrations of LPSEC
were added (Figure 5D). Since we assumed that the detected PE
fluorescence was directly proportional to the amount of bound
bioLPSBV, it can be stated that bioLPSBV was able to remove about
20% of already bound LPSEC (Figure 5C), while LPSEC was able to
remove about 50% of already bound bioLPSBV (Figure 5D).
We have already demonstrated that LPSBV is able to induce tolerant
semi-mature BMDCs in vitro (Figure 3) and reduce established intes-
tinal inflammation in T cell-transplanted Rag1/ mice harboring a
complex microbiota (Figure 4). So far, all experiments investigating
smBMDCs in vitro were performed in the absence of other LPS struc-
tures for the first 16 h of the semi-maturation process. Physiological
conditions in the colonic lumen provide the presence of different
commensal LPSs in large amounts at the same time. Therefore, we
stimulated BMDCs with weak agonistic LPSBV and prototype
agonistic LPSEC at the same time and at different concentrations
for 16 h (Figure 6A) to investigate if LPSBV-induced semi-maturation
even occurs in the presence of a strongMD-2/TLR4 receptor complex
agonist. Thus, we checked for the secretion of pro-inflammatory cy-
tokines and the surface expressions of MHC class II and TLR4.
We detected a concentration-dependent effect of LPSBV stimulation
on BMDCs in the absence of LPSEC (light blue lines in Figure 6B).
LPSBV concentrations of up to 100 ng mL1 (which equals
50 ng/106 BMDCs) led to a semi-mature BMDC phenotype, as
Figure 5. Weak Agonistic LPSBV Is Not a Competitive Inhibitor of Strong Agonistic LPS
(A) Determination of the dissociation constant (g L1, quasi KD) of LPSBV and LPSEC using an optical titration-based approach. (B) Left panel: experimental setting. 1 10
5
HEK cells expressing murine CD14, MD-2, and TLR4 (mTLR4-HEK) were incubated with a certain concentration of either LPSEC ranging from 0 to 5 mg L1 or biotinylated
LPSBV (bioLPSBV) ranging from 0 to 6 mg L1 for 1 h. After 1 h, the opposite LPS (either LPSBV or LPSEC) was added for an additional 1 h. PE-coupled streptavidin
(Strep-PE) was added for 30 min, and the resulting PE fluorescence associated with mTLR4-HEK cells was detected by flow cytometry. Right panel: gating strategy to
determine PE fluorescence of intact mTLR4-HEK cells is shown. (C) Binding curves of 4 distinct concentrations of LPSEC added first to mTLR4-HEK (n = 3 technical
replicates) plotted against varying concentrations of subsequently added bioLPSBV. (D) Binding curves of 7 distinct concentrations of bioLPSBV added first to mTLR4-HEK
(n = 3 technical replicates) plotted against varying concentrations of subsequently added LPSEC. Squares with error bars represent mean ± SD (C and D).
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previously demonstrated in Figure 3. Using 1,000 ng mL1 or 500 ng
pure LPSBV/106 cells resulted in a strong activation of BMDCs, as
indicated by high TNF, IL-6, and MHC class II surface expressions
(Figure 6B). This underlined and confirmed the observation that
LPSBV is not a MD-2/TLR4 receptor complex antagonist but rather
a weak agonist, with the overall concentration determining its final
endotoxicity. The addition of agonistic LPSEC to LPSBV-stimulated
BMDCs led to strong increases in secretion rates of pro-inflammatory
cytokines (Figure 6B) as well as in the expression of MHC class II
(Figure 6B) for all the used LPSEC concentrations. Therefore, the
simultaneous presence of LPSBV could not anticipate LPSEC-
induced maturation effects. Surprisingly, TLR4 expression on the
cell surface remained relatively constant among all differently stimu-
lated BMDCs (Figure 6B), indicating that no significant TLR4 endo-
cytosis is detectable upon binding of these two LPS structures to the
MD-2/TLR4 receptor complex, which was in opposition to what was
previously reported for other intestinal commensally derived LPSs.54
So far, these results indicated that the simultaneous encounter of
BMDCs with weak agonistic LPSBV and strong agonistic LPSEC pre-
vented LPSBV-induced semi-maturation. However, LPSBV adminis-
tration into mice harboring a complex microbiota reduced intestinal
inflammation. Since LPSBV-induced semi-maturation of CD11c+
cells might account for the observed inflammation-reducing effects
of LPSBV in vivo, we were interested to know how competition be-
tween LPSBV and endogenous LPS as well as other microbial compo-
nents from a complex mouse microbiota affects the phenotype of
CD11c+ cells. Therefore, we generated BMDCs from WT C57BL/6
mice, and we stimulated them with isolated LPSBV as described
before. Simultaneously, we added autoclaved feces that were taken
from Rag1/ mice 4 weeks after T cell transplantation, which pro-
vided severe intestinal inflammation (Figure 1B). These feces,
therefore, represent a DYSM composition that arises during intestinal
inflammation. The DYSM harbors various endogenous LPSs
competing with LPSBV for binding to the MD-2/TLR4 receptor com-
plex on LP CD11c+ cells as well as various other immunomodulating
components. Additionally, the DYSM represents the microbiota
composition LPSBV faced when it was administered to inflamed
Rag1/ mice and exhibited inflammation-ameliorating properties.
DYSM stimulation of BMDCs resulted in slight, but not statistically
significant, increases in the secretions of pro-inflammatory cytokines
and T cell co-stimulatory molecules (Figure 7A). This indicated that
the DYSM impacted CD11c+ cell maturation, albeit not as strongly as
EC with agonistic LPS (Figure S9), at least at the chosen DYSM con-
centration. Interestingly, simultaneous stimulation of BMDCs with
DYSM and LPSBV induced significantly stronger expressions of
IL-6 and TNF as well as increased surface expressions of MHC class
II and CD40 than either of the stimuli administered alone.
Since simultaneous stimulation of BMDCs with DYSM and LPSBV
resulted in fully mature BMDCs, we pre-incubated BMDCs with
LPSBV (prime) for 24 h before adding the DYSM (challenge). As
seen in Figure 7B, pre-incubation of LPSBV resulted in an induction
of tolerance of IL-6 and TNF expressions, preventing the secretion of
pro-inflammatory cytokines in response to DYSM challenge. How-
ever, surface expressions of MHC class II and CD40 were not altered
in LPSBV-primed and DYSM-challenged BMDCs compared to un-
primed and DYSM-challenged BMDCs.
These experiments demonstrate that the simultaneous stimulation of
CD11c+ BMDCs cells with LPSBV and components of an endogenous
DYSM did not lead to semi-maturation. Therefore, we concluded that
Figure 6. LPSEC-Induced BMDC Maturation Can Not Be Anticipated by the Simultaneous Presence of LPSBV In Vitro
(A) Experimental setting for (B): simultaneous stimulation of WT BMDCs (n = 3 mice) with LPSEC and LPSBV with varying concentrations of both LPSs. (B) Detection of
cytokine secretion and surface expressions of MHC class II and TLR4 of the experimental approach depicted in (A). Cytokine secretion was detected by ELISA. Surface
expressions of MHC class II and TLR4 were detected by flow cytometry. Squares with error bars represent mean ± SD.
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LPSBV-mediated induction of smBDMCs required the absence of
agonistic LPS for the initial phase of semi-maturation induction.
DISCUSSION
BVMPK belongs to the gram-negative bacterial phylum Bacteroidetes,
representing one of the two most prominent phyla in the mammalian
gut.29,30However, the proportion of Bacteroidetes in the intestinal mi-
crobiota is dependent on the inflammatory status of the gut. In ulcer-
ative colitis patients, the proportion of Bacteroides spp. is markedly
decreased,55 supporting the idea of Bacteroides spp. being important
beneficial players in the intestinal microbiota. Additionally, we have
already shown that the administration of BVMPK prevents disease
induction in different mouse models for experimental colitis,20–22
mainly by the induction of hyporesponsive semi-mature CD11c+ cells
(smDCs) in the cLP. These smDCs are responsible for the prevention
of pro-inflammatory immune responses.20–22,31 In this study, we
report that the administration of BVMPK drastically reduces estab-
lished and ongoing pathological inflammatory processes in the intes-
tine of a mouse model for experimental colitis using Rag1/ mice.
These immune response-regulating properties were mediated by
LPSBV, as the healing effects could be obtained using purified LPSBV
only. We therefore propose that LPSBV might be a novel therapeutic
agent for the treatment of chronic gut inflammatory disorders, by
restoring physiological intestinal immune homeostasis.
BVMPK is not the only Bacteroides strain that exhibits such beneficial
immunomodulatory properties. BF was reported to protect against
intestinal inflammation in a mouse model for experimental colitis56
as well as against CNS demyelination and inflammation during
experimental autoimmune encephalomyelitis.48 Interestingly, these
properties were mediated by one of its capsular PSAs through inter-
action with host TLR2.48,56,57 So far, we have no information on the
chemical structure of BVMPK capsular polysaccharides, but the close
relation between BF and BVMPK and the convincing immune sys-
tem-regulating properties of BF PSA prompted us to check for a
contribution of TLR2 signaling to the observed immunological effects
in CD11c+ cells in response to LPSBV stimulation. This is of partic-
ular interest since such a TLR2-mediated signaling might be due to
contamination of the used LPSBV preparations with capsular poly-
saccharides45–48,56,57 and lipoproteins49–51 or due to the LPS
itself.43,44,58 Although a slight TLR2 activation was detected, LPSBV
preparations crucially mediated the induction of CD11c+ cell semi-
maturation via the MD-2/TLR4 receptor complex.
In this context, we demonstrated that the immunomodulatory prop-
erties of LPSBV are clearly distinguishable from that of strong TLR4
agonists such as, e.g., E. coli-derived prototype LPS, or antagonists,
which block any TLR4-mediated signaling. Since LPSBV did not
induce the expression of pro-inflammatory cytokines but actively
induced hyporesponsiveness toward subsequent LPS stimuli in
CD11c+ cells, thereby fairly merging the properties of TLR4 antago-
nists and agonists, we propose LPSBV to be a weak agonist concern-
ing its interaction with the MD-2/TLR4 receptor complex.
To elucidate how endogenous LPSs from a complex mouse micro-
biota affect the phenotype of CD11c+ cells, we autoclaved the feces
of inflamed Rag1/ mice (DYSM). Hence, the DYSM represents
the endogenous LPS composition as well as other microbial com-
pounds LPSBV faced when it was administered to inflamed Rag1/
mice and exhibited inflammation-ameliorating properties. Interest-
ingly, simultaneous stimulation of BMDCs with DYSM and LPSBV
induced significantly stronger expressions of IL-6 and TNF as well
Figure 7. LPSBV-Mediated BMDC Tolerance Is Induced in the Absence of Agonistic LPS and Protects from Pro-inflammatory Response to a Dysbiotic
Microbiota Composition
(A) Feces from Rag1/mice providing intestinal inflammation (DYSM) was autoclaved and prepared as described in the Materials and Methods. WT BMDCs (n = 4–5 mice)
were stimulated with DYSM, LPSBV (100 ng mL1), or both simultaneously (DYSM + LPSBV). Cytokine secretion was detected by ELISA. Surface expressions of MHC class
II and CD40 were detected by flow cytometry and normalized to the mock control of BMDCs generated from the same individual. (B) WT BMDCs were stimulated (prime) with
either PBS (mock) or LPSBV for 24 h. Medium was changed and cells were stimulated afterward (challenge) with DYSM. Cytokine secretion was detected by ELISA. Surface
expressions of MHC class II and CD40 were detected by flow cytometry and normalized to an unchallenged mock control of BMDCs generated from the same individual.
Statistical analysis was performed using one-way ANOVA (A) or Student’s t test (B). p values <0.05 were considered to be statistically significant and are indicated with an
asterisk (*). Boxplots depict the mean as well as the 25th and 75th percentiles, and whiskers depict the highest and lowest values.
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as increased surface expressions of MHC class II and CD40 than
either of the stimuli administered alone. This finding is most likely
due to the fact that the induction of cytokines as well as the expression
of cell surface markers follows a dose-response effect. It can be seen in
Figure 6B that the stimulation of BMDCs with high concentrations of
LPSBV results in the induction of TNF and IL-6 secretions. Adding
LPSBV and the DYSM sample simultaneously results in the stimula-
tion of the cells with high LPS levels, hence inducing the secretions of
proinflammatory cytokines and expressions of BMDC activation sur-
face markers. The anti-inflammatory potential of LPSBV is nicely
demonstrated in Figure 7B where BMDCs were primed with either
PBS (mock) or LPSBV and challenged with DYSM. In this experi-
ment, it can be clearly seen that priming the cells with LPSBV led
to reduced secretions of TNF and IL-6 upon a challenge with DYSM.
Referring to the therapeutic effects of LPSBV in efficiently reducing
intestinal inflammation, we conclude that the concentration of
LPSBV located in the intestinal lumen is a decisive factor and must
exceed the number of endogenous agonistic LPSs in order to induce
tolerant semi-mature CD11c+ in the LP. Such exceeding LPSBV con-
centrations are thought to enhance the probability that intestinal DCs
only encounter weak agonistic LPSBV by enhancing the ratio between
weak agonistic to endogenous agonistic LPSs. This seems to be indis-
pensable since we demonstrated that a simultaneous encounter with a
strong agonistic LPS prevented LPSBV-induced DC semi-maturation
and induced pro-inflammatory responses instead. We could further
demonstrate that prototype agonistic LPSEC was able to remove
already bound LPSBV from the MD-2/TLR4 receptor complex
more efficiently than vice versa.
In a scenario of exceeding LPSBV concentrations in the gastrointes-
tinal lumen, this effect is thought to be irrelevant. As demonstrated,
the endotoxicity of LPSBV is dependent on its concentration, and a
very high LPSBV concentration leads to complete DCmaturation un-
derlying its weak agonistic properties, clearly distinguishing it from
an antagonist. Nevertheless, we demonstrated that the administration
of a daily dose of about 1 mg LPSBV/mouse via the drinking water led
to the observed inflammation-reducing effects in Rag1/ mice with
colitis, indicating that such a concentration is sufficient to exceed the
amount of endogenous LPS in the gastrointestinal tract while simul-
taneously being in a semi-maturation-inducing concentration range.
Once CD11c+ cell semi-maturation is induced, this phenotype cannot
be overcome, and it is, therefore, thought to result in the prevention of
a de novo T cell activation in the intestine. Therefore, after a phase-out
of ongoing inflammatory processes, newly induced semi-mature DCs
through LPSBV administration would prevent a continuous T cell
activation (Figure 8) and, therefore, promote healing of damaged
colonic tissue.
In general, LPS is a potent MD-2/TLR4 receptor complex agonist
leading to strong intracellular signaling in target cells, resulting in
the transcription of genes associated with pro-inflammatory immune
responses.13 LPS-induced strength of this intracellular signaling is
widely considered to be mostly mediated by its lipid A portion.59,60
Lipid A structures of various Bacteroides spp. were already reported to
harbor 4–5 acyl chains and only 0–1 phosphate group.8 Since we re-
vealed strong genetic similarities between the lipid A synthesis core of
BVMPK and other Bacteroides spp., we suggest LPSBV also to be
hypo-acylated and hypo-phosphorylated compared to LPSEC.
Hexa-acylated and bis-phosphorylated E. coli lipid A is considered
to be the most potent activator of the MD-2/TLR4 receptor com-
plex-mediated signaling, since it was demonstrated that five of the
six acyl chains are buried inside the MD-2-binding cavity while the
sixth acyl chain points out to the MD-2 surface-mediating hydropho-
bic interactions with the TLR4 ectodomain, which are necessary for
TLR4 activation.12,34 This might partly explain the lower endotoxicity
of hypo-acylated lipid A structures lacking this sixth acyl chain and
Figure 8. Proposed Mechanism of HowWeakly Agonistic LPSBV Influences MD-2/TLR4 Receptor Complex Activation and Prevents the Initiation of a CD4+
T Cell-Mediated Immune Response via Modulation of the Intestinal CD11c+ Cells
Therapeutic administration of LPS from symbiotic B. vulgatus mpk ends up in large amounts in the intestine, exceeding the amount of present LPS from other intestinal
commensal bacteria. Excess LPSBV primes naive CD11c+ cells into a tolerant, tolerogenic, and semi-mature phenotype that fails to activate CD4+ T cells. This prevention of a
de novo activation of CD4+ T cells leads to a phase-out of ongoing inflammatory processes, while de novo induction of an immune response is prevented. However, our data
indicate that this only happens if LPSBV is the only TLR4 ligand that CD11c+ cells encounter when they are still naive and immature. LPSBV needs a certain period of time to
induce CD11c+ cell tolerance. Simultaneous encounter with agonistic LPS does not lead to CD11c+ cell tolerance, and it does not, therefore, promote abrogation of in-
flammatory processes.
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the weak agonistic activity of hypo-acylated LPSBV. Furthermore,
both 1- and 4’- phosphates on the lipid A diglucosamine backbone
were demonstrated to be important moieties for MD-2/TLR4 recep-
tor complex activation.13 Since Bacteroidales possessed only one
phosphate at position 1 of the reducing glucosamine,8 this may also
contribute to its weakly agonistic effects, as a missing 4’-phosphate
was demonstrated to result in a 100-fold reduction in endotoxic
activity.61
We suppose the weak agonistic features of LPSBV to be responsible
for the observed healing effects in mice with intestinal inflamma-
tion. In this context, weak agonistic LPS is thought to induce a
weaker, but still detectable, intracellular signaling and NF-kB activa-
tion, providing a basic anti-inflammatory intracellular transcription
program without exceeding a pro-inflammatory threshold. Further-
more, LPSBV leads to the active induction of hyporesponsive
CD11c+ cells. These properties clearly distinguish LPSBV from
strong agonistic LPSEC, which induces endotoxin tolerance but
also strong pro-inflammatory signaling. However, weak agonistic
LPS is also different from antagonistic LPS, which does not promote
pro-inflammatory reactions but also does not promote tolerance in-
duction in TLR4-expressing cells. The property of LPSBV of being
an effective ligand for the MD-2/TLR4 receptor complex and, at
the same time, a weak agonist must, of course, be attributed to its
chemical structure. We think that this is a chemical paradigm of
the commensal intestinal microbiota LPS, contributing to the adap-
tion of microbes to the host. In line with this, other groups reported
on the contribution of Bacteroides LPS to the preservation of intes-
tinal homeostasis.8 However, our study represents the first success-
ful attempt to actively restore intestinal immune homeostasis in
mice providing severe intestinal inflammation by using commen-
sally derived LPS.
However, the immunogenic effects of weak agonistic LPS seem to be
situation dependent. In another study, Vatanen et al.33 revealed a
higher incidence of type 1 diabetes (T1D) in children who were less
exposed to strong agonistic LPS in early childhood, accompanied
by higher proportions of microbes harboring hypo-acylated and
hypo-phosphorylated LPS. In line with this, continuous intraperito-
neal administration of E. coli LPS starting shortly after birth delayed
the onset of T1D in non-obese diabetic (NOD)/Shilt mice while the
administration of hypo-acylated and hypo-phosphorylated BD LPS
failed to do so.33 This study supported the hygiene hypothesis that as-
sumes that early exposure to highly immunogenic microorganisms in
early childhood benefits immune system development and protects
the host from allergic and autoimmune diseases. At first sight, these
observations seem to be contradictory to our results. Though, in
our study, we aimed to actively re-establish immune homeostasis
from severe intestinal inflammation in adult animals. This approach
is different from the aim to protect from spontaneous disease onset
throughmicrobiota modulation in infants. Additionally, other groups
consider hypo-phosphorylated and hypo-acylated Bacteroides LPS to
be antagonistic. However, we have clearly demonstrated that these
LPS structures rather act as weak agonists.
Our results and those of other groups raise the question of the poten-
tial use of weak agonistic LPS as a suitable therapeutical tool to restore
homeostatic conditions not only in experimental mouse models but
also in IBD patients. Therapy of IBD patients is, to date, restricted
to a general suppression of the patient’s immune response, often asso-
ciated with undesirable side effects. LPS (derivative)-based treatment
might avoid this problem by acting only locally at the site of inflam-
mation, the intestine.
Although our results strongly indicate a direct LPS-mediated modu-
lation of CD11c+ cells in the intestinal LP to be the key driver for the
observed healing effects, we cannot completely rule out that the re-
establishment of intestinal homeostasis only represents a secondary
effect in response to a potential LPSBV-induced microbiota shift
from dysbiotic to homeostatic.
Nevertheless, we aim to promote purified LPSBV as an alternative for
the treatment of intestinal inflammatory disorders or IBD, providing
evidence that this compound demonstrated its beneficial effects as not
being an antagonist but rather a weak agonist. Concluding, we
contribute this study to IBD therapy-related research, offering a
completely new approach that avoids the disadvantages of current
state-of-the-art IBD therapies.
MATERIALS AND METHODS
Mice
C57BL/6 mice were purchased from Charles River Laboratories, and
C57BL/6J-Rag1tm1Mom (Rag1/) mice were obtained from our own
breeding. All animals were kept and bred under specific pathogen-
free (SPF) conditions in individually ventilated cages (IVCs),
receiving standard chow and regular drinking water. For the isolation
of bone marrow from C57BL/6 mice, only female mice aged
6–12 weeks were used. Rag1/ mice were used as a mouse model
for T cell transplantation-dependent experimental chronic colitis.
Animal experiments were reviewed and approved by the responsible
institutional review committee and the local authorities (Regierung-
spräsidium Tübingen, Permit H6/10, Anzeigen 01.12.11, 09.01.15,
14.06.17).
T Cell-Mediated Induction of Chronic Colitis in Rag1–/– Mice
C57BL/6J-Rag1tm1Mom (Rag1/) mice were transplanted with
5  105 splenic CD4+CD62L+CD45RBhiC WT T cells at 8–10 weeks
of age. Rag1/ mice harbored a so-called DYSM, which efficiently
triggers the induction of pathological intestinal inflammation upon
transplantation of naive T cells, as reported previously.7,22 This
microbiota was absent of Norovirus, Rotavirus, andHelicobacter hep-
aticus. Furthermore, detailed next-generation sequencing-based anal-
ysis of DYSM composition revealed a significantly increased relative
abundance of the bacterial phyla Proteobacteria, Verrucomicrobia,
and Firmicutes, while the relative abundance of Bacteroidetes was
drastically reduced compared to a symbiotic microbiota composition,
as published previously by our group.7 During the experiments,
Rag1/ mice were kept under SPF conditions in IVCs and analyzed
8 weeks after T cell transplantation, as indicated in the Results.
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Radiopharmaceuticals
[18F]fluoride was produced by using 18O (p,n) 18F nuclear reaction
on the PETtrace cyclotron (General Electric Medical Systems,
GEMS, Uppsala, Sweden). [18F]FDG synthesis was performed as
described elsewhere.62 After the synthesis, specific activity was
calculated and revealed to be >50 GBq/mmol with a radiochemical
purity of >99%.
In Vivo PET Imaging
High-resolution PET imaging was performed using two identical
small animal Inveon microPET scanner (Siemens Medical Solutions,
Knoxville, USA) with a spatial resolution of 1.4 mm in the recon-
structed images (field of view [FOV]: transaxial, 10 cm; axial,
12.7 cm).63 By applying iterative ordered subset expectation maxi-
mization (OSEM) 2D algorithm for reconstruction, list mode data
were processed. Mice were anesthetized with 1.5% isoflurane
(Abbott, Wiesbaden, Germany) vaporized with O2 (1.5 L/min)
and injected intravenously (i.v.) into the tail vein with 8.3 ±
1.3 MBq [18F]FDG. After tracer injection, animals were kept anes-
thetized for 60 min, in an anesthesia box, placed on a heating pad
to maintain body temperature of animals during tracer uptake
time. Shortly before the end of the uptake time, mice were placed
in the FOV of the PET scanner on a warmed (37C) scanner bed.
Static (10-min) PET scans were performed on weeks 0, 4, 6, and
8 after T cell application. Data were corrected for decay, normalized
to the injected activity, and analyzed using Pmod Software (PMOD
Technologies, Zurich, Switzerland) by drawing regions of interest
over the intestine.
Bacteria
The bacteria used for stimulation of the mouse BMDCs were EC and
BVMPK, which were described in detail previously.20–22,31,64 Addi-
tionally, we used BD CL02T12C06, BTIO VPI-5482, BV8482
ATCC 8482, and BF ATCC 25285, DSM 2151. The EC strain was
grown in Luria-Bertani (LB) medium under aerobic conditions at
37C. All Bacteroides strains were grown in brain-heart-infusion
(BHI) medium and anaerobic conditions at 37C.
Comparison of Bacteroides spp. Lipid A Synthesis Genes
Lipid A synthesis genes were identified in BVMPK (GenBank:
NZ_CP013020.1) using the B. vulgatus ATCC8482 type strain
genome sequence (GenBank: NC_009614.1). The amino acid
sequences of all lipid A synthesis enzymes of BVMPK were
subsequently compared to BD CL02T12C06 (GenBank:
NZ_AGXJ00000000.1), BTIO VPI-5482 (GenBank: NC_004663.1),
BF NCTC 9343 (GenBank: NC_003228.3), and E. coli K12 MG1655
(GenBank: NC_000913.3), using the standard protein BLAST
(blastp suite).
Isolation of LPSBV and LPSEC
The lyophilized bacterial pellet was washed several times with distilled
water, ethanol, and acetone, followed by several ultracentrifugation
steps (45,000 rpm at 4C) in order to remove cell, growth broth,
and capsular contaminants.
Cells were extracted by hot phenol-water extraction.65 Water and
phenol phases were both exhaustively dialyzed and lyophilized. After
inspection by SDS-PAGE, an enzymatic treatment to remove proteins
and nucleic acids was executed, followed by a dialysis step. The SDS-
PAGE executed on both purified water and phenol phases highlighted
the presence of LPS only in the water phase from which it was further
purified.
Biotinylation of LPSBV
10 mg LPSBV was biotinylated with EZ-Link Micro Sulfo-NHS-LC-
Biotinylation Kit (Thermo Scientific), according to the manufac-
turer’s protocol, using PBS as a solvent. To remove PBS, an exhaustive
dialysis against distilled water was performed. The biotinylated LPSBV
(bioLPSBV) was then collected and lyophilized. For in vitro experi-
ments, lyophilized bioLPSBV was dissolved in distilled water in con-
centrations not higher than 1 mg mL1.
Cultivation of BMDCs
Bone marrow cells were isolated from C57BL/6 WT, TLR2-deficient,
TLR4-deficient, and TLR2  TLR4 double-deficient mice and culti-
vated as described previously.66 At day 7 after isolation, the resulting
CD11c-positive dendritic cells were used for stimulation experiments.
Stimulation of BMDCs
2 106 BMDCs were stimulated with PBS, BVMPK, or EC at anMOI
of 1 or the respective isolated LPS at concentrations as indicated in the
Results. Cells were stimulated for a maximum of 24 h. If viable bac-
teria were used for stimulation, gentamycin was added at a final con-
centration of 1 mg mL1 to avoid bacterial overgrowth under aerobic
conditions. If a second challenge was used, cells were stimulated with
bacteria or LPS preparations for 24 h. Cell culture medium was
changed before challenging the cells with a second stimulus for a
maximum of additional 16 h. PBS was used as a mock stimulation
control. For stimulation with a DYSM composition, feces were
collected from living SPF Rag1/ animals exhibiting severe intestinal
inflammation, 4 weeks after T cell transplantation. Feces were auto-
claved for 15 min at 121C and weighed, and sterile PBS was added
to obtain a final concentration of 50 mg mL1. Homogemnized feces
were then filtered through a 100-mm sieve. The filtered suspension
was diluted by a factor of 2.5, and 5 mL was added to 1 mL cell culture
medium containing 106 BMDCs. The competitive TLR4 antagonist
TAK242 was added at a final concentration of 10 mM at 1 h prior
to stimulation with LPS, Pam2CSK4, flagellin from S. Typhimurium
(FLA-ST), or viable bacteria.
Stimulation of HEK Cells
2  105 HEK cells expressing murine CD14, MD-2, and
TLR4 (mTLR4-HEK) in 1 mL medium were stimulated with
1–1,000 ng mL1 isolated LPS or bacteria (MOI 1) for the time points
indicated in the Results.
Detection of Bound Biotinylated LPSBV
After incubation with biotinylated LPSBV, mTLR4-HEK cells were
scraped off, washed once in PBS + 1% fetal calf serum (FCS), and
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incubated with Strep-PE for 30 min, followed by another washing
step. Cell-attached Strep-PE was detected by flow cytometry. All ex-
periments to be compared were carried out in one experimental
setting to guarantee for comparability of the detected MFI (median
fluorescence intensity) values of the PE fluorescence.
Cytokine Analysis by ELISA
For the analysis of secreted cytokines (IL-6, IL-10, and TNF), ELISA-
based detection kits were purchased from BD Biosciences and used
according to the manufacturer’s instructions.
Flow Cytometry Analysis
Multi-color flow cytometrical (FCM) analyses were performed on a
FACS Calibur or FACS LSRII (BD Biosciences). All fluorochrome-
coupled antibodies were purchased from BD Biosciences if not stated
otherwise. Data were analyzed using the FlowJo software (Tree Star,
USA).
ALDH Activity Assay
Intracellular ALDH activity in BMDCs was assayed using the Alde-
fluor kit (STEMCELL Technologies), according to the manufacturer’s
instructions. Samples treated with the specific ALDH inhibitor dieth-
ylaminobenzaldehyde (DEAB) served for the determination of base-
line fluorescence and defining ALDH-positive cells (Figure S5).
Purification of RNA and Quantitative Real-Time PCR
Purification of RNA from colonic scrapings was performed using
QIAGEN’s RNeasyMini Kit, according to themanufacturer’s instruc-
tions. Additional DNA digestion was conducted by using 4 U rDNase
I and 40 U rRNasin for an RNA solution of 0.1 mg mL1. After 30 min
of incubation at room temperature (RT), DNase was inactivated using
Ambion DNase inactivation reagent, which was later removed by
centrifugation for 1 min at 10,000  g. SybrGreen-based qRT-PCR
was performed on a Roche LightCycler480 using QIAGEN SybrGreen
RT-PCR Kit. Primer annealing occurred at 60C. 10–100 ng DNA-di-
gested RNA was used for qRT-PCR. Relative mRNA expression in
BMDCs stimulated with bacteria to unstimulated BMDCs was deter-
mined, with b-actin as the housekeeping gene, using the DDCp
method that included the specific amplification efficiency of every
used primer pair and each PCR run.
Primer Sequences
Primers used for qRT-PCR were as follows: Aldh1a2 forward, 50-AA
GACACGAGCCCATTGGAG-30; reverse, 50-GGAAAGCCAGCCT
CCTTGAT-30; and b-actin forward, 50-CCCTGTGCTGCTCACC
GA-30; reverse, 50-ACAGTGTGGGTGACCCCGTC-30.
Isolation of LP DCs and T Cells and the Adoptive Transfer of T
Cells
Isolation of LP cells was performed as reported previously.67 For
adoptive transfer, splenic CD4+ T cells from C57BL/6 mice were pu-
rified using a magnetic-activated cell sorting (MACS)-based negative
selection kit (Miltenyi), according to the manufacturer’s instructions.
The isolated cells were stained for CD3ε, CD4, CD62, and CD45RB
for reanalysis; purity was generally >90% with >80% being
CD3ε+CD4+CD62L+CD45RBhi. 5  105 CD4+ T cells were injected
intraperitoneally (i.p.) into Rag1/ mice, as described previously.68
Histology
Colonic tissues were fixed in neutral buffered 4% formalin.
Formalin-fixed tissues were embedded in paraffin and cut into
2-mm sections. They were stained with H&E (Merck) for histological
scoring. Scoring was conducted in a blinded fashion on a validated
scale of 0–3, with 0 representing no inflammation and 3 represent-
ing severe inflammation characterized by infiltration with inflam-
matory cells, crypt hyperplasia, loss of goblet cells, and distortion
of architecture.69
Antibodies
The following antibodies were used for flow cytometry analysis of
intracellular and surface proteins: anti-mouse CD11c-allophycocya-
nin (APC) (clone H3; Becton Dickinson), anti-mouse MHC class
II-fluorescein isothiocyanate (FITC) (clone 2G9, Becton Dickinson),
anti-mouse MHC class II-BV510 (clone 2G9, Becton Dickinson),
anti-mouse CD40-FITC (clone 3/23, Becton Dickinson), anti-
mouse CD40-BV421 (clone 3/23, Becton Dickinson), anti-mouse
CD80-FITC (clone B7-1 (16-10A1), Becton Dickinson), anti-
mouse CD86-FITC (clone GL1, Becton Dickinson), anti-mouse
p65-PE (pS534) (clone 96H1, Becton Dickinson), anti-mouse
Ly6G/Ly6C-FITC (clone GR-1/RB-68C5, Becton Dickinson), anti-
mouse CD45R-FITC (clone RA3-6B2, Becton Dickinson), anti-
mouse CD64-FITC (clone X54-5/7.1, Becton Dickinson), anti-mouse
CD45-BV421 (clone 30-F11, Becton Dickinson), anti-mouse CD11b-
BV605 (clone M1/70, Becton Dickinson), anti-mouse CD103-PerCP-
Cy5.5 (clone M290, Becton Dickinson), and anti-mouse TLR4-biotin
(clone SA15-21, BioLegend).
Statistics
For comparisons of two groups, a parametric Student’s t test was used
for normally distributed values. For multiple comparison of more
than two groups, one-way ANOVAwas used for normally distributed
values and non-parametric Kruskal-Wallis test was used elsewhere.
p values are indicated in the figures; p values <0.05 were considered
to be significant.
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B cells fulfill multifaceted functions that influence immune responses during health and
disease. In autoimmune diseases, such as inflammatory bowel disease, multiple sclerosis
and rheumatoid arthritis, depletion of functional B cells results in an aggravation of
disease in humans and respective mouse models. This could be due to a lack of a
pivotal B cell subpopulation: regulatory B cells (Bregs). Although Bregs represent only a
small proportion of all immune cells, they exhibit critical properties in regulating immune
responses, thus contributing to the maintenance of immune homeostasis in healthy
individuals. In this study, we report that the induction of Bregs is differentially triggered
by the immunogenicity of the host microbiota. In comparative experiments with low
immunogenic Bacteroides vulgatus and strong immunogenic Escherichia coli, we found
that the induction and longevity of Bregs depend on strong Toll-like receptor activation
mediated by antigens of strong immunogenic commensals. The potent B cell stimulation
via E. coli led to a pronounced expression of suppressive molecules on the B cell
surface and an increased production of anti-inflammatory cytokines like interleukin-10.
These bacteria-primed Bregs were capable of efficiently inhibiting the maturation and
function of dendritic cells (DCs), preventing the proliferation and polarization of T helper
(Th)1 and Th17 cells while simultaneously promoting Th2 cell differentiation in vitro.
In addition, Bregs facilitated the development of regulatory T cells (Tregs) resulting
in a possible feedback cooperation to establish immune homeostasis. Moreover, the
colonization of germfree wild type mice with E. coli but not B. vulgatus significantly
reduced intestinal inflammatory processes in dextran sulfate sodium (DSS)-induced
colitis associated with an increase induction of immune suppressive Bregs. The quantity
of Bregs directly correlated with the severity of inflammation. These findings may
provide new insights and therapeutic approaches for B cell-controlled treatments of
microbiota-driven autoimmune disease.
Keywords: immune regulation, homeostasis, microbiota, regulatory B cells (Bregs), interleukin 10 (IL-10),
immunogenicity, inflammatory bowel disease (IBD), Toll-like receptors
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INTRODUCTION
The fact that B cells play a critical role during the onset
and course of inflammatory processes is indisputable and
has been demonstrated in many studies in both mice and
humans. However, these studies focused on the production of
autoantibodies with B cells being understood as the cause for
the development of inflammation, e.g., multiple sclerosis (MS)
(1–3). Nevertheless, it is important to discriminate between
the versatile functions of B cells. More and more studies have
revealed that the depletion of B cells leads to an aggravation of
disease in many autoimmune disorders, such as inflammatory
bowel disease (IBD) and rheumatoid arthritis (RA) (4). B cells
were shown to mediate an anti-inflammatory effect in mice that
spontaneously develop chronic colitis, exhibiting more severe
disease in the absence of B cells (5–9). Even in experimental
autoimmune encephalomyelitis (EAE), an animal model for
MS, CD20 antibody-mediated B-cell depletion substantially
exacerbated the disease when the treatment was initiated before
EAE induction (10–12). Thismay link the activation of functional
B cells with a suppressive effect in inflammation by promoting
immune tolerance.
The beneficial influence of B cells during inflammatory
processes is primarily attributable to a specific B cell
population—regulatory B cells (Bregs) (13). Hitherto, no
definitive phenotype with specific markers has been identified
for Bregs. Certain phenotypes are characterized and described,
but they differ in their expression of surface proteins. However,
these phenotypes possess similar functionalities which explain
the reason why the definition of Bregs is based on their
immune-regulatory and anti-inflammatory capabilities (14).
The main features of Bregs include the potent suppression
of type 1 T helper (Th) cell differentiation, the inhibition of
autoimmune pathogenesis and the maintenance of immune
homoeostasis (15). The three most intensely studied Breg
subsets are splenic transitional 2 marginal-zone precursor
(T2-MZP) cells (CD19+CD21hiCD23hiCD24hi), B10 cells
(CD19+CD5+CD1d+IL10+), and Tim-1+ B cells (CD19+Tim-
1+) (16–21). A common and most important feature of these
B cell subsets is the production and secretion of the anti-
inflammatory cytokine interleukin 10 (IL-10). IL-10 fulfills
regulatory functions by effectively suppressing cell-mediated
inflammatory responses, thus restoring Th1/Th2 balance (22–
25). IL-10-producing B cells have also been identified in humans
(26, 27). The powerful immune downregulation quality of IL-10-
producing Bregs has already been shown in various autoimmune
diseases, such as EAE, collagen-induced arthritis, lupus and
inflammatory bowel disease (9, 28–31). Depending on the type
of inflammatory response, there are two major mechanisms by
which Bregs suppress inflammation via IL-10: (I) in autoimmune
diseases, such as IBD where both innate and adaptive immune
responses are involved, Bregs directly dampen the production
of proinflammatory cytokines by macrophages (32–34); (II)
during inflammatory processes in, for example, EAE and RA,
in which an overshooting T cell-mediated response is the
driving force for inflammation, Bregs balance Th1/Th2 immune
homeostasis (9, 28). Moreover, Bregs shift T cell differentiation
to a regulatory phenotype (Tregs) in both mice and humans
(19, 35). The influence of regulatory B cells on the induction
of Tregs polarization has been verified in B cell-deficient µMT
mice and mice harboring a B cell-specific deletion of IL-10.
These genotypes revealed a reduction of Treg numbers with a
simultaneous increase of proinflammatory Th1 and Th17 cells
(19, 36–38).
In addition to the production of IL-10, Bregs express
and secrete suppressive molecules and thus possess further
mechanisms to regulate immune responses in an IL-10-
independent manner: CD73 is a cell-surface enzyme that
converts adenosine monophosphate to adenosine with potential
immunosuppressive effects (39); PD-L1 (programmed death
ligand 1) is an inhibitory costimulatory molecule that restricts
T cell differentiation (40–43); FasL (Fas ligand) bound with
its receptor induces apoptotic cell death (44–46); GITRL
(glucocorticoid-induced tumor necrosis factor receptor-related
protein ligand) induces proliferation of Tregs (47); EBI3/IL-
35 (Epstein-Barr virus induced gene 3) regulates inflammatory
immune responses through induction of Tregs (48–51). In
combination, these molecules perfect regulatory B cells to a
strong immune-suppressive cell subset.
However, only a few studies have been published that
investigate the activation B cells by a direct interaction with
viable bacteria in vitro and in vivo. It has thus far been shown
that several bacterial and viral pathogens, as well as parasites,
manipulate B cell function directly to modulate host immune
responses as part of an immune evasion strategy facilitating their
survival and prolonging infection (51–55). Recently published
studies highlighted the influence of the resident microbiota on
the activation of B cells that modulate intestinal inflammation
and promote immune homeostasis (16, 56). The intenseness of
B cell activation and differentiation depends on the composition
of the host microbiota and the involved resident bacteria which
interact and stimulate various immune cells (immunogenicity)
(56–58). The immunogenicity of bacteria is pivotal for the
strength of provoking an immune response. As demonstrated in
recently published studies, the immunogenicity is dependent on
the structure of different MAMPs (e.g., LPS) and consequently
to the binding affinity to PRRs (59). We thus investigate
the immunogenicity-dependent potential of the two model
commensals Bacteroides vulgatus (weak immunogenic) and
Escherichia coli (strong immunogenic) to modulate and regulate
the immune system of the host via B cells. In this context, we
could already show that a weak immunogenic signal provided by
B. vulgatus is beneficial in genetically predisposed host (deficient
for Rag1 or IL-2) in the course of inflammation. In contrast,
the administration of strong immunogenic E. coli aggravates
the disease progression due to the lack of a functional B cell
immunity which can restore immune tolerance in a healthy host
by counter-regulating the induced pro-inflammatory immune
response (59–61).
In this study we demonstrated the following: (I) B cells
can be activated directly by commensal members of the host
microbiota and, depending on the immunogenic potential of
the encountered bacterial species, B cells can mint strong
regulatory cell phenotypes to promote immune tolerance; (II)
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the intensified induction of Bregs by E. coli can counter-
regulate pro-inflammatory immune responses in a healthy host
inherently caused by the same bacteria; (III) this regulation
mechanism may serve as a feedback loop to maintain immune
homeostasis and even attenuate inflammatory processes in
autoimmune disease.
MATERIALS AND METHODS
Bacteria Cultivation
E. coli mpk was grown in Luria-Bertani (LB) medium under
aerobic conditions at 37◦C. B. vulgatusmpk was grown in Brain-
Heart-Infusion (BHI) medium and anaerobic conditions at 37◦C.
Mice
C57BL/6NCrl mice and C57BL/6-Tg(TcraTcrb)425Cbn/Crl (OT-
II) mice were purchased from Charles River Laboratories. Toll-
like receptor 2 and 4 double KO mice (Tlr2−/−, Tlr4−/−) were
provided by Jackson Laboratory. All animals were kept and
bred under SPF conditions. For isolation of B cells, T cells
and bone marrow, only female mice aged 8–10 weeks were
used. Germfree C57BL/6J mice were bred and housed in our
own gnotobiotic facility. Animal experiments were reviewed and
approved by the responsible institutional review committee and
the local authorities.
Purification and Cultivation of Naïve B
Cells and Naïve T Cells
B cells were purified from spleens of WT or TLR2−/−
× TLR4−/− mice by magnetic isolation using negative
selection with microbeads (Miltenyi Biotec) according
to the manufacturer’s instruction. The purity of
CD19+CD43−CD4−Ter119− B cell population was >95%.
B cells were cultured in complete medium (RPMI1640
supplemented with 10% FCS, 50µM 2-mercaptoethanol, 25mM
Hepes, 1% non-essential amino-acids, 1% sodium pyruvate and
1% penicillin/streptomycin) at a density of 1 × 106 cells/mL in
flat-bottom plates for subsequent stimulation experiments. The
purity of naïve CD4+CD44−CD8a−CD11b−CD11c−CD19−
CD25−CD45R−CD49b−CD105−MHCII−Ter-119−TCRγ/δ−
T cell population was >94%. After purification, T cells were
directly used for co-culture experiments. For proliferation assays,
isolated splenic B cells or T cells were adjusted to a concentration
of 106 cells/mL in PBS/1% FCS, resuspended in 10µMCFSE and
incubated at 37◦C for 20 min.
Cultivation of Bone Marrow-Derived
Dendritic Cells (BMDCs)
Bone marrow cells were isolated from femurs and tibias of WT
mice and cultivated for differentiation in GM-CSF supplemented
media as described previously (62). Cells were supplemented with
fresh DC media on days 3 and 5. Seven days after isolation, the
resulting CD11c+ bonemarrow-derived dendritic cells (BMDCs)
were harvested and used for co-culture stimulation experiments.
Stimulation of Naïve B Cells and Bone
Marrow-Derived Dendritic Cells
1 × 106/mL splenic B cells or BMDCs were stimulated with
PBS, B. vulgatus mpk or E. coli mpk at a Multiplicity of
infection (MOI) of 1 at 37◦C (“-stimulated B cells/BMDCs”). One
µL/mL gentamicin was added to prevent bacterial overgrowth.
According to the experimental setting, cells were harvested
following stimulation at different time points.
Co-culture Experiments
For B-T cell co-culture experiments B cells served as APCs
and were stimulated for 24 h with commensals as described
previously (“-primed B cells”). Prior to co-cultivation with naïve
CFSE-labeled OT-II CD4+ T cells, B cells were incubated with
10µg/mLOva-Peptide (ISQAVHAAHAEINEAGR, EMC) for 2 h
at 37◦C. B cells were washed and supernatant was exchanged
with fresh media (“-pulsed B cells”). Primed and pulsed B cells
and naïve T cells were co-cultured at different ratios for 72 h at
37◦C and 100 ng/mL purified anti-mouse IL-10 antibody (Clone:
JES5-2A5, BioLegend) was added to certain samples.
For CD11c+ dendritic cells maturation assay, naïve B cells and
differentiated immature BMDCs were simultaneously stimulated
with bacteria at MOI 1 and co-cultured at a ratio of 5:1 (B
cells/BMDCs). To show the effect of indirect cell-cell interaction,
naïve B cells and BMDCs were additionally co-cultured in
Transwells (pore-size 0.4µm) and stimulated with bacteria at
MOI 1. To mimic the influence of soluble IL-10 produced by
B cells on the maturation of BMDCs, 10µg/mL recombinant
mouse IL-10 (BioLegend) were added to BMDC mono-cultures.
DSS-Induced Colitis
Germfree (GF) C57BL/6J mice were colonized for 7 days
with 1 × 108 B. vulgatus or E. coli per mL sterile drinking
water. After day 8, mice received sterile drinking water
without bacteria. Colonization was checked weekly by collecting
fresh feces and determining CFU on selective growth agars
(Supplementary Figure 1). After 4 weeks of colonization, mice
were administered 2% DSS (molecular weight 36–50 kDa; MP
Biomedicals, Santa Ana, CA) in their drinking water for 7 days,
followed by regular drinking water for 2 days. The disease
activity index (DAI) was determined daily by assessment of
body weight, stool consistency, and detection of rectal bleeding.
On day 9, mice were sacrificed. Colon, spleen and mesenteric
lymph nodes (mLN) were removed and cleaned for histological
analysis and cell isolation. For the latter, colons were finely
minced and incubated in HBSS containing 5mM EDTA at 37◦C
for 15min in motion for 2 cycles. Then, tissue was digested in
RPMI 1640 containing 0.4 mg/ml collagenase D (Roche) and
0.01 mg/ml DNase I (Roche) for 20min at 37◦C on a shaking
platform. After collagenase digestion, mononuclear cells were
collected by centrifugation at 400 g for 5min. In addition, cells
of mesenteric lymph nodes (mLN) and spleen were extracted by
gently disrupting the tissue with a sterile syringe plunger and
passing through a nylon cell strainer (40-µm mesh) with PBS
containing 1% FBS.
Viable cells were counted and cultured for 4 h with 2
µl/mL Leukocyte Activation Cocktail with Brefeldin A (BD
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Bioscience). After incubation, cells were prepared for flow
cytometrical analysis.
Flow Cytometrical Analysis (FCM)
Harvested cells were washed and FC-receptors were blocked
to avoid non-specific binding. Cell death was measured
by LIVE/DEAD Cell Viability kit (ThermoFisher) staining
for 20min at 4◦C. Intracellular staining was performed
using Cytofix/Cytoperm (BD Biosciences) according to the
manufacturer’s description. For intracellular and cell-surface
staining, cells were labeled for 25min at 4◦C with specific
fluorophore-conjugated antibodies, washed, and resuspended in
staining buffer (PBS/1% FCS). Multi-color FCM analyses were
performed on a FACS LSRII (BDBiosciences). For compensation,
fluorescence minus one (FMO) samples served as controls.
Doublets were excluded using FSC-A/FSC-H gating. Data was
analyzed using FlowJo software (Tree Star, Ashland, OR).
Antibodies: CD11c-APC, CD19-BV421, CD1d-AF647,
CD21/CD35-BV605, CD23-BB515, CD24 AF700, CD365(TIM-
1)-PE, CD4-APC, CD4-Bv605, CD40-APC, CD40-Bv421,
CD45R(B220)-FITC, CD5-Bv605, CD80-PerCP-Cy5.5, CD86-
PE-Cy7, CD178(Fas-L)-PE, CD274(PD1-L)-PE, CD73-PE,
CD210(IL10R)-PE, FoxP3-AF647, I-A/I-E(MHC-II)-FITC,
IFNγ-PE-Cy7, IgM-APC, IL10-PE, IL17A-APC-Cy7, IL4-PE,
Vβ5.1,5.2-Bv605, GITR-L-PE, Ebi3-PE. All fluorophore-coupled
antibodies were purchased from BD Biosciences.
Cytokine Analysis by ELISA
For determination of TNF and IL-10 concentrations in cell
culture supernatants, ELISA Kits purchased from BD Bioscience
were used according to the manufacturer’s instructions.
Statistics
Data have been tested for normality using the Shapiro-Wilk
normality test. Statistical analyses were then performed via
unpaired student’s t-test or ANOVA for data with Gaussian
distribution and via Mann-Whitney or Kruskal-Wallis test for
non-parametric statistics. Correlation analyses were performed
via Spearman’s rank correlation coefficient (r). Statistical
significance: ∗p< 0.05, ∗∗p< 0.01, ∗∗∗p< 0.001, ∗∗∗∗p< 0.0001.
Error bars represent± standard deviation (SD).
RESULTS
B Cell Activation and Maturation via Strong
Immunogenic E. coli Are TLR-Dependent
B cells are mainly associated with the production of antibodies
against invaders during adaptive immune responses (4).
Activation and proliferation of B cells are achieved by either T
cell- dependent or -independent interaction, whereas the latter
is coordinated by antigen-recognition via membrane-bound
immunoglobulin on the B-cell surface, known as B-cell receptor
(BCR) (63). However, B cells express additional receptors for
the specific and initial recognition of microbial antigens: Toll-
like receptors (TLRs) (64). These surface-bound molecules play
a key role in the identification of microbe-associated molecular
patterns (MAMPs), such as LPS (via TLR4) or PGN (TLR2) by
professional antigen-presenting cells (65).
In order to show that B cells are activated and differentiated
upon the MAMP recognition via TLRs and that the activation
level is dependent on the immunogenicity of encountered
microbes, B cells isolated from wild type (WT) and TLR2−/−
× TLR4−/− (KO) mice were stimulated with two different
immunogenic bacteria: B. vulgatusmpk and E. colimpk (66–69).
Survival of CD19+ B cells was investigated in vitro after 0,
24, 48, and 72 h of stimulation with B. vulgatus or E. coli. The
viability of B cells decreased significantly 24 h after stimulation
with PBS (Mock) or B. vulgatus in comparison to E. coli-
stimulated B cells, indicating that the survival of B cells is strongly
dependent on a potent stimulus with strong immunogenic E.
coli (Figure 1A). In addition, no significant differences between
E. coli, B. vulgatus or PBS stimulated TLR2−/− × TLR4−/−
B cells were observable, indicating that the activation of naïve
B cells depends on interaction of bacterial MAMPs with the
corresponding TLRs. This is in line with the analyzed B cell
proliferation in response to bacterial encounter after 72 h: a
robust bacterial interaction with TLR2 or TLR4 on the surface
of B cells is critical for the induction of B cell proliferation
(Figure 1B). Stimulation with E. coli results in an increased
proliferation of naïve B cells expressing TLR2 and TLR4. E. coli
and B. vulgatus failed to activate naïve TLR2−/− × TLR4−/− B
cells, resulting in a lack of proliferation. Additionally, maturation
and activation markers characteristic for APCs on the surface of
splenic B cells were measured after stimulation with bacteria. As
shown in Figure 1C, the production and expression of MHC-
class-II, CD80, CD86, and IgM were strongly upregulated in
response to E. coli and increased distinctly over time. In contrast,
B. vulgatus-challenged B cells expressed only moderate levels of
cell activationmarkers with a constant surface protein expression
during 72 h of cultivation. In line with B cell survival and
proliferation, the activation of B cells was shown to be TLR2/4
dependent, as TLR2−/− × TLR4−/− splenic B cells did not
express significant levels of activation markers, regardless of the
bacterial stimulus.
Strong Immunogenic E. coli Induces
Differentiation of Regulatory B Cell
Phenotypes
We first demonstrated that B cells can interact directly with
MAMPs via TLRs resulting in differently pronounced survival,
activation and proliferation of B cells depending on the
recognized microbial antigen. We next determined the cell
phenotype of B cells stimulated with E. coli or B. vulgatus. In
order to demonstrate that, in a healthy host, immunogenic
bacteria are able to counter-regulate a pro-inflammatory
immune response, hence contributing to the maintenance of
immune homoeostasis, we focused on the differentiation of
naïve B cells to regulatory B cells (Bregs). We determined
the percentage of the best characterized Breg subsets: B10
cells, T2-MZP cells, and Tim-1+ B cells, at several time points
after stimulation with strong immunogenic E. coli or low
immunogenic B. vulgatus in comparison to naïve, unstimulated
B cells (Figure 2A) (70). As shown in Figure 2B, the induction
of the regulatory B cell phenotypes CD19+CD5+CD1d+IL10+
(B10 cells) and CD19+CD21hiCD23hiCD24hi (T2-MZP cells)
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FIGURE 1 | Toll-like receptor-dependent activation of naïve B cells by E. coli. Naïve B cells were isolated from spleens of WT or TLR2−/− × TLR4−/− (KO) mice via
magnetic cell sorting. B cells were stimulated with B. vulgatus (B.v.) or E. coli (E.c.) at MOI 1 and PBS as control (Mock) for various time points (0, 24, 48, and 72 h).
After incubation, cells were blocked for non-specific binding of antibodies, permeabilized for intracellular antibody staining and fixed prior flow cytometric analysis. (A)
Survival of CD19+ B cells was assessed by staining with life-dead dye. (B) B cell proliferation of CD19+ B cells was analyzed via CFSE cell labeling. Left panel shows
exemplary histograms for each stimulus (colored peaks) including unstained control (white peak). (C) Surface expression of IgM, MHC-II, CD80, and CD86 was
measured to determine B cell activation after bacterial stimulation (n = 3–4). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
were significantly enhanced after being challenged with
E. coli in comparison to B. vulgatus or PBS stimulation,
reaching the maximum proportion after 48–72 h of incubation
(Figure 2B; Supplementary Figures 2, 3). Furthermore, E.
coli-stimulated B cells differentiated to a higher proportion
into CD19+ Tim-1+ cells (Tim-1+ B cells), an additional
regulatory B cell phenotype compared to PBS and B. vulgatus
stimulation (Figure 2B, right; Supplementary Figure 4).
Tim-1+ B cells are found in the spleen and are reported
to produce IL-10 and suppress effector CD4+ T cells (70).
To further characterize the regulatory properties of PBS,
B. vulgatus or E. coli-stimulated B cells, we determined the
concentrations of pro- and anti-inflammatory cytokines
secreted in cell culture supernatant. The concentrations of
secreted IL-10 were significantly increased upon stimulation
of B cells with E. coli compared to stimulation with PBS
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FIGURE 2 | Induction of regulatory B cell phenotypes via E. coli. Naïve B cells were isolated from spleens of WT or TLR2−/− × TLR4−/− (KO) mice via magnetic cell
sorting. B cells were stimulated with B. vulgatus (B.v.) or E. coli (E.c.) at MOI 1 and PBS as control (Mock) for various time points (0, 24, 48, and 72 h). (A) Exemplary
flow cytometry gating strategy for CD19+CD5+CD1d+ IL10+ (B10 cells) of purified and stimulated splenic B cells (B) Induction of regulatory B cell phenotypes
CD19+CD5+CD1d+ IL10+ (B10 cells), CD19+CD21hiCD23hiCD24hi (T2-MZP cells) and CD19+Tim-1+ (Tim-1+ B cells) as determined by flow cytometry. (C)
Concentration of secreted cytokines IL-10 and TNFα by stimulated B cells measured via ELISA. (D) Expression of suppressor molecules on B cell surface after
bacterial stimulation as determined by flow cytometry (n = 3–4). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
or B. vulgatus (Figure 2C). In contrast, only low levels of
the pro-inflammatory cytokine TNFα were detectable (<80
pg/mL) and not different in the various treatments (Figure 2C).
Furthermore, we analyzed different suppressor molecules
produced by immune cells that are not directly linked to a
specific Breg phenotype: CD73, PD-L1, FasL, GITRL, and
EBI3. E. coli, but not B. vulgatus stimulation of naïve splenic
wild type B cells led to significantly elevated productions of all
analyzed immune suppressive molecules starting after 24 h of
stimulation (Figure 2D).
E. coli-Stimulated B Cells Inhibit DC
Activation and Maturation
In the next step we wanted to elucidate whether E. coli-
activated B cells featuring regulatory properties via the intensified
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production and upregulated expression of suppressive molecules
directly influence the function of other immune cells, e.g.,
dendritic cells (DCs). We primarily focused on the maturation of
differentiated CD11c+ bone marrow-derived dendritic cells co-
cultured with bacteria-stimulated B cells (Figure 3A). Interaction
of immature DCs (iDCs) with MAMPs (e.g., Lipopolysaccharide,
LPS) results in DC maturation characterized by an enhanced
expression of MHC-II, CD40, CD80, and CD86 and increased
secretion of TNFα (61, 68, 69, 71). Activated DCs, as professional
APCs, are responsible for a robust immune response via antigen-
recognition, -processing, and -presentation resulting in a proper
activation of T cells (72, 73).
In line with our group’s previous work, stimulation of iDCs
for 24 h with strong immunogenic E. coli led to a fully mature
DC phenotype with a strong upregulation of surface-bound
MHC-II, CD40, CD80, and CD86 (Figure 3B, DC dataset, red
columns) and high levels of secreted TNFα (Figure 3C, upper
panel, DC dataset, red columns). In contrast, the stimulation
with low immunogenic B. vulgatus resulted in a semi-mature DC
phenotype with an intermediate expression of T cell activation
markers and alleviated production of TNFα (Figures 3B,C, DC
dataset, blue columns) (66, 68, 69). To demonstrate the effect
of stimulated B cells on DC maturation, we co-cultured iDCs
with B cells either in direct contact (DC + B cells) or separated
via Transwell membranes (DC | B cells) and stimulated the
cells with PBS, B. vulgatus or E. coli. E. coli challenged B cells
inhibit DC maturation during stimulation, as indicated by a
notably reduced expression of MHC-II, CD40, CD80, and CD86
(Figure 3B, DC + B cells and DC|B cells dataset, red columns)
and significantly diminished secretion of the pro-inflammatory
cytokine TNFα (Figure 3C, upper panel, DC+ B cells and DC|B
cells dataset, red columns). This effect was observed in both direct
and indirect DC-B cell co-cultures stimulated with E. coli, leading
us to conclude that soluble factors able to translocate through
the Transwell membrane possess the strongest potential for
inhibiting DC maturation. However, the maturation was slightly
more suppressed in direct interaction with B cells stimulated with
E. coli.
As IL-10 has been described as an important regulatory
factor of Bregs, mainly driving the modulation of immunological
functions of other cell types, we mimicked the effect of IL-10
on DC maturation by adding recombinant IL-10 to DC culture
(Figures 3B,C, DC + IL10 dataset) (70). We propose that the
stimulation of iDCs with B. vulgatus or E. coli in the presence of
recombinant IL-10 led to a reduced maturation of DCs, indicated
by the tendency of lower expression of MHC-II, CD40, CD80,
and CD86 in comparison to the stimulation without recombinant
IL-10 (Figure 3B, DC + IL10 and DC dataset). We support
this hypothesis by the detection of significantly lower levels of
secreted TNFα (Figure 3C, upper panel, DC + IL10 and DC
dataset) (Figure 3C, upper panel, DC+ IL10 and DC dataset).
To investigate the effect of IL-10 secretion by E. coli-
stimulated B cells on DC maturation, we neutralized IL-10 in
the DC-B cell co-culture by adding anti-IL-10 (Figures 3B,C,
orange columns). The use of anti-IL-10 mAb partially blocks
the inhibitory effect of Bregs on DC maturation, resulting
in a restored production of pro-inflammatory cytokine TNFα
compared to the stimulation of DCs with E. coli-stimulated B
cells (Figure 3C, upper panel, orange and red columns). Further,
we measured the concentration of IL-10 in the cell culture
supernatant of all samples and proved the equal distribution
of secreted cytokines through the Transwell membranes in
the upper and bottom chamber (Figure 3C, lower panel).
As expected, and already shown in Figure 2B in single cell
cultures, the concentration of IL-10 in co-culture supernatant
was highest in E. coli-stimulated samples (Figure 3C, lower panel,
red columns).
E. coli-Primed B Cells Inhibit T Cell
Activation and Induce Treg Differentiation
As presented above, we were able to show that commensal primed
B cells significantly shape DC maturation and consequently
influence antigen presentation and the potential to activate
T cells. Next, we investigated the direct effect of commensal
activated B cells on the proliferation and polarization of T cells
without the involvement of professional APCs. We primed WT
B cells with PBS, B. vulgatus or E. coli for 24 h, pulsed the cells
with Ova-peptide and co-cultured these B cells at different cell
ratios (1:1, 1:5) for 72 h with naïve CFSE-labeled CD4+CD44− T
cells isolated from OT-II mice, which express an Ova peptide-
specific TCR (Figure 4A). The proliferation of naïve CD4+ T
cells was significantly lower in co-cultures with E. coli-primed
B cells, with a T cell-B cell ratio of 1:1 in comparison to
PBS or B. vulgatus-primed B cells (Figure 4B). Increasing the
number of antigen-pulsed B cells (ratio T/B 1:5) resulted in a
potent reduction of T cell proliferation in both E. coli- and B.
vulgatus-primed cells (Figure 4B). B cells as bona fide APCs,
usually direct the induction of Th2 responses by suppressing the
differentiation of Th1 and Th17 cells and promoting regulatory
T-cell expansion (74–76). Th1 (CD4+IFNγ+), Th2 (CD4+IL4+),
Th17 (CD4+IL17A+IL4−IFNγ−) cell, and Treg (CD4+FoxP3+)
differentiation in B-T cell co-culture was analyzed by flow
cytometry. PBS-primed naïve B cells appeared to favor the
differentiation of naïve T cells to Th1 and Th17 cells, whereas
E. coli-primed B cells led to a significantly enhanced T cell
polarization toward Tregs. In addition, co-culture of E. coli-
primed B cells with naïve T cells resulted in a polarization of Th2
cells at a T cell-B cell ratio of 1:5 (Figure 4C) and the frequency
of Th1 cells significantly decreased with a simultaneous increase
of Th2 cells compared to PBS control.
Induction of Begs by Strong Immunogenic
E. coli Contributes to the
Counter-Regulation of DSS-Induced
Inflammation
In the in vitro experiments, we could show that B cells, especially
regulatory B cells, play a crucial role during the initiation of
immune responses and that B cells can directly or indirectly affect
the function of other immune cells by their regulatory properties.
This led us to the hypothesis that in a host having functional B
cell immunity, E. coli with its immunogenic potential counter-
regulates inflammatory processes via the strong induction
of regulatory cell populations and can consequently help to
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FIGURE 3 | E. coli-induced regulatory B cells inhibit maturation of professional APCs in vitro. Naïve B cells were isolated from spleens of WT mice and stimulated with
B. vulgatus (B.v.) or E. coli (E.c.) at MOI 1 in co-culture with bone marrow-derived dendritic cells (DC) for 24 h. (A) Differentiated bone marrow-derived DCs were
cultured alone (DC), with recombinant IL-10 (DC + IL10) or co-cultured with primed B cells without (DC + B cells) or with Transwells (DC|B cells) and challenged with
bacteria. (B) Maturation of CD11c+ APCs was determined through the expression of MHC-II and co-stimulatory markers CD40, CD80, and CD86. (C) Concentrations
of secreted pro- and anti-inflammatory cytokines TNFα and IL-10 of mono- and co-culture stimulation were determined in the cell culture supernatants. In Transwell
stimulations, supernatant of bottom and upper chambers was analyzed (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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FIGURE 4 | E. coli-induced Bregs inhibit T cell proliferation and direct T cell polarization in vitro. (A) Naïve B cells were isolated from spleens of WT mice and primed
with B. vulgatus (B.v.) or E. coli (E.c.) at MOI 1 for 24 h. T cell proliferation and polarization assays were performed with Ova peptide-specific TCR-expressing naïve T
cells in combination with primed and with Ova peptide-pulsed B cells at various ratios. (B) Left panel shows exemplary flow cytometry gating strategy. Middle panel
shows exemplary histograms for each stimulus (colored peaks) including unstained control (white peak). Percentage of proliferated TCR+CD4+ T cells was assessed
by CFSE staining (right panel). (C) Polarization of naïve T cells incubated for 72 h with different stimulated B cell ratios: Th1 (TCR+CD4+ INFγ+), Th2
(TCR+CD4+ IL-4+), Th17 (TCR+CD4+ IL-17a+) cells, and Treg (TCR+CD4+FoxP3+) cells (n = 4). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
maintain immune homeostasis. Therefore, we used the Dextran
Sulfate Sodium (DSS)-induced colitis model in gnotobiotic
C57BL/6 mice which have a physiological B and T cell response.
We colonized germfree WT mice with B. vulgatus or E. coli
for 4 weeks via drinking water (Supplementary Figure 1) and
administered 2% DSS for 7 days in order to correlate the
bacteria-dependent induction of regulatory B cells in spleen
and mesenteric lymph nodes (mLN) with the disease pathology
(Figure 5A).
Colonization of germfree mice with E. coli, but not with
B. vulgatus, resulted in significantly reduced weight loss and a
lower disease activity index in comparison to germfree mice
in response to DSS-administration (Figures 5B,C). Additionally,
the histological score of tissue damage in the colon was
significantly attenuated in E. coli-colonized mice but not
in B. vulgatus-associated mice as compared to germfree
mice (Figure 5D). Further, the increased absolute numbers of
CD11b+Gr1+ neutrophils in the spleen and the infiltration
of these neutrophils in the colonic tissue implied a severe
inflammatory state in germfree mice after DSS treatment in
comparison to E. coli-colonized mice (Figure 5E). Interestingly,
the influx of neutrophils was also reduced in B. vulgatus-
colonized mice as compared to germfree mice. The percentage
of CD4−CD19+IL10+ regulatory B cells in the spleen and
mLN was significantly increased in E. coli-colonized mice in
comparison to B. vulgatus-colonized and germfree animals
before and after DSS-administration (Supplementary Figure 5,
Figure 6A). This enhanced Breg induction correlated with
a lower histological score, whereas highly inflamed mice
showed a minimal activation of regulatory B cells in the
spleen and mLN (Figure 6B). In addition, we analyzed the
polarization of CD4+ T cells in all three DSS-administered
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FIGURE 5 | E. coli colonization of germfree mice ameliorates DSS-induced colitis. (A) Germfree wild type mice and B. vulgatus- or E. coli-colonized wild type mice
were administered with 2% DSS in drinking water for 7 days, followed by regular drinking water for an additional 2 days. (B) Bodyweight changes and (C) disease
activity index (DAI). (D) Representative colon histological sections stained with hematoxylin and eosin (H&E) and histological score. (E) Exemplary flow cytometry
gating strategy and analysis of absolute infiltrated CD11b+GR1+ neutrophils in spleen and colonic lamina propria (cLP) (GF: n = 5; B.v/E.c: n = 5–6). *p < 0.05, **p <
0.01, ***p < 0.001, ****p < 0.0001.
groups. No significant differences were observed in the Th2
cell differentiation between the groups (Figure 6C). However, E.
coli-colonized mice showed a significant increase of regulatory
T cells (CD19−CD4+CD25+FoxP3+) in the spleen and mLN,
whereas the proportion of Th1 (CD19−CD3+CD4+IFNγ+)
and Th17 (CD19−CD3+CD4+IL-17+) cells was significantly
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FIGURE 6 | E. coli colonization of germfree mice triggers the induction of regulatory B cells accompanied by an increase of Treg cells during DSS-induced colitis. (A)
Exemplary flow cytometry gating strategy and analysis of CD4−CD19+ IL-10+ regulatory B cells (Bregs) in the spleen and mesenteric lymph nodes (mLN). (B)
Correlation between histology colitis score and percentage of CD4−CD19+ IL-10+ Bregs in the spleen (left panel) and mLN (right panel) of colonized and
DSS-administered mice (r = Spearman’s rank correlation coefficient). (C) Exemplary flow cytometry gating strategy and analysis of Th1 (CD19−CD4+ INFγ+), Th2
(CD19−CD4+ IL-4+), Th17 (CD19−CD4+ IL-17a+) cells, and Treg cells (CD19−CD4+CD25+FoxP3+) in the spleen and mesenteric lymph nodes (mLN) (GF: n = 5;
B.v/E.c: n = 5–6). *p < 0.05, **p < 0.01, ***p < 0.001, ****p < 0.0001.
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reduced in the mLN in comparison to germfree DSS-treated
mice (Figure 6C).
In summary, we showed in vitro that the activation of naïve
B cells and the differentiation of Bregs are highly dependent on
the strength of immunogenicity of the interacting commensal
bacteria. Moreover, the enhanced induction of Bregs by strong
immunogenic E. coli in combination with the differentiation of
Tregs may contribute to the regulation and even suppression of
inflammatory processes in vivo as compared to B. vulgatus.
DISCUSSION
In healthy individuals, a complex interaction between the host
immune system and commensal microbiota is required to
maintain intestinal homeostasis.
Alterations of the gut microbial communities can cause
an aberrant and dysregulated immune system resulting in the
onset or aggravation of inflammatory bowel diseases, such
as Crohn’s disease (CD) and ulcerative colitis (UC) (77–79).
Furthermore, a disturbed immune system-microbiota balance
has also been described in disease pathologies affecting tissues
other than those of the intestine (e.g., Grave’s disease, multiple
sclerosis, type-1 diabetes (T1D), systemic lupus erythematosus,
psoriasis, schizophrenia, and autism spectrum disorders) and
can be the cause for inflammatory processes during disease
development (80–89).
Beside pathogens which are typically acquired from the
environment, often provoking acute infections and are the
target of immunity, also members of the resident microbiota,
found in most healthy hosts, may be the cause for several
inflammatory disorders in a genetic or environmental
predisposed organism (90–94). The exact mechanisms
mediating pathology remain largely unclear, but commensal
bacteria are capable of triggering inflammatory disease in
immunosufficient rodents by altering barrier function, invading
the gut epithelium and stimulating local inflammatory responses
(pathobionts) (93, 94).
However, it is conceivable that pathobionts do not actively
use specific mechanisms to harm the host under certain
circumstances; rather, mechanisms, signaling pathways or cell
functions are malfunctioning or are lacking in an immune-
compromised host, which pathobionts usually activate in a
healthy host to counter-regulate inflammatory processes.
But which immune response mechanisms are consulted by
commensals in a healthy host to maintain immune homeostasis?
One possible mechanism could be the induction of regulatory
B cells.
Most studies investigate the interaction of pathogenic bacteria
with B cells during infection. Alternatively, we wanted to
demonstrate that the induction of regulatory B cell populations
is a mechanism which commensals use to suppress self-caused
pro-inflammatory immune responses in a healthy host (54, 95).
We also wanted to confirm that Bregs, although present in a
minor cell frequency, are an interface in immune-regulation and
thus an important player in counter-regulation of inflammatory
immune responses.
Primarily, naïve B cells are activated via the help of Th cells
which present microbial antigens to the B cell receptor (BCR)
followed by the uptake of the antigen through receptor-mediated
endocytosis, degradation and presentation of peptide in complex
with MHC-class-II molecules on the B cell membrane (96). The
recognition of this complex by the corresponding T cell receptor
(TCR) of Th cells and the concurrent binding of CD40L with
the CD40 receptor on the surface of B cells, as well as the
secretion of co-stimulatory cytokines, such as IL-4 and IL-21
by the T cells, promote B cell proliferation, immunoglobulin
class switching and somatic hypermutation (T cell-dependent
activation) (96, 97). However, we propose a T cell-independent
activation and induction of Bregs by commensal bacteria via the
direct interaction of MAMPs with TLRs expressed on B cells.
Especially the exposure of naïve B cells to LPS and peptidoglycan
(PGN), the two most prominent immune-stimulatory bacterial
cell components, were responsible and necessary for a potent
B cell proliferation and differentiation of Bregs since activation
markers like MHC-II, CD80 and CD86 were at lower levels
expressed on B cells lacking TLR2 and TLR4 after bacteria
encounter (65, 98–101). We could provide evidence for a T
cell-independent activation of B cells even without other co-
stimulatory factors [e.g., CD40 engagement, CD80/CD86, B cell-
activating factor (BAFF), or BCR-TLR crosstalk] that, according
to many studies, are pre-requisited to promote an optimal B cell
activation (102–105).
Further, we suggest that not only the presence of pattern
recognition receptors (PRRs), such as TLRs on the B cell surface
is crucial for B cell activation. Additionally, the antigen origin
and its immune-stimulatory level might be decisive for the
strength of activation and thus the differentiation and survival
of Breg subsets.
We could demonstrate that commensal bacteria possess
different potentials for directly activating B cells, prolonging
their survival and inducing Breg phenotypes as well. In this
comparative study of B. vulgatus (low immunogenic) and E.
coli (strong immunogenic), we were able to show that the
potent stimulation of naïve B cells with E. coli resulted in
a strong activation and differentiation of Breg phenotypes
characterized by a significantly elevated secretion of anti-
inflammatory IL-10 and higher production of suppressive
molecules like EBI3, CD73, GITRL, FasL, and PD-L1. In addition,
the secretion of the pleiotropic modulatory cytokine IL-6, that
exerts either pro-inflammatory or anti-inflammatory properties,
was upregulated past stimulation of B cells with E. coli whereas
only low levels of pro-inflammatory TNFα were detectable
(Supplementary Figure 6). IL-6 can directly promote Breg cell
differentiation and IL-10 production in vivo and therefore could
be an important trigger for the proceeding induction of Bregs
(16, 106, 107).
Important for all following experiments, we demonstrated
in in vitro stimulation a functioning direct interaction of
commensal bacteria with naïve B cells. Nevertheless, the
encounter of naïve B cells with microbial antigens in vivo is
more complex and subject to many limitations, such as intestinal
barrier functions and the translocation of microbial structures
to secondary lymphoid organs as with the lymph nodes and
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the spleen. Furthermore, B cells are not capable of recognizing
and taking up microbial components via cell protrusions as
dendritic cells perform (108). However, Hudak et al. detected a
large number of CD19+ B cells in colonic lamina propria cells
which were positive for the uptake of PGN of D-amino acid
hydroxycoumarin amino-D-alanine (HADA)-labeled bacteria 4 h
after oral gavage (109). This study indicated that CD19+ B cells
act as APC in the lamina propria and hence contribute to the
regulation of immune processes by directly recognizing MAMPs.
We determined that the bacteria-B cell interaction with the
accompanying induction of regulatory B cells had extensive
effects on other immune cells and the overall immune response.
We demonstrated this in the interplay between bacteria-induced
Bregs and DCs. It is already known that DCs, as professional
APCs, have crucial influences on B cell function by capturing
unprocessed antigen and transferring this antigen to naïve B cells,
resulting in the initiation of antigen-specific antibody response
and the provision of B cell isotype class switching (110–112).
Here, we represented the effect of activated B cells on DC
differentiation, maturation and function. The stimulation of
immature DCs (iDCs) with B. vulgatus led to a semi-mature,
tolerant phenotype characterized by a low expression of MHC-
II, CD40, CD80, and CD86 and modest secretion of TNFα and
IL-1ß. In contrast, the challenge of iDCs with E. coli resulted in
a high expression of MHC-II and co-stimulatory markers with
increased secretion of pro-inflammatory cytokines (60, 66–69,
113, 114) (Figure 7).
However, in our co-culture experiments, the interaction of
DCs with E. coli-stimulated B cells significantly inhibited DC
maturation, marked by a reduced expression of DC activation
and maturation markers and an alleviated secretion of pro-
inflammatory cytokines. This suppression of DC maturation
was mediated by distinct regulatory properties of E. coli-
induced Bregs. We could show in Transwell co-cultures that
the regulatory functions of Bregs on DC maturation were not
solely mediated by the anti-inflammatory cytokine IL-10 since
the addition of recombinant IL-10 was not as effective as the
complete repertoire of proteins secreted by stimulated B cells.
Consequently, additionally secreted molecules, such as EBI3/IL-
35 can contribute to the DC maturation inhibition properties
of E. coli-stimulated B cells in Transwell co-culture experiments
(51) (Figure 2D).
Furthermore, maturation of DCs was even more reduced
in co-culture stimulation where DCs and E. coli-stimulated
B cells had direct cell-cell contact. This is in line with our
previously findings that the stimulation of B cells with E. coli
led to an increased upregulation of suppressive molecules like
PD-L1, FasL and GITRL on the B cell surface and that these
proteins, in combination with secreted cytokines, characterize
the strong anti-inflammatory feature of Bregs (47, 51, 116).
Moreover, although the expression of T cell activation markers
and the production of pro-inflammatory cytokines by DCs
were suppressed via E. coli-stimulated B cells, the concentration
of anti-inflammatory IL-10 in the DC-B cell co-culture was
significantly higher than in single cell cultures of DCs and B cells.
This led us to the hypothesis that E. coli-challenged DCs and
B cells may even form a positive feedback loop, resulting in an
accumulated anti-inflammatory milieu to regulate overshooting
immune responses and dampen inflammatory processes in a
healthy host (117, 118).
We further demonstrated that this B cell-driven regulatory
mechanism had relevant impacts on the subsequent processes
of the adaptive immune response: the activation, proliferation
and polarization of T helper cells. Schmidt et al. revealed that
Ag-pulsed splenic B cells possess a stronger T cell stimulatory
capacity than CD11c+ DCs and that activated CD4+ T cells favor
Th2 polarization in vitro (119). Saze et al. investigated T cell
activation properties of B cells in more detail. They compared
the proliferation of T cells incubated with either naïve B cells
or activated B cells and showed that freshly purified B cells
co-cultured with separated CD4+ T cells augment proliferation
of the T cells as well as their cytokine production whereas
activated B cells significantly inhibit T cell proliferation (120).
By using two commensals featuring different immunogenic
properties for B cell stimulation, we could complement and
confirm these findings; furthermore, we could expand our
understanding of the mechanism behind microbiota-mediated
B cell regulation. The stimulation of CFSE-labeled Ova peptide-
specific TCR+CD4+ T cells with E. coli-primed and Ova peptide-
pulsed B cells resulted in a significant inhibition of T cell
proliferation at a T cell-B cell ratio of 1:1. In contrast, the
co-incubation of T cells with B. vulgatus-primed B cells did
not result in decreased proliferation. Only after increasing the
T cell-B cell ratio to 1:5, the low immunogenic bacterium
possessed T cell proliferation-preventing effects. The cultivation
of T cells with naïve unstimulated B cells led to an intense
T cell proliferation and a polarization toward Th1 and TH17
cells. In contrast, T cells incubated with E. coli-primed B cells
favored a polarization shifted toward Th2 cells and Tregs. B.
vulgatus-primed B cells also polarized T cells in a Th2 and Treg
direction but simultaneously induced Th1 and Th17 cells leading
to a more pro-inflammatory Th1/Th2/Th17/Treg balance (121–
123). The cause for the strong T cell activation, proliferation and
polarization by naïve unstimulated B cells could be the basic
expression levels of MHC-II and co-stimulatory proteins in the
absence of anti-inflammatory cytokines and surface molecules,
which were upregulated in E. coli-primed B cells, as shown in
previous experiments (124). In addition, after induction of Tregs
via E. coli-primed Bregs, these two regulatory cell populations
could cooperate to generate an IL-10-driven feedback loop to
initiate their reciprocal activation and consequently increase their
cell emergence (8, 125, 126).
The inflammation-suppressive role of Breg subsets in
autoimmune disease has been demonstrated previously in in vivo
mice models for IBD, MS, T1D, and RA, primarily achieved
by the adoptive transfer before or during inflammation of
ex vivo-activated B cells in wild type, B cell-depleted (anti-
CD20 mAb treatment), or B cell-deficient (µMT) mice (10, 28,
47, 127–132). Consequently, the ability of Bregs to contribute
to the control of the immune response during inflammation
development and disease progression is evidently. Nevertheless,
the influence of the host commensal microbiota on the induction
of this regulatory cell phenotype needs to be investigated in
more detail.
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FIGURE 7 | Counter-regulatory mechanisms of Bregs after the induction of immune responses via immunogenic bacteria. Depending on the immunogenicity of a
bacterial antigen, APCs (immature DCs and naïve B cells) are activated through the recognition of MAMPs (e.g., LPS or PGN) via Toll-like receptors to different
degrees. Potent stimulation of B cells (e.g., by strong immunogenic E. coli) induces the differentiation and proliferation of regulatory B cell phenotypes, such as B10
cells (CD19+CD5+CD1d+ IL10+), T2-MZP cells (CD19+CD21hiCD23hiCD24hi), and Tim-1+ B cells (CD19+ Tim-1+) characterized by an upregulated expression and
strong secretion of suppressive mediators. Primarily through secreted IL-10, Bregs can inhibit DC and macrophage maturation and function and consequently
dampen their antigen presentation capacity to activate and polarize T cells. Moreover, Bregs can regulate T-cell responses by suppressing the proliferation and
polarization of effector T cells (in particular TH1 and TH17 cells). These effects are mediated by secreted factors (IL-10, TGFß, and Ebi3/IL-35) and membrane-bound
molecules including MHC-II, CD73, PD-L1, FasL, and GitrL at the interface between B cells and T cells (115). Regulatory B cells also crosstalk with Treg cells to
promote their expansion and support their function. +, induction/activation; –, inhibition; semi-mature DCs, intermediate expression of DC maturation markers; LPS,
lipopolysaccharide; PGN, peptidoglycan; TLR, toll-like receptor; iDC, immature dendritic cell; CD, cluster of differentiation; PD-L1, programmed death ligand 1; FasL,
Fas ligand; GitrL, glucocorticoid-induced tumor necrosis factor receptor-related protein ligand; IL–, interleukin–; TCR, T cell receptor; TGFß, transforming growth factor
ß; Th, T helper cells; Tim-1, T cell Ig and mucin 1; IFNγ, interferon γ; TNFα, tumor-necrosis factor α; T-bet, T-box transcription factor; RORγt, RAR-related orphan
receptor gamma; GATA-3, Trans-acting T-cell-specific transcription factor GATA-3; FoxP3, Forkhead box protein P3.
In earlier studies, we could demonstrate the effect of different
immunogenic commensals on the differentiation andmaturation
of certain immune cells (e.g., CD11c+ DCs), concluding that
a potent TLR activation provided by strong immunogenic
bacteria leads to enhanced immune responses, aggravating the
course of disease (60, 61, 66, 68, 69, 133, 134). Thereby,
our and other groups used genetically susceptible colitis
mouse models (Rag1-, IL-2-, and IL-10-deficient) exhibiting a
dysregulated immune system to mimic disease development
in an immune suppressed host (60, 61, 135). In detail,
B cell immunity is inoperative, either due to the lack of
mature B cells (Rag1−/−), the disturbed proliferation and
induction of Bregs (IL-2−/−), or the dysfunction of Bregs
(IL-10−/−) in all three colitis mouse models. Hence in these
colitis models, a potent immune-stimulatory signal mediated
by strong immunogenic E. coli exacerbated inflammation,
since important counter-regulation mechanisms (such as the
induction of Bregs) for the compensation of overshooting
immune responses malfunctioning. Similar observation could be
made with the bacterium Helicobacter hepaticus. H. hepaticus
is a member of the mouse microbiota colonizing the lower
intestine and activating innate immunity via Toll-like receptors
without inducing immune pathology in a healthy host (136). H.
hepaticus thus induces an anti-inflammatory immune response
through the activation of regulatory macrophages to maintain
immune homeostasis (137). However, in immune-deficient IL-
10−/− or Rag2−/− mice, H. hepaticus triggered exacerbated
intestinal inflammation as a result of aberrant regulatory T cell
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function (138–140). In conclusion, strong immunogenic bacteria,
which are benignant commensals in a healthy host, provoke
an uncontrolled activation of the immune system in hosts
with a dysfunctional immune response, leading to inflammatory
processes and the exacerbation of disease severity.
However it has already been published in mouse models for
IBD and T1D that strong immunogenic bacteria, such as E.
coli Nissle or Helicobacter pylori have inflammation-suppressive
properties and can even prevent the onset of disease, on the
condition that the host provides a functional immune system
(141–143). In our study, we wanted to demonstrate the specific
impact of commensal bacteria featuring different immunogenic
properties on the activation of the immune system and the
development of inflammation while deciphering the crucial role
of regulatory B cells in these processes. Therefore, we colonized
DSS-administered germfree wild type mice providing a full-
featured immune system (no genetic susceptibility) to induce
intestinal inflammation.
The comparison of germfree, low immunogenic B. vulgatus-
or strong immunogenic E. coli-associated mice emphasizes
the importance of a potent immune stimulus in DSS-induced
inflammation since the colonization with E. coli significantly
prevented intense weight loss, alleviated disease symptoms
and reduced inflammation in the affected tissue. In contrast,
colonization with B. vulgatus alleviated disease symptoms
slightly, but not significantly, compared to germfreemice. Reason
for that could be the weak immunogenic properties of B. vulgatus
still provoking a low activation of B cells, minor induction
of Bregs and modest inhibition of T cell proliferation and
polarization, as observed in in vitro experiments. In addition,
other bacteria-associated host immune modulating effects which
are B cell- and T cell-independent, such as the restoration and
education of the immature immune system and mucosal barrier
present in germfree mice could be causal for the attenuated
inflammation development shown in B. vulgatus-colonized
mice. However, these potential immunogenic-independent
regulatorymechanismsmay be insufficient to significantly reduce
inflammation processes in DSS-induced colitis. Though, these
findings could explain the non-significant differences between B.
vulgatus- and E. coli-colonized mice in some read outs (144, 145).
Moreover, we provide evidence that the induction of Bregs
directly correlated with the severity of colonic inflammation and
therefore negatively correlated with the immunogenicity of the
colonizing bacteria. These findings are in line with other studies
reporting a decrease of intestinal regulatory B cells in colonic
inflammation in mice and humans (146–148). In line with our in
vitro experiments, the colonization of germfree mice with E. coli
prior to DSS-administration, and the accompanying induction of
Bregs, resulted in a significantly enhanced development of Tregs
and inhibition of a Th1 and Th17 polarization (Figure 7). Even
though B. vulgatus-colonization resulted in a slightly and non-
significant increased induction of Bregs, the differentiation of T
helper cells is not altered in comparison to germfree mice. In
contrast, the significant enhanced induction of Bregs in vitro and
in vivo in E. coli-associated mice leading to an anti-inflammatory
balance of Th1/Th2/Th17/Treg cells, marked by a pronounced
differentiation of Tregs, which is decisive for the development
of inflammation and consequently the possible reason for the
extenuated inflammation in E. coli-colonized and DSS treated
mice (121–123).
Thus, the increased accumulation of Bregs and Tregs
established an immune-homoeostatic state in vivo. In
combination, these two crucial regulatory cell populations
might develop a powerful anti-inflammatory milieu capable of
suppressing inflammation in various autoimmune diseases (149).
In conclusion, Bregs are an important interface in microbiota-
driven immune regulation. They contribute to maintenance of
immune homeostasis in a healthy host and counter-act emerging
inflammatory processes in immune-compromised hosts via the
production of suppressive molecules and the interaction with
other immune cell populations. The induction and longevity
of Bregs specifically depend and correlate with the strength
of TLR-ligation and subsequent cell activation, provided by
commensal antigens. The presented results directly link different
characteristics of commensal bacteria with the immune response
of the host and thus provide new insights in the inter-kingdom
communication between commensals and their hosts.
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Supplementary Figure 1 | Determination of colony forming units (CFU) of
germfree mice after colonization with B. vulgatus or E. coli. Feces of every mouse
were collected under germ free conditions before and after colonization with
bacteria and DSS-administration and were plated timely to determine the CFU.
Supplementary Figure 2 | Representative flow cytometry plots of B10 cells
induced by E. coli stimulation. Naive B cells were stimulated with E. coli at MOI 1
for 0, 24, 48, and 72 h. Doublets wee excluded via FSC-A/FSC-H gating and
death cells were excluded by fixable viability dye. B10 cells were defined as
CD19+CD5+CD1d+ IL10+.
Supplementary Figure 3 | Representative flow cytometry plots of T2-MZP B
cells induced by E. coli stimulation. Naive B cells were stimulated with E. coli at
MOI 1 for 0, 24, 48, and 72 h. Doublets were excluded via FSC-A/FSC-H gating
and death cells were excluded by fixable viability dye. T2-MZP B cells were
defined as CD19+CD21+CD23+CD24+.
Supplementary Figure 4 | Representative flow cytometry plots of Tim-1+ B cells
induced by E. coli stimulation. Naive B cells were stimulated with E. coli at MOI 1
for 0, 24, 48, and 72 h. Doublets were excluded via FSC-A/FSC-H gating and
death cells were excluded by fixable viability dye. Tim-1+ B cells were defined as
CD19+ Tim-1+.
Supplementary Figure 5 | Analysis of Bregs in germfree mice after colonization
with B. vulgatus or E. coli prior DSS administration. Changes in Bregs amount of
germfree, B. vulgatus or E.coli -colonized mice 2 weeks after colonization and 2
weeks prior DSS-administration measured via flow cytometry. ∗p < 0.05, ∗∗p <
0.01, ∗∗∗p < 0.001.
Supplementary Figure 6 | Concentration of secreted cytokine IL-6 by stimulated
B cells measured via ELISA. Naïve B cells were stimulated with B. vulgatus (B.v.)
or E. coli (E.c.) at MOI 1 and PBS as control (Mock) for various time points (0, 24,
48, and 72 h) (n = 4). ∗p < 0.05, ∗∗p < 0.01.
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